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Abstract 
Cardiovascular diseases are the leading cause of death worldwide, both in developed and 
developing countries. The incidence of cardiovascular diseases is linked to several risk factors that 
are either non-modifiable (age, gender, genetic background) or modifiable. The modifiable risk 
factors include lifestyle (western diet, tobacco use, alcohol abuse, physical inactivity) and treatable 
diseases such as hypertension, dyslipidemia, obesity, and diabetes. Many preclinical and clinical 
studies have shown that development of cardiovascular diseases and risk factors are associated 
early with an endothelial dysfunction. 
The endothelium, the monocellular layer lining all blood vessels, represents the largest cell 
compartment in contact with blood flow. Endothelial cells contribute to the vascular tone and 
constitute a protective surface with anti-thrombotic properties, mainly through the release of potent 
vasoprotective factors such as nitric oxide (NO). In cardiovascular diseases and also during 
physiological ageing, the endothelial dysfunction is characterized by a decreased formation of 
vasoprotective factors and an increased formation of vasoconstricting factors, resulting in an 
imbalance leading towards the accelerated development of vascular pathologies. Endothelial 
dysfunction is involved in atherosclerotic lesion formation by the promotion of both the early and 
late mechanisms of atherosclerosis including up-regulation of adhesion molecules, increased 
chemokine secretion and leukocyte adherence, increased cell permeability, enhanced low-density 
lipoprotein oxidation, platelet activation, cytokine elaboration, and vascular smooth muscle cell 
proliferation and migration. 
In addition, several studies have demonstrated that endothelial dysfunction and cardiovascular 
diseases development are also associated with an increased vascular oxidative stress and an up- 
regulation of the local angiotensin system. Angiotensin II (Ang II) contributes to the 
pathophysiology of atherosclerosis and vascular diseases not only via its role in hypertension but 
also via its direct effects on vascular cell growth and migration. Ang II also contributes to the 
development of cardiovascular diseases through the induction of oxidative stress by up-regulating 
NADPH oxidase, the main producer of reactive oxygen species (ROS) in the vascular wall. 
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Diets could play a role in the development of cardiovascular diseases. Indeed, while western diet 
rich in saturated fatty acids has been associated with an increased risk of cardiovascular diseases, 
other diets such as the Mediterranean diet rich in unsaturated fatty acids have been associated with 
a reduced incidence of cardiovascular diseases up to 30 %. Several epidemiological studies and 
clinical trials have shown that dietary intake of fish, fish oil or omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) have beneficial effects against coronary heart disease, stroke, and hypertension. 
Moreover, the dietary consumption of the major n-3 PUFAs, namely eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA), has been related to a reduced risk of cardiovascular disease 
morbidity/mortality. The exact mechanism by which n-3 PUFAs inhibit atherosclerosis is still 
unclear, but it may relate to the modulation of lipid metabolism, decrease in pro-inflammatory 
cytokine production, and inhibition of inflammatory processes. 
It has been demonstrated in endothelial cells that EPA stimulates the endothelial nitric oxide 
synthase (eNOS) activation by inducing its detachment from the inhibitory supportive protein 
caveolin, while DHA stimulates eNOS activity by increasing the interaction between eNOS and 
heat shock protein 90 (HSP-90) which activates PKB/Akt pathway resulting in eNOS 
phosphorylation and activation. In conditions like hypertension or renal failure, n-3 PUFA could 
reduce the increased level of asymmetric circulating dimethylarginine (ADMA, an endogenous 
inhibitor of eNOS) resulting in an increase of eNOS activity. 
Moreover, our research team recently demonstrated that the stimulation of the endothelial function 
by n-3 PUFAs is dependent on both the purity and the ratio of EPA and DHA. Indeed, an optimized 
EPA:DHA 6:1 formulation is a potent stimulator of the endothelial formation of NO, and to a 
lesser extent, of an increased endothelium-dependent hyperpolarisation (EDH) response. The 
induction of the endothelial formation of NO by omega-3 fatty acids is mediated by redox-sensitive 
activation of the Src/PI3-kinase/Akt and MAPKs pathways leading to eNOS activation, which is 
dependent on the ratio and amount of the EPA:DHA in the formulation. 
In humans, a direct vasodilatory effect has been demonstrated following intake of DHA, which 
inhibits the vasoconstrictor response produced by angiotensin and norepinephrine. A large body 
of studies demonstrated that n-3 PUFA are able to reduce systemic blood pressure and a recent 
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meta-analysis confirmed that a consumption of more than 2 g/d of EPA + DHA can reduce systolic 
and diastolic blood pressure in humans. 
The aim of the present study was to determine whether chronic oral intake of the optimized 
EPA:DHA 6:1 formulation is able to prevent the hypertension and endothelial dysfunction induced 
by Ang II in rats. 
Male Wistar rats received by daily gavage 500 mg/kg BW of either corn oil (control) or the 
EPA:DHA 6:1 formulation. After one week, the rats underwent either sham surgery or 
implantation of an osmotic mini-pump infusing 0.4 mg/kg/day of angiotensin II. Systolic blood 
pressure was measured twice weekly using the tail cuff sphingomanometry method. After 4 weeks 
of gavage, the animals were euthanized and the organ was collected. The secondary branch of 
mesenteric artery were used for vascular reactivity studies using a wire myograph, for 
immunofluorescence and fluorescence histochemistry studies on frozen section, and for western 
blot analysis of protein expression. 
The major results of our study show that infusion of Ang II (0.4 mg/kg/day) caused a significant 
increased in systolic blood pressure, which was reaching 194±5.9 mmHg compared to 120±5.6 
mmHg in control rats. Oral intake of EPA:DHA 6:1 (500 mg/kg/day) significantly prevented the 
Ang II-induced hypertension (147±5.9 mmHg), while having no effect on basal systolic blood 
pressure (110±3.9 mmHg). 
The chronic intake of the optimized EPA:DHA 6:1 formulation is associated with significantly 
increased plasmatic presence in omega-3 fatty acids, mainly as EPA, DHA and the intermediate 
elongated metabolite of EPA, the docosapentaenoic acid (DPA), resulting in a decreased omega-
6/omega-3 ratio. The reduction of this ratio have been associated with a shift towards beneficial 
health effects of omega-3, including reduced cardiovascular and cancer risk, whereas increased 
ratios such as the Western diet has been associated with increased prevalence of cardiovascular 
and chronic diseases Vascular reactivity studies in the secondary branch of mesenteric artery 
indicate that Ang II induced an endothelial dysfunction characterized by reduced relaxations in 
response to acetylcholine affecting both the NO- and EDH-mediated component, and increased 
formation of endothelium-derived contractile factors (EDCFs) in response to acetylcholine. The 
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chronic intake of EPA:DHA 6:1 normalized both the NO, EDH and EDCF responses in secondary 
branch of mesenteric artery (Simopoulos 2002). 
To better characterize the molecular mechanisms involved in the protective effects of EPA:DHA 
6:1 intake, we performed quantitative analysis of protein expression in the secondary branch of the 
mesenteric artery by immunofluorescence. 
Firstly, we studied the expression of eNOS, arginase-1, SKCa and Cx37 (EDH component of 
relaxation), and cyclooxygenases (COXs, involved in EDCFs). Compared to the controls, Ang II 
significantly up-regulate the expression of eNOS, arginase 1, COX-1 and COX-2, the inducible 
isoform of COXs, while down-regulating the expression of SKCa and Cx37. The intake of 
EPA:DHA 6:1 also normalized the expression levels of eNOS, arginase 1, SKCa, Cx37, COX-1 
and COX-2. 
As endothelial dysfunction is associated with a vascular oxidative stress, we measured the level of 
oxidative stress in the vascular wall of the secondary branch mesenteric artery using the redox- 
sensitive fluorescent probe dihydroethidium (DHE). Ang II induced a significant increases of DHE 
fluorescence throughout the vascular wall as compared to control rats, which was significantly 
prevented by the EPA:DHA 6:1 intake. As the increased vascular oxidative stress in Ang II-
induced hypertension has been attributed, at least in part, to the up-regulation of NADPH oxidase 
expression through the activation of the Ang II type 1 receptor (AT1R), we then determined that 
expression levels of both AT1R and NADPH oxidase sub-units p22phox and p47phox. Compared to 
control rats, the secondary branch of the mesenteric artery of rats infused with Ang II exhibit a 
significantly increased expression level of AT1R, p22phox and p47phox. The EPA:DHA 6:1 
treatment significantly improves the Ang II-induced vascular oxidative stress, up-regulation of 
AT1R and NADPH oxidase. 
To confirm the results obtained by immunofluorescence in the secondary branch of the mesenteric 
artery, we performed Western blot analysis of the expression levels of eNOS, COX-2, and the 
NADPH oxidase subunit p22phox in the main mesenteric artery. The Ang II group presented a 
significantly increased expression of eNOS, COX-2, and the NADPH oxidase subunit p22phox, that 
was prevented by the chronic oral intake of EPA:DHA 6:1. 
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Altogether, the present findings indicate that chronic intake of the optimized EPA:DHA 6:1 
formulation prevented the development of hypertension and endothelial dysfunction induced by 
the infusion of Ang II in rats. The Ang II-induced endothelial dysfunction is associated to an up-
regulation of the local angiotensin system and an increased vascular oxidative stress. The 
beneficial effect of EPA:DHA 6:1 is mediated by an improvement of both the NO- and the EDH-
mediated relaxations and a reduction of endothelium-dependent contractile response, most likely 
by preventing the oxidative stress induced by the up-regulation of the local angiotensin system. 
 
Résumé 
Les maladies cardiovasculaires représentent la première cause de mortalité dans le monde, que 
cela soit dans les pays développés ou ceux en cours de développement. L’incidence des maladies 
cardiovasculaires est associée à de nombreux facteurs de risques pouvant être non-modifiables 
(âge, sexe, patrimoine génétique …) ou modifiables. Parmi ces derniers, on trouve des facteurs 
liés au style de vie (régime occidental, tabagisme, alcoolisme, sédentarité) ou des pathologies 
pouvant être traitées comme l’hypertension, les dyslipidémies, l’obésité ou les diabètes. De plus, 
de nombreuses études précliniques et cliniques ont montré que les maladies cardiovasculaires sont 
précocement associées à une dysfonction endothéliale. 
L’endothélium, la monocouche cellulaire tapissant l’intérieur des vaisseaux sanguins, est le plus 
grand organe en contact direct avec le flux sanguin. Les cellules endothéliales ont un rôle clé dans 
le maintien du tonus vasculaire et constituent une couche protective exerçant des effets anti-
thrombotiques, principalement grâce à la formation et libération de puissants facteurs 
vasoprotecteurs tels que le monoxyde d’azote (NO). Dans les maladies cardiovasculaires ou au 
cours du vieillissement physiologique, apparait une dysfonction endothéliale caractérisée par une 
diminution de la formation des facteurs protecteurs et une augmentation de la formation des 
facteurs vasoconstricteurs, le tout engendrant un déséquilibre menant au développement accéléré 
des pathologies vasculaires. La dysfonction endothéliale est impliquée dans la formation de lésions 
athéromateuses en favorisant les mécanismes précoces et tardifs du développement de 
l’athérosclérose dont l’augmentation de l’expression des molécules d’adhésion, de la sécrétion de 
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chimiokines, de l’adhésion des leucocytes, de l’oxydation des LDL, de l’activation plaquettaires, 
et de la prolifération et de la migration des cellules musculaires lisses vasculaires. De plus, 
plusieurs études ont montré que la dysfonction endothéliale et le développement des maladies 
cardiovasculaires sont associés à une augmentation du stress oxydant vasculaire et à une 
surexpression du système angiotensine local. L’angiotensine II (Ang II) participe à la 
physiopathologie de l’athérosclérose et des maladies vasculaires non seulement de par son rôle 
dans l’hypertension, mais aussi de par son effet direct sur la prolifération et la migration des 
cellules vasculaires. L’Ang II contribue aussi au développement des maladies cardiovasculaires 
de par l’augmentation du stress oxydant vasculaire induit par la surexpression de la NAPDH 
oxydase, la principale source des espèces réactives de l’oxygène dans la paroi vasculaire. 
L’alimentation peut jouer un rôle dans le développement des maladies cardiovasculaires. Ainsi, 
alors que le régime occidental riche en graisses saturées a été associé à une augmentation du risque 
de maladies cardiovasculaires, d’autres types d’alimentation tels que le régime Méditerranéen 
riche en graisse non-saturées ont montrées une réduction de l’incidence de maladies 
cardiovasculaires allant jusqu’à 30 % de réduction. De nombreuses études épidémiologiques ou 
d’intervention ont montré que la consommation alimentaire de poisson, d’huile de poisson ou 
d’acides gras polyinsaturés omega-3 (n-3 PUFAs) exerçait des effets bénéfiques vis-à-vis de la 
maladie coronarienne, des accidents vasculaires cérébraux et de l’hypertension. De plus, la 
consommation des acides gras n-3 PUFAs majeurs, à savoir l’acide eicosapentaénoïque (EPA) et 
l’acide docosahexaénoïque (DHA), est associée à une réduction de la morbi-mortalité 
cardiovasculaire. Les mécanismes par lesquels les n-3 PUFAs inhibent le développement de 
l’athérosclérose restent à éclaircir, mais pourraient être dû, au moins partiellement, à une 
modulation des métabolites lipidiques, une diminution de la production de cytokines pro-
inflammatoires et une réduction des processus inflammatoires. Il a été montré que dans les cellules 
endothéliales, l’EPA stimule l’activation de la NO synthase endothéliale (eNOS) en induisant sa 
dissociation d’avec la protéine inhibitrice cavèoline, alors que le DHA stimule la formation 
endothéliale de NO en augmentant les interactions entre la eNOS et la protéine chaperonne HSP-
90 qui active la voie PKB/Akt conduisant à la phosphorylation activatrice de la eNOS. Dans les 
situations physiopathologiques comme l’hypertension ou l’insuffisance rénale, les n-3 PUFAs 
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peuvent réduire l’augmentation des niveaux circulants de diméthylarginine (ADMA, un inhibiteur 
endogène de la eNOS), ce qui induit une augmentation de l’activité de la eNOS. 
De plus, notre équipe de recherche a récemment démontré que la stimulation de la fonction 
endothéliale par les n-3 PUFAs dépend à la fois du ratio et du degré de pureté de la formulation en 
EPA et DHA. En effet, la formulation optimisée EPA:DHA 6:1 est un puissant activateur de la 
formation endothéliale de NO, et de façon moindre de l’augmentation de la réponse 
d’hyperpolarisation dépendante de l’endothélium (EDH). L’induction par les n-3 PUFAs de la 
formation endothéliale de NO due à l’activation de la eNOS via les voies de signalisation redox-
sensibles Src/PI3-kinase/Akt et MAPKs, est dépendante du ratio et de la quantité de EPA et DHA 
dans la formulation. Un grand nombre d’études clinique montre que la consommation des n-3 
PUFAs réduit la pression artérielle systolique chez l’homme, et une récente méta-analyses a 
confirmé que la consommation de EPA plus DHA supérieure à 2 g/j pouvait réduire les pressions 
artérielles systolique et diastolique. 
L’objectif de la présente étude est de déterminer si la consommation chronique de la formulation 
optimisée EPA:DHA 6:1 est capable de prévenir l’hypertension et la dysfonction endothéliale 
induites par l’Ang II chez le rat. 
Des rats Wistar males ont reçu quotidiennement par gavage 500 mg/kg soit d’huile de maïs 
(contrôle) soit de la formulation EPA:DHA 6:1. Après une semaine, les rats subissent soit une 
procédure simulée, soit l’implantation d’une mini-pompe osmotique infusant 0,4 mg/kg/j d’Ang 
II. La pression artérielle est mesurée deux fois par semaine pendant l’ensemble de la procédure 
expérimentale à l’aide de la méthode de sphyngomanométrie par brassard caudal. Après 4 
semaines de gavage, les animaux sont euthanasiés et les organes sont prélevés. Les branches 
secondaires de l’artère mésentérique sont utilisées pour l’étude de la réactivité vasculaire à l’aide 
d’un myographe à fil, pour des études en immunofluorescence et histochimie fluorescente sur 
coupes congelées, et pour des analyses en Western blot de l’expression de protéines. 
Les principaux résultats de notre étude indiquent que l’infusion d’Ang II (0,4 mg/kg/j) à des rats 
induit une augmentation significative de la pression artérielle systolique, qui atteint 194±5,9 
mmHg par rapport au 120±5,6 mmHg chez les rats contrôles. La consommation orale de 
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EPA:DHA 6:1 (500 mg/kg/j) prévient significativement l’hypertension induite par l’Ang II 
(147±5,9 mmHg) mais n’a aucun effet sur la tension artérielle normale (110±3,9 mmHg). 
Les études de réactivité vasculaire dans les branches secondaires de l’artère mésentérique montrent 
que l’Ang II induit une dysfonction endothéliale caractérisée à la fois par une diminution des 
relaxations en réponse à l’acétylcholine affectant les composantes NO et EDH de la relaxation, et 
par une augmentation de la formation des facteurs constricteurs dérivés de l’endothélium (EDCFs) 
en réponse à l’acétylcholine. La consommation chronique de EPA:DHA 6:1 normalise les réponses 
NO, EDH et EDCFs dans les branches secondaires de l’artère mésentérique. 
Afin de mieux caractériser les mécanismes moléculaires impliqués dans l’effet protecteur de 
EPA:DHA 6:1, des analyses quantitatives des niveaux d’expression de protéines ont été effectués 
dans les branches secondaires de l’artère mésentérique par immunofluorescence sur coupes 
congelées. 
Dans un premier temps, nous avons étudié l’expression de la eNOS et de l’arginase 1 (composante 
NO de la relaxation), de SKCa et Cx37 (composante EDH de la relaxation), et de cyclooxygénases 
(COXs, impliquées dans les réponse EDCFs). Par rapport aux animaux contrôles, l’Ang II induit 
une augmentation significative de l’expression de la eNOS, d’arginase 1, et de COX-1 et COX-2, 
la forme inductible des COXs, et une diminution significative de l’expression de SKCa et Cx37. La 
prise chronique de EPA:DHA 6:1 prévient significativement les effets de l’Ang II sur l’expression 
des protéines cibles. 
Comme la dysfonction endothéliale est associée à un stress oxydant vasculaire, nous avons évalué 
le niveau de stress oxydant dans les branches secondaire d’artère mésentérique à l’aide de la sonde 
fluorescente redox-sensible dihydroethidium (DHE). L’Ang II induit une augmentation 
significative de la fluorescence dans l’ensemble de la paroi vasculaire en comparaison des rats 
contrôles, qui est significativement prévenue par la prise chronique de EPA:DHA 6:1. Du fait que 
l’augmentation de stress oxydant dans l’hypertension induite par l’Ang II est due, du moins 
partiellement, à une surexpression de la NAPDH oxydase liée à l’activation du récepteur de 
l’angiotensine II de type 1 (AT1R), les niveaux d’expression d’AT1R et des sous-unités p22phox et 
p47phox de la NADPH oxydase ont été déterminés. En comparaison des branches secondaires 
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d’artère mésentérique de rat contrôles, les rats recevant l’Ang II montrent une augmentation 
significative des niveaux d’expression d’AT1R, p22phox et p47phox. Le traitement avec EPA:DHA 
6:1 prévient significativement cette augmentation de stress oxydant vasculaire et de l’expression 
d’AT1R et des deux sous-unités de la NADPH oxydase. 
Afin de confirmer ces résultats obtenus par immunofluorescence et histochimie fluorescente sur 
les branches secondaires d’artère mésentérique, l’analyse par Western blot de l’expression des 
protéines eNOS, COX-2, et la sous-unité p22phox de la NADPH oxydase a été réalisée dans l’artère 
mésentérique principale. L’Ang II induit une augmentation significative de l’expression de eNOS, 
COX-2, et p22phox, et cette surexpression est significativement prévenue par la prise de EPA:DHA 
6:1. 
L’ensemble des résultats obtenus lors de la présente étude indique que la prise chronique de la 
formulation optimisée EPA:DHA 6:1 prévient le développement de l’hypertension et de la 
dysfonction endothéliale induites par l’infusion d’Ang II chez le rat. La dysfonction endothéliale 
induite par l’Ang II est associée à une régulation positive du système angiotensine local et une 
augmentation du stress oxydant vasculaire. Les effets bénéfique de la consommation chronique de 
EPA:DHA 6:1 impliquent une amélioration des composantes de relaxations NO et EDH, et à une 
diminution des réponses contractiles dépendantes de l’endothélium, probablement via la 
prévention du stress oxydant vasculaire induit par la régulation positive du système angiotensine 
local. 
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1 Chapter 1 
Physiology of the endothelium 
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1.1 Cardiovascular diseases 
    Cardiovascular diseases are a group of several pathologies including coronary heart 
diseases (CHD) such as myocardial infarction, cerebrovascular diseases (stroke), hypertension, 
peripheral artery diseases, rheumatic heart diseases, congenital heart diseases and heart failure 
(Cheng, Austin et al. 2002). Cardiovascular diseases are the leading cause of mortality and 
morbidity worldwide, with an estimated 17 million annual deaths (WHO 2011) (Towfighi and 
Saver 2011). Amongst cardiovascular diseases, CHD accounts for 7.2 million deaths and 5.7 
million are due to stroke (Lloyd-Jones, Adams et al. 2009). It is now well established that 
endothelial dysfunction is an early hallmark of major cardiovascular and other diseases (Figure 1), 
which is thought to contribute to the initiation and the development of these diseases (Austin, Lentz 
et al. 2004).   
Figure 1. Endothelial dysfunction: A hallmark of major cardiovascular and other related diseases. 
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1.2 Vascular endothelium  
All blood vessels including arteries, arterioles, capillaries, veins and venules are the part of 
the circulatory system. The wall of the blood vessels can be divided into three distinguished layers 
which are the intima, the media and the adventitia  (Pugsley and Tabrizchi 2000) (Figure 2). The 
intima (tunica interna/intima) is the innermost monocellular layer called endothelium which is 
supported by connective tissue and the internal elastic lamina (Krstic 2013). The endothelium is 
located at the interface between the blood flow and the vessel wall. The media (tunica media) is 
mainly buildup of smooth muscle cells, collagen fibers and elastic lamina. (Severs and Robenek 
1992). 
The adventitia (tunica externa or tunica adventitia) is the outermost layer comprising of 
collagen, elastin, fibroblasts, macrophages, vasa vasorum, nerve endings and fibers for the 
protection of the blood vessels (Mulvany 1990). The importance of each layer depends on the size 
and location of the arteries. In large conducting arteries, a high number of elastic fibers are present 
in the media. Muscular arteries contain more smooth muscles cells while only few smooth muscle 
cells along the internal elastic lamina are found in arterioles. Capillaries only contain endothelial 
cell and the basement membrane with connective tissues (Pais, Meiselman et al. 2010). 
Endothelial cells line the whole circulatory system starting from large arteries arising from 
the heart to the capillaries and veins. They regulate the flow of nutrient substances and blood cells 
(Mangge, Becker et al. 2014) and act as a selective barrier between the lumen of blood vessel and 
surrounding tissues (Galvão, Araújo et al. 2006). Covering a largest surface area, the endothelium 
plays an important role in the regulation of blood flow and is a chief regulator of body homeostasis 
through the synthesis and secretion of various active molecules, including vasodilatating factors 
and vasoconstricting factors finely controlling vascular tone. Endothelial cells also regulate 
smooth muscle cells (SMC) proliferation, exchanges of molecules between the plasma and the 
interstitial fluid. They also play a vital role in the balance between pro- and anticoagulant 
mechanisms and in immunity (Klein 2013). 
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Figure 2. Structure of the blood vessel (adapted from Boston University School of Public Health). 
1.3  Endothelial regulation of vascular tone 
The vascular endothelium plays a major role in the regulation of vascular tone through a 
variety of mechanisms. Several mediators which can modify vascular tone are derived from the 
endothelium (Schalkwijk and Stehouwer 2005; Klein 2013). In 1980, Furchgott and Zawadzki 
demonstrated the phenomenon of endothelium-dependent arterial relaxation. Acetyle choline 
induces relaxation in arterial rings by releasing endothelium-derived relaxing factor (EDRF) which 
stimulates soluble guanylyl cyclase responsible for the conversion of GTP to cyclic GMP. Later 
on, EDRF was identified as the radical gas nitric oxide (NO) (Arnal, Dinh-Xuan et al. 1999). NO 
diffuses from the endothelium to the underlying smooth muscle where it activates soluble guanylyl 
cyclase to cause a rise in intracellular cyclic GMP and relaxation of the vessel wall (Gryglewski, 
Palmer et al. 1986; Rubanyi and Vanhoutte 1986). 
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The endothelium has the capacity to regulate the local vascular homeostasis by maintaining 
the balance between vasodilation and vasoconstriction, by controlling vascular smooth muscle cell 
(VSMC) proliferation and migration, and by acting on thrombosis and fibrinolysis via the release 
of various factors (Davignon and Ganz 2004). Imbalance of these different mechanisms promotes 
endothelial dysfunction, which may lead to serious cardiovascular diseases such as hypertension, 
a major CVD risk factors. 
In response to physical and chemical stimuli such as changes in pressure, shear stress, and 
pH as well as to substances released by autonomic and sensory nerves and circulating hormones, 
autacoids, and cytokines, the vascular endothelium synthesizes relaxing and contractile factors 
responsible for the modulation of VSMC tone. Relaxation factors include nitric oxide (NO), 
prostacyclin (PGI2), endothelium-derived hyperpolarization (EDH), and contractile factors 
includes thromboxane A2, isoprostanes, superoxide anions (ROS), endothelin-1, and angiotensin-
II factors (Figure 3) (Mombouli and Vanhoutte 1999; Feletou and Vanhoutte 2006). 
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Figure 3. Endothelium-dependent release of vasocontracting and vasorelaxing factors. 
NO, nitric oxide; PGI2, prostacyclin; EDHF, endothelium-derived hyperpolarizing factor; A-II, angiotensin II; ET, 
endothelin; TxA2/PGH2, thromboxaneA2/prostaglandin H2O2, hydrogen peroxide (Abeywardena and Head 2001).
               
1.3.1 The endothelium-derived vasorelaxing factors 
1.3.1.1             Nitric oxide (NO) 
NO is a key cellular signaling molecule involved in a number of physiological and 
pathological processes. In the beginning, it was identified as a factor capable of activating soluble 
guanylyl cyclase responsible for the relaxation of vascular smooth muscle cells (Katsuki, Arnold 
et al. 1977). In 1980, Furchgott and Zawadski  revealed that the endothelium causes vasorelaxation 
by the production of endothelium-derived relaxing factor (EDRF) which was later identified as 
NO (Furchgott and Zawadzki 1980; Palmer, Ferrige et al. 1987; Palmer, Ashton et al. 1988; Palmer 
and Moncada 1989). Besides its role in regulation of vascular tone, NO inhibits leukocytes 
adhesion, platelet aggregation, and has anti-apoptotic and antithrombotic effects. Moreover, NO 
is an important factor of endothelium viability, longevity and cardiovascular health (Morello, 
Perino et al. 2009). 
vasorelexants vasoconstrictors
•NO
•PGF2
•EDHF
•Ang-II
•ET
•TxA2/PGH2
•O°2/Isoprostane
•Hydroxy fatty acids
Relaxation VascularSmooth muscle Contraction
Endothelium
 
 
- 26 - 
 
 The endothelium-derived NO is produced by the endothelial NO synthase (eNOS) from 
L-arginine and plays a critical role in normal vascular biology and pathophysiology (Cai and 
Harrison 2000) (Figure 4).  
 
 
Figure 4. NO generation from L-Arginine and its functional properties (Ghalayini 2004) 
 
There are three different isoforms of NO synthase; the neuronal NOS (NOS1 or nNOS), the 
inducible NOS (NOS2 or iNOS) and the endothelial NOS (NOS3 or eNOS)(Weiming, Liu et al. 
2002).  iNOS is an inducible isoform whereas  nNOS and eNOS are being consititutively expressed 
(Mombouli and Vanhoutte 1999; Stuehr 1999). Under normal conditions, the majority of eNOS is 
bound to the protein caveolin-1, which inactivates eNOS, and this complex is located in micro 
domains in the cell membrane named caveolae (Michel, Feron et al. 1997; Bucci, Gratton et al. 
2000). eNOS can be activated by Ca2+ dependent and independent pathways. eNOS can be 
activated by substituting caveolin-1 by Ca2+/CaM in response to Ca2+-mobilizing agonists. When 
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intracellular Ca2+ levels increase, calmodulin detaches eNOS from caveolin-1 thus permitting the 
enzyme to become active. Furthermore, eNOS has been shown to be regulated by the interaction 
with positive and negative protein modulators such as heat shock protein 90 (Ju, Zou et al. 1997; 
Garcia-Cardena, Fan et al. 1998; Pritchard, Ackerman et al. 2001) (Figure 5). 
 
 
 
Figure 5. Nitric oxide synthesis pathway in the endothelial cell and its actions in the vascular smooth muscle 
cell. 
ACh, acetylcholine; BK, bradykinin; ADP, adenosine diphosphate; 5-HT, serotonin; VEGF, vascular endothelial 
growth factor; PDGF, platelet-derived growth factor; Src, Sarcoma-family kinases; PI3/kinase, phosphoinositide 3-
kinase; Akt, Protein kinase B; Ca2+ / CaM, calcium calmodulin; L-Arg, L-arginine; eNOS, endothelial Nitric Oxide 
Synthase; NO, nitric oxide; sGC, soluble guanylyl cyclase; GTP, Guanosine 5'-Triphosphate; cGMP, cyclic Guanosine 
3'-5' monophosphate
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NO freely diffuses to the underlying VSMC where it activates the soluble guanylyl cyclase 
converting GTP into cyclic guanosine 3’-5’monophosphate (cGMP), which leads to vascular 
smooth muscle cells relaxation. 
In addition to vasorelaxation, NO exerts several vasoprotective and anti-atherogenic effects 
including inhibition of platelets aggregation, monocyte adhesion, vascular smooth muscle cell 
migration and proliferation, oxidation of LDL, and of the expression of pro-inflammatory and pro-
atherothrombotic mediators such as monocyte chemoattractant protein-1 (MCP-1), adhesion 
molecules and tissue factor (Tsao, Buitrago et al. 1996; Dimmeler, Haendeler et al. 1997; Hermann, 
Zeiher et al. 1997). (Figure 6) 
 
Figure 6. The pleiotropic effects of NO. 
VCAM-1; Vascular cell adhesion molecule-1, MCP-1; Monocyte chemoattractant protein-1, LDL; Low density 
lipoproteins. 
 
 
- 29 - 
 
 
eNOS can also be regulated in endothelial cells at a post-translational level primarily 
through multisite phosphorylations and protein/protein interactions. Residues Ser1177 and Ser 615 
are the activation sites and the residues Thr495 and Ser114 are the inhibition sites on eNOS 
(Dimmeler, Haendeler et al. 1997; Bohm, Ahlborg et al. 2002; Bauer, Fulton et al. 2003; Fleming 
2010) (Figure 7). In response to several physiological stimuli, phosphorylation of eNOS across key 
regulatory sites plays an important a role in the regulation of the enzymatic activity (Ju, Zou et al. 
1997; Newby, Hess et al. 2012). Phosphorylation of eNOS at Ser1177 is associated with an 
increased enzyme activity (Gallis, Corthals et al. 1999; McCabe, Fulton et al. 2000). Akt, one of 
the major regulatory targets of PI3-kinase, has been shown to directly phosphorylate eNOS at 
Ser117 and activate the enzyme in response to vascular endothelial growth factor (VEGF), 
sphingosine-1-phosphate, and estrogen (Dimmeler, Haendeler et al. 1997; Fulton, Gratton et al. 
1999). Furthermore, eNOS can be also activated by phosphorylation on Ser1177 by AMP-activated 
protein kinase, protein kinase A (PKA), and protein kinase G (PKG) (Busse, Edwards et al. 2002; 
Flemming and Wingender 2010). 
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Figure 7. The activation and inhibition sites of eNOS. 
Green arrows for activation, red arrows for inhibition, black arrow for no direct effect on enzyme activity. The 
numbers refer to the human sequence (Fleming 2010). 
 
 
There are various assumed phosphorylation sites, but the most extensively studied eNOS residues, 
are serine residue in the reductase domain (human eNOS sequence: Ser1177; bovine sequence 
Ser1179), which positively regulates NO production, and a threonine residue within the CaM-
binding domain (human eNOS sequence: Thr495; bovine sequence Thr497) (Boo, Hwang et al. 
2002). Ischemia-reperfusion injury is another eNOS regulator which leads to the eNOS 
phosphorylation at Ser1177 and Ser 633 through the activation of PKA pathway (Li, Yang et al. 
2010). Furthermore, there are numerous kinases reported to be involved in the phosphorylation of 
eNOS following cell activation by different stimuli such as shear stress, vascular endothelial 
growth factor (Butt, Bernhardt et al. 2000), hypoxia (Michell, Griffiths et al. 1999; Chen, Liu et al. 
2008), including extracellular signal-regulated kinase 1/2 which alters eNOS protein expression 
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and activity (Ramasamy, Parthasarathy et al. 1998). eNOS can be phosphorylated on serine, 
tyrosine, and threonine residues leading to eNOS activation or inactivation (Figure 8).  
 
 
Figure 8. Regulation of eNOS activity. 
(1) At rest, the eNOS is coupled to cav-1 (caveolin-1, a structural protein of caveolae) that decreases its activity. (2) 
eNOS is constitutively phosphorylated at Thr 495 preventing its activation by the Ca2+/CaM. (3) eNOS may be 
inhibited in response to oxidative stress by tyrosine phosphorylation by PYK2 (proline-rich tyrosine kinase). (4) eNOS 
can be activated by both Ca2+/CaM (calcium / calmodulin) and phosphorylation of Ser1177. Hsp90 (heat shock protein) 
facilitates the recruitment of Akt responsible for the phosphorylation of eNOS (Fleming 2010). 
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1.3.1.2 Endothelium-derived hyperpolarization (EDH) 
EDH is defined as a hyperpolarization of endothelial origin that is transmitted to the 
vascular smooth muscle leading to its relaxation. The EDH was formerly known as the 
Endothelium-Derived Hyperpolarizing Factor (EDHF). Beside NO and prostacyclin, the EDH 
mediated component of relaxation plays a major role in endothelium-dependent relaxation in most 
of the medium to small calibre resistance arteries, small arteries and arterioles such as second and 
third-branch mesenteric artery as well as in coronary arteries (Feletou and Vanhoutte 1996; 
Shimokawa, Yasutake et al. 1996). The role of the EDH component of relaxation is more important 
in resistance blood vessels as compare to that of NO and prostacyclin, including in humans 
(Nakashima, Mombouli et al. 1993; Shimokawa, Yasutake et al. 1996). 
The EDH component of the relaxation is evaluated in the presence of the combination of inhibitors 
of eNOS like L-NAME and of COXs like indomethacin (Gerber, Anwar et al. 1998). In the EDH 
mediated response, SKCa and IKCa are activated so that potassium ions move from the intracellular 
compartment to the extracellular space of endothelial cells, which leads to their hyperpolarization 
(Figure 9). This higher concentrations of potassium ions in the extracellular space can activate 
inwardly rectifying K+ (KIR) channels and Na+/K+-ATPase to cause potassium ions efflux from 
VSMC leading to hyperpolarization and hence, relaxation (Edwards, Dora et al. 1998; Félétou and 
Vanhoutte 2006). In 1998, Edwards et al reported that hyperpolarization can also be transferred 
from endothelial cells to VSMC via myo-endothelial gap junctions. Myo-endothelial gap junctions 
are intracellular channels which can transfer signals from the endothelial cells to the underling 
vascular smooth muscle cells (Sandoo, van Zanten et al. 2010). Hyperpolarization of VSMC leads 
to the reduction in cytosolic calcium concentration following closure of voltage-activated calcium 
channels leading to relaxation. Endothelial hyperpolarization can also be mediated by hydrogen 
peroxide (H2O2) (Matoba, Shimokawa et al. 2002) or arachidonic acid-derived metabolites 
including epoxyeicosatrienoic acids (Quilley and McGiff 2000). 
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Figure 9. Hypothesis describing the endothelium-derived hyperpolarizing pathway. 
AA, arachidonic acid; ACh, acetylcholine, [Ca2+]i, intracellular calcium concentration; CYP, cytochrome P450 
epoxygenase; EC, endothelial cell; EETs, epoxyeicosatrienoic acids; ER, endoplasmic reticulum; GPCR, G protein-
coupled receptor; BKCa, large conductance Ca2+-activated K+ channel; SKCa, small-conductance Ca2+-activated K+ 
channel subtype 3; IKCa, intermediate-conductance Ca2+ -activated K+ channel; Kir, inwardly rectifying K+ channel; 
meGJ, myo-endothelial gap-junction; RyR, ryanodine receptor; SR, sarcoplasmic reticulum; VDCC, voltage-
dependent Ca2+ channel; VSMC, vascular smooth muscle cell (Grgic, Kaistha et al. 2009). 
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1.3.1.3 Prostacyclin 
Prostacyclin (PGI2) is the major product of cyclooxygenase (COX) catalyzed metabolism 
of arachidonic acid in the endothelium (Cheng, Austin et al. 2002). Prostacyclin is produced from 
prostaglandin under the action of the enzyme prostacyclin synthase (Dogne, de Leval et al. 2004). 
PGI2, PGG2 and PGH2 are major products of vascular cyclooxygenase (COX). There are two 
isoforms of COX encoded by two separate genes. COX-1 is constitutively expressed and is present 
in many tissues, including endothelial cells (Gryglewski, Uracz et al. 2002). COX-2 is not 
constitutively expressed, but can be induced rapidly and transiently in many cells, including 
vascular endothelial cells and smooth muscle cells, under the effect of physical stimuli and pro-
inflammatory agents. PGI2 stimulates smooth muscle relaxation by stimulating adenylyl cyclase 
and formation of cyclic adenosine -3', 5'- monophosphate (cAMP) that activates protein kinase A, 
which reduces intracellular Ca2+ by decreasing Ca2+ release from the endoplasmic reticulum and 
by stimulating its uptake by it. The vasodilator activity of PGI2 is determined by the expression of 
specific receptors which are prostaglandin I2 receptors of the G-protein coupled receptor family in 
vascular smooth muscle cells. PGI2 is a potent vasodilator, and an effective endogenous inhibitor 
of platelet aggregation (Coleman, Smith et al. 1994). In addition, PGI2 facilitates the release of NO 
by endothelial cells (Shimokawa, Flavahan et al. 1988) and in turn, the action of PGI2 in vascular 
smooth muscle cells and platelets is potentiated by NO (Delpy, Coste et al. 1996). PGI2 synthase 
preferentially couples with COX-2 rather than COX-1 in coexpression systems  (Figure 10) (Ueno, 
Takegoshi et al. 2005). 
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Figure 10. Production and action of prostaglandins (Araujo, Soeiro et al. 2005). 
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1.3.2       The endothelium-derived vasocontracting factors 
1.3.2.1 Angiotensin II 
The octapeptide Angiotensin II (Ang II) is a potent vasoconstrictor hormone of the renin-
angiotensin system (RAS) that is formed following the conversion of Ang I into Ang II by 
Angiotensin I Converting Enzyme (ACE) (Baker, Chernin et al. 1990). Angiotensin II (Ang II) is 
a multifunctional peptide hormone that regulates blood pressure (BP), plasma volume, as well as 
cardiac, renal and neuronal function, and controls thirst responses. This peptide is of central 
importance in hypertension and myocardial remodeling, and is the main effector of the renin-
angiotensin system (RAS) (Weber and Brilla 1991). Taken as a whole, the RAS is involved in 
different cardiovascular pathologies such as left ventricular hypertrophy, post-infarct remodeling, 
or neointima formation (Li, McTiernan et al. 2000). The classical effects of Ang II on its target 
organs are mostly mediated by two membrane receptors, the Ang II type 1 receptors (AT1R) and 
type 2 receptors (AT2R), which mediate tissue-specific functions (Horiuchi, Akishita et al. 1999). 
AT1R and AT2R are a G-protein coupled receptors involved in the regulation of vascular cell 
proliferation and cell death (Kaschina and Unger 2003). AT1R are expressed in all organs, 
including heart, kidney, liver, adrenal glands, brain, lung and in all cells of the cardiovascular 
system, namely endothelial cells, smooth muscle cells, fibroblasts, monocytes, macrophages and 
cardiac myocytes and, thus, is important in cardiovascular pathobiology. While AT2R is highly 
expressed in fetal heart and fetal aorta, lung and liver (Dasgupta and Zhang 2011), AT2R 
expression declines fast after birth, but can be induced later in adult life under pathological 
conditions (Figure 11).  
The acute vasoconstrictor function of Ang II is primarily mediated through AT1R by 
classical G-protein-dependent signaling mechanisms. Depending on cell types, Ang II activates 
AT1R that can in turn activate at least four different effector, namely voltage-gated Ca2+ channels, 
phospholipase C, phospholipase D and phospholipase A-2 (PLA-2) and can inhibit adenylyl 
cyclase (Greco 2007). In addition, Ang II stimulation of AT1R activates the extracellular-signal-
regulated kinase (ERK) cascade, platelet-derived growth factor, epidermal growth factor receptor 
(EGFR), insulin receptor pathways and non-receptor tyrosine kinases belonging to the c-Src family, 
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proline-rich tyrosine kinase 2, focal adhesion kinase and janus kinases (JAKs) (Berry, Touyz et al. 
2001). 
Unlike AT1R, the AT2R contributes to the maintenance of blood pressure by controlling the 
vascular tone through vasodilatation (Dasgupta and Zhang 2011). AT2R stimulation by Ang II 
leads to an increase in cGMP levels through a mechanism involving bradykinin B2 receptor, 
causing endothelial formation of NO (Abadir, Periasamy et al. 2006). Although AT2R expression 
decreases after birth, it can increase again in some pathophysiological conditions. Stimulation of de 
novo AT2R expression may inhibit neointima formation, cell proliferation, and inflammation in 
vascular injury, myocardial infarction and ischemic diseases, suggesting its protective role (Ichiki, 
Takeda et al. 2001). 
  
Figure 11. Summary of acute and chronic stimulation of angiotensin II receptors (Dasgupta and Zhang 2011). 
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1.3.2.2 Endothelin-1 
Endothelin (ET)-1 is a potent vasoconstrictor peptide originally isolated from endothelial 
cells. There are three structurally different ET isoforms (i.e. ET-1, ET-2, ET-3) as well as a 
vasoactive intestinal constrictor (Böhm and Pernow 2007). Amongst the three ET isopeptides, the 
21-amino acid peptide ET-1 is regarded as the most prominent isoform in the cardiovascular 
system, accounting for the majority of pathological effects exerted by ETs (Barton, Traupe et al. 
2003). 
Under physiological conditions, ET-1 is produced in small amounts mainly in endothelial cells, 
primarily acting as an autocrine/paracrine mediator (Pernow, Shemyakin et al. 2012). Under 
pathophysiological conditions, however, the production is stimulated in a large number of different 
cell types, including endothelial cells, vascular smooth muscle cells, cardiac myocytes, and 
inflammatory cells such as macrophages and leukocytes (Grieve, Byrne et al. 2004). 
The biological effects of ET-1 are transduced by two distinguishable receptor subtypes, 
ETA and ETB receptors, respectively (Hunley and Kon 2001). In the vasculature, the ETA receptor 
is mainly located on vascular smooth muscle cells and mediates potent vasoconstriction. ET-1 may 
also induce indirect vasoconstrictor effects due to the generation of endothelium-derived 
thromboxane A2 (Marasciulo, Montagnani et al. 2006). The ETB receptor is primarily located on 
endothelial cells, but may also be present on vascular smooth muscle cells (Schneider, Boesen et 
al. 2007). Stimulation of the endothelial ETB receptor results in release of NO and prostacyclin 
which cause vasodilatation, whereas stimulation of the vascular smooth muscle cell ETB receptor 
results in vasoconstriction (Seo, Oemar et al. 1994). Thus, the net effect produced by ET-1 is 
determined on the receptor localization and the balance between ETA and ETB receptors (Davie, 
Haleen et al. 2002) (Figure 12). 
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Figure 12. The biological effect of endothelin-1 on arteries in physiological and pathophysiological conditions. 
In healthy arteries the production of ET-1 is small and the bioavailability of NO is preserved. In endothelial dysfunction there is 
increased expression of ET-1 in smooth muscle cells and macrophages (MØ). Both the ETA and the ETB receptor on smooth muscle 
cells may mediate formation of superoxide (O2−). Collectively the balance of effects is shifted towards more vasoconstriction, 
inflammation and oxidative stress in endothelial dysfunction (Böhm and Pernow 2007). 
 
 
- 40 - 
 
1.3.2.3 Thromboxane A2 & Prostacyclin I2 (TxA2 & PGI2) 
The prostanoids prostacyclin (PGI2) and thromboxane A2 (TXA2) play an essential role in 
the maintenance of vascular homeostasis. PGI2 is a vasodilator and an inhibitor of platelet 
aggregation, whereas TXA2 is a vasoconstrictor and a promoter of platelet aggregation (Gamble, 
James et al. 2001). 
PGI2 and TXA2 are products of arachidonic acid (AA) metabolism by cyclooxygenase (COX), 
followed by metabolism of the COX product, PGH2, by the terminal synthase enzymes, 
prostacyclin or TX synthase, respectively (Ruan, So et al. 2011). Two isoforms of COX have been 
identified: COX-1 is expressed constitutively in most cell types, whereas COX-2 is induced by 
inflammatory stimuli such as bacterial endotoxin and cytokines (Caughey, Cleland et al. 2001). It 
is considered that PGI2 is the main prostanoid synthesized by vascular endothelium and TXA2 is 
the main prostanoid produced by platelets (Smith, Borgeat et al. 1991). However, the endothelium 
has been reported to synthesize TXA2 in addition to PGI2, and both COXs isoforms have been 
observed, with only COX-1 being detectable in unstimulated cells (Morteau 2001). Endothelial 
COX-2 can be up-regulated in vitro by inflammatory stimuli and shear stress (Brown and DuBois 
2005). Because the balance between PGI2 and TXA2 production is central in the maintenance of 
vascular tone and platelet aggregation (Konturek and Pawlik 1986; Sobrino, Oviedo et al. 2010), 
determination of the roles of endothelial COX isozymes, particularly with regard to the contribution 
of COX-2 in the regulation of prostanoids biosynthesis by the endothelium, is important (Figure 
13) (Caughey, Cleland et al. 2001).  
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Figure 13. Prostanoids biosynthesis and response pathways (Zhang, Gong et al. 2010). 
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1.3.2.4 Oxidative stress and reactive oxygen species (ROS) 
Reactive oxygen species (ROS) are recognized as important signaling molecules in the 
cardiovascular system and are released by vascular cells during pathophysiological conditions like 
hypertension, diabetes mellitus, atherosclerosis and in acute and chronic inflammatory diseases 
(Eisenberg and Ghigliotti 1999). NO, (O2●-) the hydroxyl radical (·OH), H2O2, and peroxynitrite 
(ONOO−·) are produced in the vasculature under both normal and stress conditions such as 
inflammation or injury. Superoxide anions (O2●-) can be generated by different enzymes (e.g., 
NADPH oxidase, xanthine oxidase, cyclooxygenases, NO synthases, cytochrome P450 
monooxygenases, and enzymes of the mitochondrial respiratory chain) in virtually all cell types, 
including vascular smooth muscle and endothelial cells (Félétou and Vanhoutte 2006). ROS and in 
particular superoxide anions can also act directly or indirectly as potent contracting agents via the 
reduction of the NO bioavailability or by activating COXS in vascular smooth muscle cells (Hibino, 
Okumura et al. 1999), leading to attenuated endothelium-dependent relaxations (Aubin, Carrier et 
al. 2006; Liu, You et al. 2007). Moreover, ROS can also impair EDH-mediated endothelium-
dependent relaxations through the reduction of calcium-activated potassium channels activity 
(Kusama, Kajikuri et al. 2005) or by modifying the transmission of the hyperpolarization from 
endothelial cells to the underlying smooth muscle cells through myoendothelial gap junctions 
(Griffith, Chaytor et al. 2005). Several studies have shown the beneficial effects of antioxidants on 
the deleterious effect of oxidative stress on the endothelial function (Kanani, Sinkey et al. 1999; 
Aubin, Carrier et al. 2006; Liu, You et al. 2007).  
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1.4 Endothelial dysfunction  
Endothelial dysfunction is a broad term which implies dysregulation of endothelial cell 
functions, including impairment of the barrier functions of endothelial cells, vasodilation, 
disturbances in proliferative capacities, migratory as well as tube formation properties, angiogenic 
properties, attenuation of synthetic function, and deterrence of white blood cells from adhesion and 
diapedesis. Several factors contribute to endothelial dysfunction including smoking, high blood 
pressure, diabetes, high cholesterol levels, obesity, hyperglycemia, advance glycation end products 
(AGEs), and genetic factors. Endothelial dysfunction has been associated with an impairment of 
endothelium-dependent relaxations involving a reduced bioavailability of NO in major CV diseases 
such as hypertension, atherosclerosis, chronic renal failure, and diabetes (Griendling and 
FitzGerald 2003; Rush, Denniss et al. 2005). The mechanism underlying endothelial dysfunction 
has been linked to increased oxidative stress which is associated with a reduced NO bioavailability 
and the formation of inflammatory mediators such as vascular cell adhesion molecule-1 (VCAM-
1) expression (Figure 14) (Khan, Harrison et al. 1996; Libby 2002). In addition, different enzymes 
have been involved in the arterial oxidative stress involving NADPH oxidases, xanthine oxidases, 
COX-1 and COX-2, cytochrome P450 monooxygenases, enzymes of the mitochondrial respiratory 
chain, and uncoupled eNOS. Superoxide anion can  react with NO to form the radical peroxynitrite 
(Koppenol, Moreno et al. 1992), leading to the oxidation of the eNOS cofactor tetrahydrobiopterin 
(BH4) and the subsequent uncoupling of eNOS, thereby further promoting oxidative stress (Cai and 
Harrison 2000). 
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Figure 14. The effects of vascular endothelial factors on the function of vascular smooth cells in healthy and pathological 
conditions. 
In the healthy endothelium, the eNOS is responsible for most of the vascular NO production. However, eNOS becomes a potential 
ROS generator when in the pathological uncoupled state, due to oxidative stress. ACE, angiotensin-converting enzyme; Ach, 
acetylcholine; AT-I, angiotensin I; AT-II, angiotensin II; AT1, angiotensin 1 receptor; BH4, tetrahydrobiopterin; BK, bradykinin; 
cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; ECE, endothelin converting enzyme; eNOS, 
endothelial nitric oxide synthase; EDHF, endothelium derived hyperpolarizing factor; ETA and ETB, endothelin A and B receptors; 
ET-1, endothelin-1; L-Arg, L-arginine; L-Cit, L-citruline; M, muscarinic receptor; O2-, superoxide anion; ONOO-, peroxynitrite; 
NADPH, nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; NOX, nicotinamide adenine dinucleotide phosphate 
oxidase; PGH2, prostaglandin H2; PGI2, prostaglandin I2; ROS, reactive oxygen species; S1B, serotonin receptor; TP, thromboxane 
prostanoid receptor; TXA2, thromboxane; 5-HT, serotonin; Θ, inhibition; , stimulation. (Park and Park 2015). 
 
 
- 45 - 
 
1.5 Endothelial dysfunction and hypertension 
Hypertension is associated with endothelial dysfunction, where the delicate balance between 
vasodilators and vasoconstrictors produced by the endothelium is disrupted, with disturbance in 
the NO pathway leading to predominance of vasoconstrictors like ET-1, which contribute to high 
blood pressure (Sandoo, Veldhuijzen van Zanten et al. 2010). Even though it is still unclear whether 
endothelial dysfunction is the cause or the consequence of elevated blood pressure (Program 2000), 
it appears to be an essential factor in hypertension. Studies in humans have reported a significant 
impairment of the vasodilator response of small resistance vessels to acetylcholine, but not to 
sodium nitroprusside (SNP), in hypertensive patients (Endemann and Schiffrin 2004). Importantly, 
investigations have indicated a larger incidence of cardiovascular events in hypertensive patients 
with more severe endothelial dysfunction compared to hypertensive patients with less severe 
endothelial dysfunction, and therefore it is suggested as a marker for future cardiovascular events 
in hypertensive patients (Calhoun, Jones et al. 2008). Treatment with angiotensin-converting 
enzyme (ACE) inhibitors has been shown to improve endothelial function (Mancini, Henry et al. 
1996). ACE inhibitors reduce oxidative stress and stimulate bradykinin to help increase NO 
bioavailability (Hornig, Landmesser et al. 2001). Products blocking Ang II type 1 receptor (AT1R), 
known as Ang II receptor blockers (ARBs), are successful primarily in the therapy of hypertension, 
but may also be beneficial in patients with intolerance to angiotensin-converting enzyme (ACE) 
inhibitors for the treatment of several cardiovascular diseases, such as stable coronary heart disease 
and heart failure (Dézsi 2014). Moreover, the renin–angiotensin–aldosterone system (RAAS), as 
well as AT1R and AT2R, play an important role in the regulation of cell proliferation and neoplastic 
progression (Ager, Neo et al. 2008). 
In particular, endothelial dysfunction leading to diminished NO bioavailability impairs 
endothelium-dependent vasodilation in patients with essential hypertension and may also lead to 
premature development of atherosclerosis (Figure 15) (Vallance and Chan 2001). Different 
mechanisms of reduced NO bioavailability have been shown both in hypertensive states and several 
cardiovascular diseases, and endothelial dysfunction is likely to occur prior to vascular dysfunction 
(Cai and Harrison 2000). Thus, the strategies currently used to improve endothelial dysfunction 
may result in the improved outcome for  hypertensive patients (Quyyumi 1998).  
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Figure 15. Mechanisms implicated in essential hypertension-associated endothelial dysfunction.  
(a): In healthy artery endothelium produces vasoprotectors (PGI2, NO and EDH) which induces relaxation in vascular 
smooth muscle cells. (b) In pathological artery, the release and activity of vasoprotectors is decreased while the local 
angiotensin system is activated resulting in the increased production of vasoconstrictors (ROS, EDCFs and ET1) 
which induces contraction in the vascular smooth muscle cells leading to endothelial dysfunction and hypertension. 
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1.5.1 Models of Hypertension 
The Spontaneously Hypertensive Rat (SHR) is the most commonly used model of cardiovascular 
disease, with over 4000 Medline references in the last 10 years. The male SHR is usually used as 
a model of established human hypertension, for example to define hypertension-induced changes 
in signaling mechanisms and to test new antihypertensive drugs. One of the major advantages of 
the SHR is lack of inter-individual variation, with the limitation that the SHR can only model one 
of many possible causes of human hypertension. The SHR is a useful model as compounds that are 
able to lower blood pressure in SHR are likely to also be effective in hypertensive humans (Ching 
2008).  
Different experimental protocols have been described to induce DOCA-salt hypertension in the 
literature, including subcutaneous implantation of DOCA pellets (Churchill, Churchill et al. 1997). 
DOCA administration (synthetic mineralocorticoid derivative), in combination with salt loading in 
the diet, to young adult Wistar rats followed by surgical removal of one kidney is associated with 
hypertension with cardiovascular remodeling, hypertrophy, fibrosis, conduction abnormalities and 
endothelial dysfunction. Similar cardiovascular remodeling occurs in patients with hypertension 
and heart failure but these patients are usually not young, nor on a high salt diet, nor taking salt-
retaining compounds nor functioning with a single kidney (Iyer, Chan et al. 2010). The DOCA–
salt model markedly depressed renin–angiotensin system and hence has been extensively used in 
hypertension research as an angiotensin-independent model (Schenk and McNeill 1992). 
NO synthesis can be blocked by inhibitors such as L-NAME (Nω-nitro-L-arginine methyl ester) and 
nitro-L-arginine (Roche, Cook et al. 1996). Chronic administration of L-NAME increased systolic 
blood pressure and heart weight, and decreased renal function. Chronic administration of L-NAME 
to rats during gestation induces the development of a pre-eclamptic syndrome similar to humans 
(Hropot, Grötsch et al. 1994). The role of reduced NO production in human hypertension is still 
unclear; therefore it is too early to decide whether NO synthase inhibition is an appropriate model. 
However, this model deserves more attention as it is technically easy with low mortality rate 
(Richer, Boulanger et al. 1996). 
Ang II induced hypertension is one of the most widely used pharmacological model of hypertension 
in rats. Blockade of the renin-angiotensin system (RAS) with ACE inhibitors or angiotensin II type 
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1 receptor (AT1R) antagonists has become one of the most successful therapeutic approaches in 
medicine. This has led to the concept of combined RAS blockade. RAS is a complex system which 
plays a major role in the maintenance of hemodynamics by regulation of arterial pressure and water 
and electrolyte balance. Ang II increases the risk of cardiovascular event by increasing arterial 
blood pressure and directly acts on cardiac and renal tissues (Schmieder, Hilgers et al. 2007). It 
induces endothelial dysfunction and stimulates inflammatory, proliferative, fibrotic and thrombotic 
processes in the vasculature, and is a key regulator of vascular remodeling and inflammation. Ang 
II increase vascular tone, constricts smooth muscle cells, regulates vascular cell growth, apoptosis, 
fibrosis, matrix metalloproteinase production and degradation of extracellular matrix (Schiffrin, 
Park et al. 2000; Touyz 2005). These effects are observed often in arterial hypertension and 
atherosclerosis (Kane, Etienne-Selloum et al. 2010). Ang II may also affect blood pressure by its 
effects on kidney, brain and sympathetic nervous system (Reid 1992). 
1.5.2 Excessive Reactive Oxygen Species Production in Hypertension 
ROS play a major role as intracellular signaling molecules to regulate normal biological cellular 
responses (Griendling, Sorescu et al. 2000). In pathological conditions, loss of redox homeostasis 
contributes to vascular oxidative damage (Gao and Mann 2009). Multiple sources of oxidative 
stress have been implicated in the pathogenesis of hypertension-related endothelial dysfunction. 
Recently, evidences have indicated that specific enzymes, the NOX family of NADPH oxidases, 
have an important function in generating ROS in a highly regulated fashion in physiological 
conditions, and that in disease states, hyper activation of NOXs contributes to oxidative stress and 
consequent cardiovascular diseases (Figueira, Barros et al. 2013). Investigations have gone further 
to demonstrate the potential mechanisms controlling two important sources of hypertension-
associated oxidative stress, NADPH oxidase and mitochondria (Montezano and Touyz 2012). 
Taken together with recent reports demonstrating the coordinated formation of reactive oxygen 
species (ROS) from NADPH oxidase and mitochondria in hypertensive states, a model of 
hypertension-induced ROS originating from coordinated mitochondrial sources and NADPH 
oxidase appears to be promising (Dikalov and Ungvari 2013). 
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1.5.2.1 Inflammatory Regulation of Hypertension-Associated Endothelial 
Dysfunction 
Inflammatory mechanisms appear to play a significant role in some types of pulmonary 
hypertension (PH), including monocrotaline-induced PH in rats and pulmonary arterial 
hypertension of various origins in humans, such as connective tissue diseases (Sadoughi, Zhang et 
al. 2011). Inflammation in adipose tissue is associated with impaired endothelial function in obese 
patients. Adipose tissue also plays a major role in regulating metabolism and inflammation through 
the production of both pro-inflammatory and anti-inflammatory adipokines (Fantuzzi 2005).  
Though most investigations relating the process of adipose inflammation to vascular endothelial 
function concentrate on insulin resistance and obesity, recent studies have evaluated the effect of 
perivascular adipose tissue on vascular homeostasis in hypertension. Adipose tissue from 
hypertensive rats applied to thoracic aorta segments failed to suppress phenylephrine-induced 
vasoconstriction, in contrast to adipose tissue from normotensive animals (Baranowska-Kuczko, 
Kozłowska et al. 2016).  
Recent data also define novel roles for elements of both innate and adaptive immune responses in 
regulating endothelial function under hypertensive conditions (Pauletto and Rattazzi 2006). 
Activation of innate immunity’s complement pathway may negatively impact vascular endothelial 
function in hypertension, whereas increased anti-inflammatory interleukin-10 expression from the 
adaptive immune response blunts the adverse effects of angiotensin II–associated hypertension on 
endothelial function (Ferri, Croce et al. 2007). Circulating endothelial progenitor cells (EPCs), 
derived from myeloid pluripotent stem cells that also give rise to mature mononuclear cells, also 
play significant roles in maintaining endothelial homeostasis through their regenerative and repair 
mechanisms (Urbich and Dimmeler 2004). Overall, these newer data suggest that hypertension-
associated vascular endothelial dysfunction relates to local vascular inflammation as well as to 
systemic inflammation (Cottone and Cerasola 2008).  
Animal studies have shown that oxidative stress and renal tubulointerstitial inflammation are 
associated with, and have major roles in, the pathogenesis of hypertension (Vaziri 2008). This 
relation is supported by the observations that increase level of oxidative stress and renal 
tubulointerstitial inflammation increase arterial pressure in animal models (Vaziri and Rodriguez-
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Iturbe 2006). Conversely, hypertension has been shown to cause oxidative stress and inflammation 
in renal and cardiovascular tissues in experimental animals. All together, these observations 
indicate that oxidative stress, inflammation and arterial hypertension participate in a self-
perpetuating cycle which can lead to progressive cardiovascular disease (Brasier, Recinos et al. 
2002)  
1.5.3 Antihypertensive treatments 
In clinical settings today, a variety of antihypertensive medicines are being used alone and in 
combination with other drugs to reach target goal of blood pressure.  
Calcium channel blockers 
Calcium channel blockers inhibits the entrance of calcium ions via voltage-operated calcium 
channel in cells of the heart and blood vessel walls, resulting in lower blood pressure (Epstein and 
Braunwald 1982) and hence are also called calcium antagonists. They relax and dilate blood vessels 
by affecting the smooth muscle cells in the arterial walls.  
Beta-blockers 
The exact mechanisms of action of beta-blockers as anti-hypertensive drugs is still largely 
unknown. The proposed mechanism is that beta-blockers inhibit the effects of the 
sympathetic nervous system on beta-adrenergic receptor of the heart (Parati and Esler 2012). They 
reduce the work of the heart and requirement blood and oxygen. As a result, the heart doesn't have 
to work as hard, which decreases blood pressure. Also, they help to control heart rate and are used 
in the treatment of abnormal heart rhythms that may be too fast or irregular. Beta-blockers are also 
widely used to treat hypertension, although they are no longer a first choice for initial treatment of 
most patients according to current guidelines (Hunt, Abraham et al. 2005).  
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Diuretics  
Diuretics acts on kidneys to remove more sodium and water from the body, which helps to relax 
the blood vessel walls, thereby lowering blood pressure. Moreover, they are combined with other 
blood pressure medicines as they can enhance the effect of the other antihypertensive drugs and 
prevent the fluid retention (Weber, Schiffrin et al. 2014). Thiazide diuretics are recommended as 
the first line of treatment for hypertension and are usually prescribed as one of at least two 
medicines to control hypertension.  
Vasodilators 
Vasodilators are medications that cause dilatation of blood vessels predominantly by the release of 
NO. They act directly on the VSMC in the walls of arteries resulting in vasorelaxation and 
preventing vasoconstriction. As a result, blood flows more easily through arteries.  
ACE inhibitors 
ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor and 
mitogenic. Therefore, they lower arteriolar resistance and increase venous capacity; 
decrease cardiac output, cardiac index, stroke work, and decrease resistance in blood vessels in the 
kidneys; and lead to increased natriuresis.  
Angiotensin II receptor antagonists (AT1R blockers) 
The angiotensin II receptor antagonists (AT1R blockers, ARBs, sartans) are a group 
of antihypertensive drugs that act by blocking the effects of Ang II-mediated via AT1R activation 
in the body, thereby lowering blood pressure. Their structure is similar to Ang II and they bind to 
Ang II receptors as inhibitors. AT1 blockers are widely used drugs for mild to moderate 
hypertension, chronic heart failure, secondary stroke prevention and diabetic nephropathy.  
 
AT1 blockers and ACE inhibitors directly inhibit RAS and are the most effective for the treatment 
of hypertension (Taal and Brenner 2000).   
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1.6 Endothelial Dysfunction and Diabetes  
Diabetes Mellitus (DM) is a major health problem worldwide, associated with morbidity and 
mortality. DM is characterized by persistent elevation of the blood glucose level (Monesi, Baviera 
et al. 2012). There are two types of diabetes: the type 1 diabetes (T1DM), which occurs due to the  
absence of  the formation of insulin, and type 2 diabetes (T2DM), which is characterized by insulin 
insensitivity as a result of insulin resistance usually associated with metabolic syndrome and 
obesity (Figure 16) (Sharma, Bernatchez et al. 2012). Several clinical studies with both types 1 and 
type 2 diabetic patients have shown the presence of an endothelial dysfunction (McVeigh, Brennan 
et al. 1992; Nathan, Lachin et al. 2003). In addition, studies report that endothelial dysfunction 
appears early in the development of DM, which may suggest a role of impaired endothelium-
dependent vasodilatation in the initiation and development of both macro-vascular and micro-
vascular complications of diabetes. Individuals with type I and type II diabetes have evidence of 
both microvascular and macrovascular endothelial dysfunction (Caballero, Arora et al. 1999). 
Endothelial dysfunction can even be evident in healthy individuals with a family history of 
diabetes, suggesting a genetic link (Alvarado Vásquez, Zapata et al. 2007). Patients with diabetes 
often have reduced NO bioavailability which results from increased oxidative stress, and oxidation 
of LDL due to hyperglycaemia (Endemann and Schiffrin 2004). Patients with type 1 diabetes have 
shown improved endothelial function when taking ACE inhibitors, through a reduction in oxidative 
stress, and an increase in NO bioavailability (Heitzer, Schlinzig et al. 2001). 
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Figure 16. Progression of endothelial dysfunction in relation to the progression of insulin resistance (Cosentino and Lüscher 1997). 
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2. Lipids 
 Lipids are defined as small hydrophobic or amphipathic (or amphiphilic) molecules that may 
originate entirely or, in part, through condensations of thioesters and/or isoprene units (Fahy, 
Subramaniam et al. 2005)  
Lipids are a chemically diverse group of substances that are poorly soluble or insoluble in water, 
but soluble in a polar organic solvents such as chloroform, hydrocarbons, alcohols or ethers (Rane 
and Anderson 2008). They are mostly composed of carbon, hydrogen, oxygen and also sometimes 
nitrogen and phosphorous. Triglyceride, phospholipids sterols and waxes are the main types of 
lipids (McDonald 2002). The triglycerides exists in both foods and in the body, and usually serve 
as energy sources and can be stored in the adipose tissue for later use within the body (Turchini, 
Francis et al. 2011) 
The lipid classification system enables categorization of lipids and their properties in a way 
that is compatible with other macromolecular databases. Using this approach, lipids from biological 
tissues are divided into eight categories: fatty acids (Table 1), glycerolipids, glycerophospholipids, 
sphingolipids, saccharolipids, polyketides (derived from condensation of ketoacyl subunits); sterol 
lipids and prenol lipids (derived from condensation of isoprene subunits). Each category contains 
distinct classes and subclasses of molecules (Fahy, Subramaniam et al. 2005).  
Table 1. Structure and taxonomy of fatty acids (Simopoulos 1998) 
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2.1  Saturated fatty acids (SFA) 
SFA only have carbon-carbon single bonds in their chain and these carbons are fully occupied with 
hydrogen atoms, thus forming straight chains giving strength to the structure (Brownstein 1959). 
They are a useful source of energy and also have some important physical properties including 
poorly soluble in water in their undissociated (acidic) form, whereas they are relatively hydrophilic 
as potassium or sodium salts. (Fuhrhop and Endisch 2000). The most prevailing SFA are palmitic 
acid (C16), and stearic acid (C-18), found most commonly in animal products (Table 2). Vegetable 
derivatives of SFA such as palm oil, palm kernel oil, and coconut oil are produced from vegetables 
(Healy, Pfeifer et al. 1994). High consumption of SFA is associated with high LDL levels which 
is an independent risk factors of cardiovascular diseases (CVD) (Siri-Tarino, Sun et al. 2010; 
Colquhoun, Ferreira-Jardim et al. 2011). 
Table 2. Structure of different unbranched fatty acids with a methyl end and a carboxyl (acidic) end (Hagan 
2015). 
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2.2 Monounsaturated fatty acids (MUFA) 
Upon losing one or more pairs of hydrogen atoms from the carbon chain, the fatty acids are called 
unsaturated fatty acids. The fatty acids containing one double bond are MUFA (Figure 17). Some 
common MUFA are palmitoleic acid (16:1 n−7), cis-vaccenic acid (18:1 n−7) and oleic acid 19 
(18:1 n−9). Palmitoleic acid has 16 carbon atoms with the first double bond occurring 7 carbon 
atoms away from the methyl group and 9 carbons from the carboxyl end, which can be lengthened 
to the 18-carbon cis-vaccenic acid. Oleic acid has 18 carbon atoms with the first double bond 
occurring after the ninth carbon atom from the methyl end of fatty acid chain. Vegetable oils such 
as olive oil and canola oil are good sources of MUFA. MUFA consumption is strongly associated 
with a decrease in LDL cholesterol (Corrao, Bagnardi et al. 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Monounsaturated fatty acids MUFAs 
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2.3 Polyunsaturated fatty acids (PUFA) 
PUFA contain more than one double bonds in there chains (Figure 18). According to the 
international nomenclature, the positioning of the first double bond is given by (n-x) notation, 
counting the number of carbon atoms from the methyl end (Keller, Dreyer et al. 1993). For 
example, in omega-3 (n-3) and omega-6 (n-6) fatty acids, the first double bond starts at 3 and 6 
carbons from the methyl end, respectively. Thus α-Linoleic acid symbol 18:3 n-3 identifies a fatty 
acid having 18 carbon atoms and 3 double bonds, the first double bond occurring after the third  
carbon atom from the methyl end of the fatty acid chain, known as the n end (Mateos 2012). 
  
Figure 18. Major Polyunsaturated fatty acids (PUFA). (Nair, Leitch et al. 1997). 
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2.3.1 Trans fatty acids (TFA) 
Trans fatty acids are unsaturated fatty acids of plant origin that have a trans arrangement of the 
carbon atoms adjacent to its double bonds resulting from the hydrogenation process, which gives 
a more rigid molecule close to a saturated fatty acids. The two hydrogen atoms of the carbons 
adjacent to the double bond point to opposite directions, which is different from the double bond 
of cis-configuration in the fatty acids of mammals. Furthermore, the location of the double bond is 
not fix and it may appear anywhere along the molecule, so that many positional isomers may exist. 
In trans fatty acids, angle of the double bond is smaller than the cis-isomeric configuration and 
hence acyl chain is more linear, resulting in a more rigid molecule with different physical properties 
such as greater thermodynamic stability and a higher melting point.  The trans configuration is 
designated by a t-; the number preceding the t- indicates the position of the trans bond acids counted 
from the carboxyl end of the molecule, and c- designates the cis isomers. Consumption of such 
acids is thought to increase the risk of atherosclerosis. 
2.3.2 n-3 polyunsaturated fatty acids (n-3 PUFAs) 
Long-chain polyunsaturated fatty acids with the first double bond at the third position from the 
methyl terminal that are found in plants and some types of fish. n-3 PUFAs are found in short and 
long-chain varieties. The short chain form is alpha-linolenic acid, 18:3 n-3 (ALA) which contains 
18 carbons having 3 double bonds and is considered as essential fatty acids because it can’t be 
synthesized within the body (Sen 2013). The long chain n-3 PUFA includes EPA, DPA 
(docosapentaenoic acid) and DHA, and as compared to ALA, these fatty acids are elongated and 
highly unsaturated; EPA has 20 carbons with 5 double bonds while DPA and DHA has 22 carbons 
with 5 and 6 double bonds, respectively (Figure 19). 
Main vegetal sources of n-3 PUFA include flax seed, camelina seed, perilla and chiaseed oils which 
contain the 18-carbon ALA as the major n-3 PUFA (Turchini, Francis et al. 2011). The carbon-20 
and carbon-22 n-3 PUFA such as EPA and DHA are abundantly found in seafood such as fish and 
shellfish. These fatty acids are also considered as essential fatty acids. Fish such as tuna, sardines, 
salmon, mackerel and herring contains higher concentration of these fatty acids. Shellfish like 
abalone, oyster, mussel and scallop are also good sources of these long chain n-3 PUFA (Su, 
Wiltshire et al. 2004).The National Heart Foundation of Australia recommends the consumption 
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of 500 mg per day of combined DHA and EPA, which is associated with a reduction in the risk of 
coronary heart disease (Colquhoun, Ferreira-Jardim et al. 2011) .  
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Figure 19. Structures of dietary ω 3 and ω 6 polyunsaturated fatty acids. A: C18 ω 3 and ω 6 
PUFA. B: C20–22 ω 3 and ω 6 PUFA (Jump, Depner et al. 2012). 
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2.3.3 n-6 polyunsaturated fatty acids 
Long-chain polyunsaturated fatty acids with the first double bond at the sixth position from the 
methyl terminal that are found in plants and in animal muscles and organ meat. n-6 PUFA has its 
short-chain representative, linoleic acid, which is an essential fatty acid and the most prevalent one 
in western diets. Linoleic acid, is most abundantly found in nature, having high proportion in most 
of the vegetable oils such as sunflower, safflower, corn, soybean and canola oils (Mateos 2012). 
Evening primrose and borage oil are also enriched in linoleic acid. Animal products also serve as 
a major source of n-6 PUFA in the form of arachidonic acid predominantly found in both muscle 
and organ meats (Sinclair 1991).  
2.4 The importance of the ratio of omega-6/omega-3 essential fatty acids 
Western diets are deficient in omega-3 fatty acids, and have excessive amounts of omega-6 fatty 
acids. Excessive amounts of omega-6 polyunsaturated fatty acids (PUFA) and a very high omega-
6/omega-3 ratio promote the pathogenesis of many diseases, including cardiovascular disease, 
cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 PUFA 
(a low omega-6/omega-3 ratio) exert suppressive effects (Simopoulos 2008) (Figure 20). 
Mammalian cells cannot convert omega-6 to omega-3 fatty acids because they lack the converting 
enzyme, Δ3 desaturase. Linoleic acid,  α-Linoleic acid and their long-chain derivatives are 
important components of animal and plant cell membranes (Barceló-Coblijn and Murphy 2009). 
These two classes of essential fatty acids, are metabolically and functionally distinct, and often 
have important opposing physiological functions. An optimal balance of EFA is important for good 
health and normal development (Simopoulos 2006). When humans ingest fish or fish oil, the EPA 
and DHA from the diet partially substitute the omega-6 fatty acids, especially AA, in the 
membranes of probably all cells, but especially in the membranes of platelets, erythrocytes, 
neutrophils, monocytes, and liver cells (Simopoulos 2009). 
AA and EPA are the parent compounds for eicosanoid production. Due to the increased amounts 
of omega-6 fatty acids in the Western diet, the eicosanoid metabolic products from AA, specifically 
prostaglandins, thromboxanes, leukotrienes, hydroxy fatty acids, and lipoxins, are formed in larger 
quantities than those formed from omega-3 fatty acids, specifically EPA (Simopoulos 2008). The 
eicosanoids from AA are biologically active in very small quantities, and, they promote to the 
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formation of thrombus and atheromas, allergic and inflammatory disorder, particularly in 
susceptible people (Simopoulos 2011). Thus, a diet rich in omega-6 fatty acids shifts the 
physiological state to one that is prothrombotic and proaggregatory, with increases in blood 
viscosity, vasospasm, and vasocontriction and decreases in bleeding time (Hussein 2013). 
Omega-3 fatty acids inhibit the production of platelet-derived growth factor (PDGF) in bovine 
endothelial cells (De Caterina, Cybulsky et al. 1994). Thus, the reduction in its production by 
endothelial cells, monocytes/macrophages, and platelets could inhibit both the migration and 
proliferation of smooth muscle cells, monocytes/macrophages, and fibroblasts in the arterial wall. 
Omega-3 fatty acids also increase endothelium-derived relaxing factor (EDRF) which facilitates 
relaxation in large arteries and vessels (Nicolosi and Stucchi 1990). Supplementing the diet with 
omega-3 fatty acids (3.2 g EPA and 2.2 g DHA) in normal subjects increased the EPA content in 
neutrophils and monocytes more than sevenfold without changing the quantities of AA and DHA 
(Nicolosi and Stucchi 1990). The antiinflammatory effects of fish oils are partly mediated by the 
inhibition of  the 5-lipoxygenase pathway in neutrophils and monocytes (Lee, Hoover et al. 1985). 
Moreover, several studies show that omega-3 fatty acids influence interleukin metabolism by 
decreasing IL-1 and IL-6, suggesting an important role in the prevention of atherosclerosis (Jung, 
Torrejon et al. 2008) 
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2.5 Metabolim of PUFA 
Free arachidonic acid (AA) is oxidized through three major metabolic routes: (i) the 
cyclooxygenase (COX) pathway producing prostaglandins and thromboxanes, (ii) the 
lipoxygenase (LOX) pathway leading to leukotrienes, hydroxyeicosatetraeneoic acids (HETEs) 
Figure 20. Importance of omega-6/omega-3 ratio.  
A very high omega-6/omega-3 ratio promotes the pathogenesis of many diseases, including cardiovascular disease, 
cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 PUFA (a low omega-
6/omega-3 ratio) exert suppressive effects. 
PGH2, Prostaglandin H2; TXA2, Thromboxane A2; LT E4, Leukotriene E4; LT B4, Leukotriene B4; PDGF, Platelet 
derived growth factor; IL-1, Interleukin-1; IL-2, Interleukin-2. 
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and lipoxins, whereas (iii) the cytochrome P450 (CYP) pathway implies oxidation by 
monooxygenases to produce hydroxylated and epoxidised fatty acids (Hong, Bose et al. 2004).  α-
linolenic acid (ALA) can be metabolized to some extent by mechanisms including desaturation and 
elongation to yield EPA, DHA, while linoleic acid (LA) is the metabolic precursor of arachidonic 
acid (AA) (Holub 2002). In the omega-6 fatty acids pathway, linoleic acid can be first converted 
into gamma-linolenic acid (GLA, 18:3, omega-6 fatty acid) by the enzyme Δ6-desaturase before 
elongation leading to (DGLA) dihomo-GLA (DHGLA, 20:3, omega-6 fatty acids) (Das 2008). The 
dihomo-GLA can be further converted into arachidonic acid (AA, 20:4, omega-6 fatty acids) by 
the Δ5-desaturase. The omega-3 fatty acids pathway uses the same series of enzymes for converting 
α-linolenic acid (ALA) into EPA and then into docosapentaenoic acid (DPA) by elongase (Figure 
21). The conversion of ALA to EPA and DPA occurs primarily in the liver in the endoplasmic 
reticulum, whereas the final conversion of DPA to DHA requires a translocation to the peroxisome 
for a β-oxidation reaction (Arterburn, Hall et al. 2006). 
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Figure 21.  Synthesis pathway of omega-6 and omega-3 fatty acids in mammals. 
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2.6 Health benefits of n-3 polyunsaturated fatty acids 
2.6.1 n-3 polyunsaturated fatty acids and diabetes 
Intake of n-3 fatty acids, either as fish oil or ethyl ester formulations is related with a variety of 
biochemical changes that might be beneficial in diabetes: reduced triglyceridemia, mainly through 
enhanced triglyceride lipolysis and enhanced fatty acid oxidation (Sirtori and Galli 2002). 
Increasing the consumption of n-3 long chain PUFAs improves several cardiovascular risk factors 
in persons with diabetes and may reduce the risk of conversion from impaired glucose tolerance to 
type 2 diabetes (Carpentier, Portois et al. 2006). Many epidemiologic studies reported that type 2 
diabetes was less prelevant among Japanese as compared to their mainland counterparts. Lower 
prevalence was attributed mainly to diets rich in n-3 long chain PUFAs (Montmayeur, le Coutre et 
al. 2010). 
n-3 long chain PUFAs have beneficial effects in lowering triglyceride levels and reducing remnant 
lipoprotein (RLP) levels in subjects with type 2 diabetes or hypertriglyceridemia and may increase 
high-density lipoprotein (HDL) cholesterol levels (Okumura, Fujioka et al. 2002). RLPs are higly 
atherogenic lipoproteins produced in the hydrolysis of chylomicrons and very low density 
lipoprotein (VLDL) (Shin, Kim et al. 2004). Modest amounts of purified EPA 0.9 to 1.8 g/day 
reduced the RLP levels significantly by 77% in patients with type 2 diabetes treated for 3 months 
(Nettleton and Katz 2005). 
It is of interest that in in vitro studies EPA has been shown to increase glucose-induced insulin 
secretion from beta-TC3 insulinoma cells (Dubnov and Berry 2004). Other potentially beneficial 
aspects of n-3 treatment in diabetes may be related to the role of these dietary components in 
providing a source of vasoactive compounds, potentially leading to reduced blood pressure and 
improved peripheral perfusion (Hornstra 2012). 
 
2.6.2 n-3 polyunsaturated fatty acids and cardiovascular diseases 
Long chain PUFAs including EPA and DHA are the key nutrients in fish responsible for the 
potential cardioprotective effects of fish consumption (Kris-Etherton, Harris et al. 2002). A 
beneficial effect of fish consumption on CVDs has been suggested to be related to overall favorable 
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effects on lipid profile, threshold for arrhythmias, platelets activity, inflammation, endothelial 
function, atherosclerosis and hypertension (Figure 22). 
Figure 22. Physiological effects of n-3 PUFA that might influence CVD Risk (Mozaffarian and Wu 2011). 
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2.6.2.1 Lipid Profile 
Hypertriglyceridemia is one of the components of metabolic syndrome. Several studies reported 
that long chain n3 PUFAs reduce the blood triglyceride levels (Kris-Etherton, Harris et al. 2002). 
Recently, 47 trials showed that fish oil supplementation with 1 g/day was effective in reducing 
triglyceride levels by 0.34 mmol/L over an average treatment period of 24 weeks in participants 
with hypertriglyceridemia (He 2009).  
PUFA have multiple CVD-related physiological effects such as  lowering of plasma triglycerides 
including reduced fatty acid availability for triglyceride synthesis (Reddy and Katan 2004). 
Moreover, they reduced delivery of nonesterified fatty acids to the liver reduced, hepatic enzyme 
activity for triglyceride synthesis; and increased hepatic synthesis of phospholipids rather than 
triglycerides (Nakamura and Nara 2003). 
2.6.2.2 Inflammation and endothelial function 
Several epidemiological studies reported that n-3 PUFA fatty acids have beneficial effects on 
inflammation and endothelial function (Mori and Beilin 2004). Omega-3 fatty acids are anti-
inflammatory. Indeed inverse association  has been found between Omega-3 or fish consumption 
and circulating levels of C-reactive protein, interlukin-6, endothelial-leukocytes adhesion 
molecule-1, soluble intercellular adhesion molecule-1, tumor necrosis factor, INF-α soluble 
receptor 1, and matrix metalloproteinases-3 (He 2009).  
Omega 3 fatty acids have recognized anti-inflammatory actions that may contribute to their 
beneficial cardiac effects (Russo 2009). Omega 6 fatty acids can be converted into arachidonic acid 
and then metabolised into the omega 6 eicosanoids. Consumption of omega 3 fatty acids increases 
eicosapentanoic acid in the cell membrane. This competes with arachidonic acid for enzymatic 
conversion into its own metabolites, the omega-3-derived eicosanoids (Wall, Ross et al. 2010). 
Independent of the effects on the metabolism of eicosanoids, fish oils suppress pro-inflammatory 
cytokines and reduce expression of cell adhesion molecules (Calder 2006) which are critical in 
recruiting circulating leucocytes to the vascular endothelium, an important event in the 
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pathogenesis of atherosclerosis and inflammation. Omega-3 fatty acids also have direct effects on 
endothelial vasomotor function. Higher plasma concentrations are associated with improved 
dilatation of the brachial artery in young adults with cardiovascular risk factors, which implies a 
protective effect on endothelial function (Din, Newby et al. 2004). In hyperlipidaemic men, omega-
3 fatty acid supplementation improved systemic arterial compliance, and supplementation with 
docosahexanoic acid increased vasodilator responses in the human forearm arteries. These effects 
may be mediated through actions on intracellular signalling pathways, leading to reduced activation 
of transcription factors such as NF-ĸB (Egert and Stehle 2011). However, the precise effects of 
omega 3 fatty acids on these fundamental cellular processes and their potential impact on coronary 
heart disease are yet to be delineated completely. 
2.6.2.3 Atherosclerosis 
Although high dose supplementation of omega-3 fatty acids exerts a hypotriglyceridemic effects, 
these fatty acids also increase and enhance oxidation of LDL cholesterol (Larsson, Kumlin et al. 
2004). However, data from both animal models and humans are inconsistent. It is unclear whether 
omega-3 fatty acids have a direct effect on the pathogenesis of atherosclerosis. Consumption of 
6g/d EPA and DHA for 2 years had no major favorable effects on the thickness of atherosclerotic 
coronary arteries (Woodman 2003). Several other studies showed that dietary intake of omega-3 
fatty acids or nonfried fish is associated with a lower prevalence of subclinical atherosclerosis 
classified by significant changes in common carotid intima-media thickness, in percent stenosis, 
while no modification in coronary artery calcium score, and ankle-brachial index were observed 
(Von Schacky, Angerer et al. 1999).  
2.6.2.4 Platelets aggregation 
Omega-3 FAs compete with omega-6 FAs for prostaglandin and leukotrines synthesis at the 
cyclooxygenase and lipoxygenase level. omega-3 fatty acids modulate prostaglandin metabolism 
by increasing prostaglandin E3, an active vasodilator and inhibitor of platelets aggregation, 
thromboxane A3, leukotrines B5, and by decreasing production of thromboxane A2, a potent 
platelet aggregation and vasoconstrictor, and leukotrines B4 formation (an inducer of inflammation 
and a powerful inducer of leukocyte chemotaxis and adherence) (Jha 2004). In addition, omega-3 
fatty acids may react with reactive oxygen species because of their double bonds and lead to 
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decreased production of hydrogen peroxide, which is a critical activator of the nuclear NF-ĸB. 
Other studies also indicate that high intake of omega-3 fatty acids would produce a lower platelet 
count, less platelet aggregation, a longer bleeding time and lower concentrations of thromboxane 
metabolites. 
2.7 Clinical implications of omega-3 fatty acids  
Omega 3 fatty acids from fish or fish oil supplements should be considered in the secondary 
prevention regimen of patients after myocardial infarction (Holub and Holub 2004). Patients should 
consume about 1 g/day of eicosapentanoic acid and docosahexanoic acid, preferably by increasing 
their intake of oily fish to at least two servings per week (Harris and Von Schacky 2004). Fish oil 
capsules may be considered for those unable to tolerate fish or change their diet effectively. 
Approved pharmaceutical grade capsules should be prescribed rather than encouraging over the 
counter supplements (Din, Newby et al. 2004). Recent guidelines from the American Heart 
Association have gone further, supporting the use of fish oil supplements for patients with 
“documented” coronary heart disease. However, they believe that more evidence is required before 
considering fish oil supplements for patients with coronary heart disease outside the specific 
indication of myocardial infarction. Others have argued that fish oil supplements should not be 
recommended routinely for patients after myocardial infarction until more definitive evidence is 
available (Rahman, Haque et al. 2005). No trial has assessed the effects of fish oils on risk of 
coronary heart disease in primary prevention, and therefore explicit recommendations for this 
group cannot be made currently. Such a trial may prove impractical in terms of the numbers 
required. However, on the basis of evidence from epidemiological and observational studies the 
consumption of (preferably oily) fish at least twice weekly should be encouraged as part of a 
balanced diet (Din, Newby et al. 2004). Any recommendations regarding fish and fish oils should 
be balanced against safety issues. Side effects such as fishy aftertaste are uncommon, and 
gastrointestinal upset is infrequent at moderate intakes. Some reports show that fish oil may worsen 
glycemic control in diabetes, but two meta-analyses found no adverse effect. Furthermore, a recent 
prospective cohort study found that a higher consumption of omega 3 fatty acids was associated 
with a lower incidence of coronary heart disease and mortality in diabetic women (Din, Newby et 
al. 2004; Borghi and Cicero 2005). Concerns have been raised regarding adverse effects on low 
density lipoprotein (LDL) cholesterol and oxidative stress, but increases in LDL cholesterol are 
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modest and studies into oxidative stress have been contradictory. Overall these effects are unlikely 
to be dominant given the apparent cardiac benefits of omega 3 fatty acids. More specific concerns 
regarding dietary fish relate to environmental contaminants, and a recent study showed that 
mercury in fish may attenuate their cardioprotective effects (Cicero, Ertek et al. 2009). 
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AIM OF THE STUDY 
The endothelial cells are the major regulator of vascular homeostasis and play a key role by 
synthesis and secretion of various potent vasodilatating and vasoconstricting factors. In addition, 
they also inhibit platelet aggregation, decrease the endothelial expression of adhesion molecules 
and smooth muscle cell proliferation, thus reducing the risk of cardiovascular diseases.  Endothelial 
dysfunction is an early hallmark for the development and progression of most of the cardiovascular 
diseases, like hypertension, atherosclerosis, myocardial infarction, cerebrovascular diseases 
(stroke), peripheral artery diseases, rheumatic heart diseases, congenital heart diseases and heart 
failure, which are the leading cause of mortality and morbidity worldwide. Endothelial dysfunction 
is associated with an impairment of endothelium-dependent relaxations involving a reduced NO 
bioavailability, EDH component of relaxation and an increased production of endothelium derived 
contractile factors (EDCF). Endothelial dysfunction could lead to hypertension. 
Several naturally occurring constituents like red wine polyphenols, caffeine, omega-3 fatty acids, 
carotenoids, vitamins E and C have received significant consideration because of their potential 
antioxidant activity. Consuming a diet rich in these natural antioxidants has been associated with 
prevention and treatment of endothelial dysfunction and associated cardiovascular diseases 
(Potashkin 2014).  
Antihypertensive treatments affecting RAS (AT1R and ACE inhibitors) contributes to 60 % to 
65 % of overall hypertensive therapy and, therefore, Ang II-induced hypertension is one of the 
most widely used pharmacological model of hypertension in rats. In several experimental models 
of endothelial dysfunction, an overexpression of the local angiotensin system associated to a 
vascular oxidative stress has been described. Red wine polyphenols (RWPs) are able to prevent 
the Ang II-induced endothelial dysfunction mostly due to their antioxidant properties (Kane, 
Etienne-Selloum et al. 2010). RWPs intake caused a persistent improvement of the endothelial 
function, particularly the EDH component of relaxation, in middle-aged rats and this effect seems 
to involve the normalization of the expression of IKCa,  SKCa and the angiotensin system (Khodja, 
Chataigneau et al. 2012).Various studies demonstrates that regular intake of fish products and 
dietary consumption of fish or fish oil rich in omega-3 PUFAs, particularly EPA (eicosapentaenoic 
acid) and DHA (docosahexaenoic acid) has been related to a reduced risk of cardiovascular disease 
morbidity/mortality. 
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In a previous study of our group different ratio of EPA and DHA (EPA:DHA 1:1, EPA:DHA 3:1, 
EPA:DHA 6:1, EPA:DHA 1:3, EPA:DHA 1:6) and alone EPA and DHA were studied and they 
found that omega-3 EPA:DHA 6:1 is the most potent formulation for the induction of both NO-
mediated and EDH-mediated response in porcine arteries by the activation of eNOS through Src 
PI3K Akt Pathway (Zgheel, Alhosin et al. 2014). Being the most superior formulation of omega-3 
EPA:DHA 6:1 was selected to treat angiotensin II induced endothelial dysfunction and 
hypertension in rats. The major goal of this thesis was to determine whether chronic intake of EPA: 
DHA 6:1 affects hypertension and endothelial dysfunction induced by angiotensin II infusion in 
rats. 
More specifically the aims were 
1. To study the effect of EPA:DHA 6:1 in angiotensin induced hypertension. 
2. To study the impregnation of EPA:DHA 6:1 in plasma and its effects on omega6/omega3 
ratio. 
3. To study the effect of EPA:DHA 6:1 in the endothelium -dependent relaxation in second 
branch mesenteric arterial rings. 
4. To characterize the mechanisms underlying EPA:DHA 6:1 induced endothelium-dependent 
relaxation mediated by NO and EDH, in second branch mesenteric  arteries. 
5. Evaluate the ability of EPA:DHA to reduce contractile responses in second branch 
mesenteric  arterial rings. 
6. To study Ang II induced oxidative stress responses (ROS) in second branch mesenteric 
arteries. 
7. To find the source of ROS. 
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EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: 
role of NADPH oxidase and COX-derived oxidative stress  
Zahid Rasul Niazi, Grazielle C. Silva G, Thais Porto Ribeiro, Antonio J León-González, Mohamad 
Kassem, Abdur Mirajkar, Azhar Alvi, Malak Abbas, Faraj Zgheel, Valérie B. Schini-Kerth, Cyril 
Auger 
 Submitted to the British Journal of Pharmacology 
Cardiovascular diseases are the major of death worldwide and should remain the leading cause of 
mortality and morbidity over the next few decades. Hypertension and other risk factors of 
cardiovascular diseases are associated early with the development of an endothelial dysfunction. 
The endothelial dysfunction is generally characterized by a reduced formation of vasoprotective 
factors including nitric oxide (NO) and endothelium-dependent hyperpolarization (EDH), and an 
increased production of vasocontracting factors such as cyclooxygenase (COX)-derived 
metabolites of arachidonic acid involved in the endothelium-dependent contractile factors. 
While current antihypertensive treatment are able to potently reduce the blood pressure, they seems 
to have a limited ability to protect and/or improve the endothelial dysfunction, a pivotal event in 
the protection of the cardiovascular system. Several epidemiological and both primary and 
secondary prevention studies have indicated that dietary intake of omega-3 polyunsaturated fatty 
acids (PUFAs), including the two major compounds eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), reduces the risk of cardiovascular diseases. Moreover, studies have 
reported that purified formulations of EPA and DHA are able to induce potent and sustained 
endothelium-dependent relaxations of isolated artery rings via an increased formation of NO and 
EDH. A previous study of the research team has shown that the endothelium-dependent 
vasorelaxant effect of omega-3 PUFAs is dependent on both the purity and ratio of EPA:DHA, 
with EPA:DHA ratio of 6:1 and 9:1 being superior formulations (Zgheel et al., 2014).  
The aim of the present study was to determine whether chronic oral intake of the optimized 
EPA:DHA 6:1 formulation is able to prevent the hypertension and endothelial dysfunction induced 
by Ang II infusion in rats. 
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Results  
The major results of our study show that infusion of Ang II caused a significant increase in systolic 
blood pressure, as compare to control rats. EPA:DHA 6:1 treatment significantly prevented the 
increase in systolic blood pressure by about 57%, while having no effect on the systolic blood 
pressure of normotensive rats. The chronic intake of the optimized EPA:DHA 6:1 formulation is 
associated with significantly increased plasma levels of omega-3 fatty acids, mainly as EPA, DHA 
and the intermediate elongated metabolite of EPA, the docosapentaenoic acid (DPA), resulting in 
a decreased omega-6/omega-3 ratio. The reduction of this ratio have been associated with a shift 
towards beneficial health effects of omega-3, including reduced cardiovascular and cancer risk. 
Vascular reactivity studies in the secondary branch of the mesenteric artery indicate that Ang II 
induced an endothelial dysfunction characterized by reduced relaxations in response to 
acetylcholine affecting both the NO- and EDH-mediated components, and increased formation of 
endothelium-derived contractile factors (EDCFs) in response to acetylcholine. The chronic intake 
of EPA:DHA 6:1 normalized both the NO, EDH and EDCF responses in the secondary branch of 
the mesenteric artery. To better characterize the molecular mechanisms involved in the protective 
effects of EPA:DHA 6:1 intake, we performed quantitative analysis of protein expression in the 
secondary branch of the mesenteric artery by immunofluorescence. The Ang II treatment increased 
the level of vascular oxidative stress and the expression of NADPH oxidase subunits p22phox and 
p47phox, AT1R, AT2R, eNOS, arginase-1, COX-1 and COX-2, and decreased the expression of 
SKCa and connexin 37, which were improved by the omega-3 treatment. To confirm the results 
obtained by immunofluorescence in the secondary branch of the mesenteric artery, we performed 
Western blot analysis of the expression levels of eNOS, COX-2, and the NADPH oxidase subunit 
p22phox in the secondary branch mesenteric artery. The Ang II group presented a significantly 
increased expression of eNOS, COX-2, and the NADPH oxidase subunit p22phox, that was 
prevented by the chronic oral intake of EPA:DHA 6:1. 
Altogether, the present findings indicate that chronic intake of the optimized EPA:DHA 6:1 
formulation prevented the development of hypertension and endothelial dysfunction induced by 
the infusion of Ang II in rats. The Ang II-induced endothelial dysfunction is associated to an up-
regulation of the local angiotensin system and an increased vascular oxidative stress. The beneficial 
effect of EPA:DHA 6:1 is mediated by an improvement of both the NO- and the EDH-mediated 
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relaxations and a reduction of endothelium-dependent contractile response, most likely by 
preventing the oxidative stress induced by the up-regulation of the local angiotensin system. 
Conclusions and perspective 
In conclusion, the present work has assessed the potency of an optimized EPA:DHA 6:1 
formulation to protect the endothelial function in vivo. The present findings shows that Ang II 
infusion is associated with the development of endothelial dysfunction in the secondary branch of 
the mesenteric arteries, which affects markedly the EDH-mediated component of relaxation and 
also, to some extent, the NO-mediated component of relaxation. The Ang II-induced endothelial 
dysfunction involves a redox-sensitive mechanism implicating NADPH oxidase, COX-1 and 
COX-2. The chronic oral intake of the optimized EPA:DHA 6:1 formulation prevents Ang II-
induced endothelial dysfunction and hypertension most likely by decreasing oxidative stress-
mediated impairment of  both NO and EDH components as well as a reduction of endothelium-
dependent contractile response. 
There are numerous reports that support an important role of omega-3 fatty acids in preventing 
endothelial dysfunction, hypertension and cardiovascular diseases. The impregnation of omega-3 
fatty acids in vascular tissues is also important, and needs to be clarified. However, the active 
molecules involved in the protective effects of omega-3 intake on endothelial function remains to 
be identified. Recent studies have reported that metabolites of omega-3 fatty acids, such as the 
resolvins, are key elements in the anti-inflammatory effect of omega-3. They also have been 
reported to exert beneficial vascular effect such as reducing the hyperreactivity induced by 
endothelin-1 and pro-inflammatory cytokines in pulmonary arteries. Since Ang II-induced T cell 
activation and the subsequent vascular inflammatory response have been identified as key 
mechanisms in Ang II-induced hypertension and endothelial dysfunction, a reduced pro-
inflammatory responses due to production of anti-inflammatory omega-3 metabolites is likely to 
contribute to the EPA:DHA 6:1 antihypertensive and vasoprotective effect. Thus, further work is 
needed for the identification of active metabolites of omega-3 fatty acids in the vascular wall 
including resolvins, protectins, thromboxane A3, leukotriene 5 and lipoxins.  
The present study has assessed the potency of the EPA:DHA 6:1 formulation to prevent the Ang 
II-induced hypertension and endothelial dysfunction. However, the curative potential of the 
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optimized EPA:DHA 6:1 formulation on an established hypertension and associated endothelial 
dysfunction needs to be determined. Indeed, while the current antihypertensive treatments 
effectively reduce blood pressure, they seems to have limited ancillary effect on the endothelial 
dysfunction and hence to protect the cardiovascular system. Thus, the potency of the EPA:DHA 
6:1 formulation to improve the endothelial dysfunction associated with an established hypertension 
could be an interesting novel therapeutic approach to reduce the cardiovascular mortality risk of 
hypertension. 
Finally, on the basis of the beneficial vasoprotective effect of the EPA:DHA 6:1 formulation 
demonstrated in the present study and the reported beneficial effect of omega-3 intake in humans,  
a clinical study can be designed to determine the potential of EPA:DHA 6:1 to reduce 
cardiovascular risk factors in hypertensive patients. 
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Arterial hypertension 
Arterial hypertension is a major problem of public health, being associated with end organ damage 
and cardiovascular morbidity and mortality. Arterial hypertension is the most important risk factor 
for a number of cardiovascular diseases including CAD, CHF, peripheral vascular disease, stroke 
and chronic kidney disease (Sarnak, Levey et al. 2003). Prevalence of arterial hypertension in 
United States is very high and continues to increase with a control rate of just 30 % in treated 
patients (Ong, Cheung et al. 2007). At the age of 75 years or older, about 70 % of men and women 
develop arterial hypertension (Chobanian, Bakris et al. 2003). Although effective antihypertensive 
drugs such as AT1R antagonists (ARAs), angiotensin-converting enzyme inhibitors (ACEI), beta-
blockers, and calcium channel blockers, diuretics, and vasodilators exist, the control rate of 
hypertension remains low possibly due to poor observance and side effects. Treatments blocking 
pathological effects of the RAS at different levels have been shown to limit target-organ damage 
in hypertension and to decrease cardiovascular morbidity and mortality. AT1R and ACE inhibitors 
based treatments contributed to 60 % and 65 % of overall hypertensive therapy. 
Omega-3 polyunsaturated fatty acids 
Interest in natural products research is strong and can be attributed to several factors, including 
unmet therapeutic needs, the remarkable diversity of both chemical structures and biological 
activities of naturally occurring secondary metabolites. In this context, the adverse effects 
associated with synthetic molecules, decreased patients acceptability, contributed to shift the 
interest into natural products.  
Numerous experimental and clinical studies have documented that omega-3 fatty acids can benefit 
the cardiovascular system, and particularly in patients diagnosed with CAD (Harris, Mozaffarian 
et al. 2009). The American Heart Association recommends the intake of 1 g/day of the two omega-
3 fatty acids EPA and DHA for cardiovascular disease prevention, treatment after a myocardial 
infarction, prevention of sudden death, and secondary prevention of cardiovascular disease (Von 
Schacky and Harris 2007).  
Omega-3 fatty acid lower plasma triglycerides mainly through reduced fatty acid availability for 
triglyceride synthesis due to decreased de novo lipogenesis, increased fatty acid beta-oxidation 
(Kusunoki, Kanatani et al. 2006), reduced delivery of nonesterified fatty acids to the liver, reduced 
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hepatic enzyme activity for triglyceride synthesis, and increased hepatic synthesis of phospholipids 
rather than triglycerides (Nakamura and Nara 2003). Omega-3 fatty acids have anti-inflammatory 
properties and an inverse association has been found between regular intake of  fish oil or fish and 
C-reactive protein, interleukin-6, E-selectin, soluble intercellular adhesion molecule-1, tumor 
necrosis factor, IFN-α soluble receptor 1, and matrix metalloproteinase-3 (He 2009). Fish oils 
inhibit pro-inflammatory cytokines production and reduce expression of cell adhesion molecules 
(Calder 2006). These factors are critical in recruiting circulating leucocytes to the vascular 
endothelium, an important early event in the pathogenesis of atherosclerosis and inflammation.  
Omega-3 fatty acids compete with omega-6 fatty acids for prostaglandin and leukotrienes synthesis 
at the cyclooxygenase and lipoxygenase level. Omega-3 fatty acids modulate prostaglandin 
metabolism by increasing synthesis of prostaglandin E3, an active vasodilator and inhibitor of 
platelets aggregation, thromboxane A3, leukotrienes B5, and by decreasing production of 
thromboxane A2, a potent inducer of platelet aggregation and vasoconstrictor, and leukotriene B4 
formation (an inducer of inflammation and a powerful inducer of leukocyte chemotaxis and 
adherence). Other studies also indicate that high intake of fish oil would produce a lower platelet 
count, less platelet aggregation, a longer bleeding time and lower concentrations of thromboxane 
metabolites. The omega-3 fatty acids-induced hypotriglyceridemia effect requires doses of DHA 
and EPA of 3 to 4 g/day. In American population such doses reduce triglyceride levels by 30 % to 
40 % (Harris, Ginsberg et al. 1997; Lavie, Milani et al. 2009). However, data from both animal 
models and humans on cardiovascular protection are inconsistent. Consumption of 6 g/d EPA and 
DHA for 2 years by 59 patients had no major favorable effects on the diameter of atherosclerotic 
coronary arteries (Woodman 2003). Several studies showed that dietary intake of fish oil or non-
fried fish is associated with a lower prevalence of subclinical atherosclerosis classified by 
significant changes in common carotid intima-media thickness and in percent stenosis while no 
modification in coronary artery calcium score, and ankle-brachial index were observed (Von 
Schacky, Angerer et al. 1999). DHA is the precursor to a newly described metabolite called 10,17S
docosatriene, which is part of a family of compounds called resolvins. These have firstly been 
described as being released in the brain in response to an ischemia and respond to the 
proinflammatory actions of infiltrating leukocytes by blocking interleukin-1-beta-induced NF-ĸB 
activation and cyclooxygenase-2 expression (Layé 2010). 
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 The previous studies of our research team have shown that EPA and DHA, the major omega-3 
fatty acids, induced concentration-dependent relaxations in coronary artery rings (Zgheel, Alhosin 
et al. 2014). The relaxation in response to EPA was slightly but significantly greater than those to 
DHA at 0.4 % (v/v) (77.8±10.3 and 64.7±12.8 %, respectively). Then, the ability of optimized 
omega-3 ratios to induce endothelium-dependent relaxation was determined and the results showed 
that EPA:DHA at ratio of either 6:1 or 9:1 induced relaxations significantly more potent than ratio 
of 3:1, 1:1, 1:3, 1:6, and 1:9. Similarly, the role of the purity of the EPA:DHA ratio was determined. 
The endothelium-dependent relaxation in porcine coronary artery rings in response to a product 
with a high purity of omega-3 EPA:DHA (694:121 mg/g) was significantly greater than those in 
response to a product with a lower purity of omega-3 EPA:DHA (352:65 mg/g). Thus, the 
biological activity of omega-3 products is critically dependent on the consumption, ratio and purity. 
Beneficial effects of omega-3 fatty acid on endothelial function 
Dietary omega-3 fatty acids have a variety of anti-inflammatory and immune-modulating effects 
that may be of relevance to atherosclerosis and its clinical manifestations of myocardial infarction, 
sudden death, and stroke (Mori and Beilin 2004). The omega-3 fatty acids that appear to be most 
potent in this respect are the long-chain polyunsaturated derived from marine oils, namely 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Riediger, Othman et al. 2009). 
Several studies have indicated an inverse correlation between the risk of cardiovascular diseases 
and the increased consumption of omega-3 fatty acids, such as eicosapentaenoic acid (EPA, C20:5 
n-3) and docosahexaenoic acid (DHA, C22:6 n-3), that are found mainly in fatty fish (e.g., salmon, 
trout, herring, sardines, and mackerel) (Lavie, Milani et al. 2009). The beneficial cardiovascular 
effects of dietary supplementation with omega-3 fatty acids include decreased arrhythmias, 
decreased triglycerides plasma concentrations, decreased blood pressure, and decreased platelet 
aggregation, all leading to reduced risk of cardiovascular mortality in patients with cardiovascular 
diseases (Harris, Miller et al. 2008). In addition, the protective effect of omega-3 fatty acids could 
also be explained by their ability to improve endothelium-dependent relaxation of the arteries by 
stimulating the formation of the endothelium vasoprotective factors NO and EDH, as well as 
reduction in endothelium-dependent contractile responses (Ribeiro, Oliveira et al. 2016). 
Since EPA:DHA 6:1 and 9:1 are more efficient than 1:1 (which is the only available prescribed 
drug) for endothelium-dependent relaxations in porcine coronary artery rings (Zgheel, Alhosin et 
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al. 2014), the EPA:DHA 6:1 formulation was selected for the present study and given at the dose 
of 500 mg/kg/d to rats, which is equivalent to 5.67 g/d for a 70 kg Human (Reagan-Shaw, Nihal et 
al. 2008). This dose is in line with reported clinical trials and meta-analysis, where doses range 
from 0.18 up to 10 g/d of various omega-3 products (Delgado-Lista, Perez-Martinez et al. 2012; 
Enns, Yeganeh et al. 2014).  
 
Ang II can be infused to mice or rats subcutaneously by Alzet osmotic mini pumps over a period 
of 4 weeks (Zimmerman, Lazartigues et al. 2004). Ang II doses of 0.7-1 mg/kg/day in mice and of 
0.3-10 mg/kg/day for rats can induce hypertension rapidly in 7-10 days or slowly in 4-8 weeks 
(Edgley, Kett et al. 2001). Rats develop cardiac and renal fibrosis as well as aortic and cardiac 
hypertrophy after two weeks of infusion (Huentelman, Grobe et al. 2005)..  
Ang II was infused at 0.4 mg/kg/day to male Wistar rats subcutaneously by Alzet osmotic mini 
pumps over a period of 4 weeks. Ang II is a multifunctional peptide hormone that regulates blood 
pressure, plasma volume, cardiac, renal and neuronal functions, and also controls thirst responses. 
This peptide is of central importance in hypertension and myocardial remodeling and is the 
principle effector molecule of the renin-angiotensin system (RAS) playing an important role in the 
regulation of arterial blood pressure (Zhuo and Li 2011). In the present study Ang II infusion 
induced a rapid increase in systolic blood pressure of rats within a couple of days that remained 
elevated throughout the study. The chronic intake of the EPA:DHA 6:1 formulation was able to 
partially but significantly prevent  the Ang II-induced increased systolic blood pressure. This result 
is in line with previously published studies reporting that omega-3 intake 3.3 to 7 g/d is associated 
with decreased blood pressure by 2.9 and 1.6 mm Hg among hypertensive patients (He 2009). 
Indeed, the recent meta-analysis by Miller et al. indicates that EPA+DHA provision is associated 
with reduced systolic blood pressure, whereas diastolic blood pressure is reduced for EPA+DHA 
provision exceeding 2 g/d (Miller, Van Elswyk et al. 2014).  
In our experimental model, we observed that the continuous infusion of 0.4 mg/kg/d of Ang II in 
rats induced endothelial dysfunction in secondary branch of the mesenteric artery that is 
characterized by reduced endothelium-dependent relaxing responses, involving mainly blunted 
EDH-mediated responses and to a lesser extent NO-mediated relaxations, and an increased 
formation of EDCFs. As a result, omega-3 prevented Ang II induced endothelial dysfunction as 
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indicated by a significant improvement of both components of the relaxation and a decreased in 
endothelium-dependent contractile response. The chronic oral intake of the optimized EPA:DHA 
6:1 significantly reduced Ang II induced over expression of eNOS, arginase-1, COX-1 and COX-
2 as well as prevented the down-regulation of SKCa  and Cx37. Supplementation with omega-3 fatty 
acids also significantly improved the endothelial function in Humans without affecting 
endothelium-independent dilation (Wang, Liang et al. 2012). Endothelial dysfunction has been 
associated with an impairment of endothelium-dependent relaxations involving a reduced 
bioavailability of NO in major CV diseases such as hypertension, atherosclerosis, chronic renal 
failure, and diabetes (Griendling and FitzGerald 2003; Rush, Denniss et al. 2005; Félétou and 
Vanhoutte 2006). The mechanism underlying endothelial dysfunction has been linked to increased 
oxidative stress which is associated with a reduced bioavailability of (NO), an alteration of the 
production of prostanoids, including prostacyclin, thromboxane A2, and/or isoprostanes, an 
impairment of endothelium-dependent hyperpolarization, these phenomena being able to 
contribute to endothelial dysfunction individually or in association. 
In the present study, infusion of Ang II in rats induced an increase in vascular oxidative stress, 
mainly through the AT1R-mediated overexpression and activation of NADPH oxidase, in the 
vascular wall, which, in turn, affects the endothelial function by reducing both NO and EDH 
mediated relaxations and an increased in the formation of EDCFs (Figure 23). Indeed, the increased 
formation of NADPH oxidase-derived superoxide anions most likely reduces the bioavailability of 
NO by chemical reaction leading to peroxynitrite formation, which, in turn, promotes the 
uncoupling of eNOS that increases further the oxidative stress (Förstermann 2010; Rochette, Zeller 
et al. 2014). Increased oxidative stress also impairs functioning of the Ca2+-activated K+ channels, 
SKCa and IKCa, resulting in an impaired electrical conduction and electrical signaling, leading to 
reduced EDH-mediated relaxation (Behringer, Shaw et al. 2013; Ellinsworth, Sandow et al. 2016).  
This result highlights the key role of the oxidative stress in the Ang II-induced endothelial 
dysfunction by reducing both EDH- and NO-mediated relaxations subsequent to the upregulation 
of NADPH oxidase subunits (p47phox and p22phox). The chronic oral intake of the optimized 
EPA:DHA 6:1 formulation significantly decreased the level of vascular oxidative stress, at least in 
part, by decreasing the expression of both the NADPH oxidase subunits p22phox and and p47phox 
and AT1R. Our results are well in line with clinical studies showing a decreased level of oxidative 
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vascular stress following omega-3 treatment in atherosclerotic patients (Eftekhari, Aliasghari et al. 
2013). 
 
 
 
Figure 23. Omega-3 EPA:DHA 6:1 prevents Ang II-induced endothelial dysfunction and hypertension in rats. 
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In the cardiovascular system, Ang II activates NADPH oxidase through AT1R activation which 
increases vascular oxidative stress that is strongly associated with the progression of cardiovascular 
disease (Manrique, Lastra et al. 2009). Several signaling pathways in response to Ang II are 
mediated by ROS (Mehta and Griendling 2007). Different enzymes have been involved in the 
increased arterial oxidative stress involving AT1R, NADPH oxidases, xanthine oxidases, COX-1 
and COX-2, cytochrome P450 monooxygenases, enzymes of the mitochondrial respiratory chain, 
and eNOS uncoupling. ROS (O2●-) can  react with NO to form peroxynitrite (Koppenol, Moreno et 
al. 1992), leading to the oxidation of the eNOS cofactor tetrahydrobiopterin (BH4) and the 
subsequent uncoupling of eNOS thereby further promoting oxidative stress (Cai and Harrison 
2000). 
The chronic intake of the optimized EPA:DHA 6:1 formulation is associated with significantly 
increased plasma level of omega-3 fatty acids, mainly as EPA, DHA and the intermediate elongated 
metabolite of EPA, the docosapentaenoic acid (DPA), resulting in a decreased omega-6/omega-3 
ratio. Excessive amounts of omega-6 polyunsaturated fatty acids (PUFA) and a very high omega-
6/omega-3 ratio promote the pathogenesis of many diseases, including cardiovascular disease, 
cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 fatty 
acids (a low omega-6/omega-3 ratio) exert protective effects. 
The reduction of this ratio has been associated with a shift towards beneficial health effects of 
omega-3, including reduced cardiovascular and cancer risk (Simopoulos 2008). Human beings 
have  evolved on a diet with a ratio of omega-6 to omega-3 essential fatty acids of approximately 
1, whereas in Western diets this ratio is 10/1-22.5/1 (Simopoulos 2011). Western diets are 
excessive in omega-6 fatty acids and deficient in omega-3 fatty acids as compared with the diet on 
which human beings evolved (Simopoulos 2008). 
 
In the present study, chronic oral intake of the optimized EPA:DHA 6:1 formulation significantly 
decreases Ang II-induced over-expression of AT1R, COX-1 and COX-2. Omega-3 fatty acids have 
recognized anti-inflammatory actions in humans that may contribute to their beneficial cardiac 
effects (Wall, Ross et al. 2010). Omega-6 fatty acids can be converted into arachidonic acid and 
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then metabolized into the omega-6 eicosanoids. Consumption of omega-3 fatty acids increases 
EPA in the cell membrane. This PUFA competes with arachidonic acid for enzymatic conversion 
into its own metabolites, the omega-3 derived eicosanoids (Wall, Ross et al. 2010). 
Increased concentration and activity of Ang II is strongly associated with inflammation. Ang II has 
a key proinflammatory effect on the cardiovascular system by stimulating vascular damage, 
inducing adhesion molecule-1 expression, recruiting inflammatory cells, increasing cytokine 
expression and tissue repairing (Brasier, Recinos et al. 2002). The physiological effects of Ang II 
are mediated by Ang II receptor subtype 1 (AT1R), which is widely distributed in many organs. In 
a rat experimental model Ang II infusion caused hypertension accompanied by marked monocyte 
infiltration as well as VCAM-1 and MCP-1 expression in the microvessels wall or perivascular  
tissue (Cheng, Vapaatalo et al. 2005). In endothelial, VSMC and mononuclear cells, Ang II is 
associated with an increased expression of MCP-1, the main chemokine for 
monocyte/macrophages and of interleukin-8 (IL-8), which are potent chemoattractants and 
activators of neutrophils (Yadav, Saini et al. 2010). Ang II also increased IL-6 production in 
macrophages and vascular cells, and upregulated TNF-α and IL-6 gene expression (Libby, Ridker 
et al. 2002). ACE inhibitors and AT1 antagonists reduced the expression of inflammatory markers, 
adhesion molecules, and also cytokines (Mezzano, Ruiz-Ortega et al. 2001). Ang II activates 
vascular and inflammatory cells to secrete proinflammatory mediators that assist to recruit new 
mononuclear cells, and, hence, results in additional inflammatory response contributing to the 
progression of vascular damage. 
Independent of their effects on the metabolism of eicosanoids fish oils suppress pro-inflammatory 
cytokines and reduce expression of cell adhesion molecules in humans (Calder 2006). 
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Conclusions and perspective 
In conclusion, the present work has assessed the potency of optimized EPA:DHA 6:1 formulation 
to protect the endothelial function in vivo. The present findings shows that Ang II infusion is 
associated with the development of endothelial dysfunction in second branch mesenteric arteries, 
which affects markedly EDH-mediated component and also, to some extent, the NO-mediated 
component of relaxation. The Ang II-induced endothelial dysfunction involves a redox-sensitive 
mechanism implicating NADPH oxidase, COX-1 and COX-2. The chronic oral intake of the 
optimized EPA:DHA 6:1 formulation prevents Ang II-induced endothelial dysfunction and 
hypertension most likely by decreasing oxidative stress-mediated impairment of  both NO and 
EDH components as well as a reduction of endothelium-dependent contractile response. 
There are numerous reports that support an important role of omega-3 fatty acids in preventing 
endothelial dysfunction, hypertension and cardiovascular diseases. Further work is needed for the 
determination of active metabolites of omega-3 fatty acids other than resolvins, protectins, 
thromboxane A3, leukotriene 5 and lipoxins.  
Further studies are needed to determine the curative potential of the optimized EPA:DHA 6:1 
formulation in treatment of endothelial dysfunction and hypertension in Ang II-induced 
hypertensive models of rats (Figure 24). The impregnation of omega-3 fatty acids in vascular 
tissues is also important, which needs to be clarified. Furthermore, additional investigations are 
required to determine the role of the omega-3 purity and ratio to improve hypertension-related 
dysfunction of the vascular system including endothelial dysfunction and vascular remodeling.  
On the basis of vasoprotective results established by the current study a clinical study can be 
designed to determine the potential of EPA:DHA 6:1 to reduce cardiovascular risk factors in 
hypertensive patients (Figure 25). 
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Figure 24. Perspectives in animal models. 
Determination of active metabolites of omega-3 fatty acids, curative potential of the optimized EPA:DHA 6:1 
formulation, importance of the omega-3 purity and ratio and impregnation of omega-3 fatty acids in vascular tissues.  
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Figure 25. Clinical perspective. 
Determination of EPA:DHA 6:1 potential to reduce cardiovascular risk factors in hypertensive patients. 
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Hypertension artérielle 
L’hypertension artérielle est un problème de santé publique majeur car associé à des lésions 
hypertensives d’organes cibles et à une morbi-mortalité cardiovasculaire. L’hypertension artérielle 
est ainsi le facteur de risque principal pour un nombre de maladies cardiovasculaires dont la 
maladie coronarienne, l’insuffisance cardiaque, les maladies vasculaires périphériques, les accident 
vasculaires cérébraux et la néphropathie chronique (Sarnak, Levey et al. 2003). La prévalence de 
l’hypertension artérielle aux Etats-Unis est très élevée et continue d’augmenter, avec de plus un 
taux de stabilisation d’à peine 30 % chez les patients traités (Ong, Cheung et al. 2007). Après l’âge 
de 75 ans, environ 70 % des hommes et des femmes vont développer une hypertension artérielle 
(Chobanian, Bakris et al. 2003). Il a été montré que les traitements visant à bloquer le système 
rénine-angiotensine à divers niveaux peuvent limiter les lésions hypertensives aux organes cibles 
et diminuent la morbidité et la mortalité cardiovasculaires. Parmi ces traitements, les antagonistes 
des AT1R (ARA II ou sartans) et les inhibiteurs de l’enzyme de conversion de l’angiotensine (IEC) 
représentent entre 60 et 65 % de l’ensemble des traitements antihypertenseurs. 
Les acides gras polyinsaturés omega-3  
La recherche sur les produits naturels présente un fort intérêt du fait de plusieurs critères dont la 
non-couverture des besoins thérapeutiques, et la diversité remarquable des métabolites secondaires 
naturels au niveau à la fois des structures chimiques et des activités biologiques. Dans ce contexte, 
les effets indésirables associés aux molécules de synthèse et la diminution de l’acceptabilité des 
patients contribuent à augmenter l’intérêt pour les produits naturels. 
De nombreuses études expérimentales et cliniques ont montré que les acides gras omega-3 peuvent 
avoir une répercussion bénéfique sur le système cardiovasculaire, et plus particulièrement chez les 
patients souffrant de maladie coronarienne (Harris, Mozaffarian et al. 2009). Ainsi, l’American 
Heart Association recommande la prise quotidienne de 1 g des deux acides gras omega-3 EPA et 
DHA dans le cadre de la prévention primaire et secondaire des maladies cardiovasculaires, après 
un infarctus du myocarde, et pour la prévention des morts subites cardiovasculaires (Von Schacky 
and Harris 2007).  
Les acides gras omega-3 réduisent le taux plasmatique en triglycérides principalement en réduisant 
la disponibilité des acides gras pour la synthèse de triglycérides par diminution de la lipogenèse de 
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novo, augmentation de la bêta-oxydation des acides gras (Kusunoki, Kanatani et al. 2006), 
réduction de l’influx hépatique d’acides gars non-estérifiés, diminution des activités enzymatiques 
hépatiques de synthèse des triglycérides, et augmentation de la synthèse hépatique des 
phospholipides au dépend des triglycérides (Nakamura and Nara 2003). De plus, les acides gras 
omega-3 ont des propriétés anti-inflammatoires, et une corrélation négative a été montrée entre la 
consommation régulière de poisson ou d’huile de poisson et les taux circulants de protéine C-
réactive, d’interleukine 6, d’E-selectin, de sICAM-1, de TNF, de la forme soluble du récepteur à 
l’interferon alpha, et de la métalloprotéase matricielle 3 (He 2009). Les huiles de poisson inhibent 
la production des cytokines pro-inflammatoires et réduisent l’expression de molécules d’adhésion 
cellulaire (Calder 2006). Ces facteurs sont critiques dans le recrutement des leucocytes circulants 
sur l’endothélium vasculaire, un événement précoce clé dans la pathogenèse de l’athérosclérose.  
Les acides gras omega-3 entrent en compétition avec les acides gras omega-6 au niveau des 
cyclooxygénases et des lipoxygénases pour la synthèse des prostaglandines et des leucotriènes. 
Ainsi, les acides gras omega-3 modulent le métabolisme des prostaglandines en augmentant la 
synthèse de prostaglandine E3, un vasodilatateur et inhibiteur de l’agrégation plaquettaire, du 
thromboxane A3, de leucotriène B5 et en diminuant la synthèse de thromboxane A2, un puissant 
vasoconstricteur et inducteur de l’agrégation plaquettaire, et de leucotriène B4 (un inducteur de 
l’inflammation et la chimiotaxie et de l’adhérence des leucocytes). D’autres études ont aussi montré 
que la consommation élevée d’huile de poisson conduisait à une diminution du taux de plaquettes, 
de l’agrégation plaquettaire, de la concentration des métabolites du thromboxane, ainsi qu’à une 
augmentation du temps de saignement. Les effets hypotriglycéridémiants des acides gras omeag-3 
requièrent des doses d’EPA et DHA de 3 ou 4 g par jour. Dans les populations américaines, ces 
doses peuvent réduire le taux de triglycérides de l’ordre de 30 à 40 % (Harris, Ginsberg et al. 1997; 
Lavie, Milani et al. 2009). Cependant, la consommation quotidienne de 6 g d’EPA et DHA pendant 
2 ans par 59 patients n’a pas montré d’effet favorable sur l’évolution du diamètre d’artères 
coronaires athéromateuses (Woodman 2003). A l’inverse, plusieurs études ont montré que la 
consommation d’huile de poisson ou de poissons non frits était associée à une diminution de la 
prévalence de l’athérosclérose subclinique caractérisée par un changement significatif de 
l’épaisseur intima-media de l’artère carotide commune et du pourcentage de sténose, alors 
qu’aucun changement n’ont été observé pour la quantification du calcium dans l’artère coronaire 
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ou pour l’index de pression systolique (Von Schacky, Angerer et al. 1999). Le DHA est le 
précurseur d’un métabolite récemment décrit sous le nom de 10,17S docosatriène, qui est un 
membre de la famille des résolvines. Ces molécules ont d’abord été décrites comme relâchées par 
le cerveau en réponse à l’ischémie, et elles s’opposent à l’effet pro inflammatoire des infiltrats 
leucocytaires en bloquant l’activation de NF-κB et l’expression de la cyclooxygénase-2 induites 
par l’interleukine 1-bêta (Layé 2010). Les études précédentes de notre équipe de recherche ont 
montré que l’EPA et le DHA, les acides gars omega-3 majeurs, induisent des relaxations 
dépendantes de la concentration dans les anneaux d’artères coronaires de porc (Zgheel, Alhosin 
et al. 2014). La relaxation en réponse à l’EPA est légèrement mais significativement plus 
importante que celle en réponse au DHA (77.8±10.3 et 64.7±12.8 % à 0.4 % v/v, respectivement). 
Ensuite, la capacité de ratios optimisés d’omega-3 à induire la relaxation dépendante de 
l’endothélium a été déterminée, et les résultats indiquent que les ratios EPA:DHA de 6:1 et 9:1 
induisent des relaxations significativement plus importantes que celles en réponse aux ratios 3:1, 
1:1, 1:3, 1:6, et 1:9. De plus, la relaxation dépendante de l’endothélium obtenu en réponse à un 
produit ayant un degré de pureté en EPA:DHA élevé (694:121 mg/g) était significativement plus 
importante celle obtenu en réponse à un produit ayant un degré de pureté plus faible (352:65 mg/g). 
Ainsi, les effets bénéfiques des omega-3 dépendent fortement de la dose consommée, de la 
composition et de la pureté des omega-3.   
Effets bénéfiques des acides gras omega-3 sur la fonction endothéliale 
Les acides gras omega-3 de l’alimentation présentent divers effets anti-inflammatoire et de 
modulation du système immunitaire qui pourrait jouer un rôle dans le ralentissement du  
développement de l’athérosclérose et de l’apparition de ses signes cliniques comme l’infarctus du 
myocarde, la mort subite et l’accident vasculaire cérébral (Mori and Beilin 2004). Les acides gras 
omega-3 qui semblent les plus efficaces dans ce cadre sont les polyinsaturés à longues chaines des 
huiles d’origine marine, c’est-à-dire l’acide ecosapentaénoïque (EPA) et l’acide 
docosahexaénoïque (DHA) (Riediger, Othman et al. 2009). Plusieurs études ont montré une 
corrélation inverse entre le risque de maladies cardiovasculaires et une augmentation de la 
consommation d’acides gras omega-3, comme l’EPA et le DHA, qui sont principalement retrouvés 
dans les poissons gras (saumon, truite, hareng, sardines, maquereau, etc.) (Lavie, Milani et al. 
2009). Les effets bénéfiques d’une augmentation de la consommation alimentaire en acides gras 
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omega-3 sur le système cardiovasculaire incluent une baisse des arythmies, de la triglycéridémie, 
de la pression artérielle et de l’agrégation plaquettaire, l’ensemble de ces effets résulte en une baisse 
de risque de mortalité cardiovasculaire chez les patients atteints de maladies cardiovasculaires 
(Harris, Miller et al. 2008). De plus, les effets protecteurs des omega-3 peuvent être attribués à leur 
capacité à améliorer les relaxation dépendante de l’endothélium dans les artères en stimulant la 
formation endothéliale des facteurs vasoprotecteurs NO et EDH, ainsi qu’en réduisant les réponses 
contractiles dépendantes de l’endothélium (Ribeiro, Oliveira et al. 2016). 
Du fait que les formulations EPA:DHA 6:1 et 9:1 sont plus efficaces que le ratio 1:1 (qui 
correspond à la seule spécialité avec AMM sur le marché) pour l’induction des relaxations 
dépendantes de l’endothélium dans des anneaux d’artère coronaire de porc (Zgheel, Alhosin et al. 
2014), la formulation EPA:DHA 6:1 a été retenue pour l’étude présente et donnée à des rats à la 
dose de 500 mg/kg/j, ce qui équivaut à 5,67 g/j for pour un homme de 70 kg (Reagan-Shaw, Nihal 
et al. 2008). Cette dose est cohérente avec les études cliniques et les méta-analyses, où les doses 
rapportées vont de 0,18 à 10 g/j sous forme de divers produits à base omega-3 (Delgado-Lista, 
Perez-Martinez et al. 2012; Enns, Yeganeh et al. 2014).  
 
L’angiotensine II (Ang II) peut être infusé à des rats ou des souris grâce à des mini pompes 
osmotiques sur une durée allant jusqu’à 4 semaines (Zimmerman, Lazartigues et al. 2004). 
L’infusion d’Ang II  à la dose de 0,7-1 mg/kg/j chez la souris ou de 0,3-10 mg/kg/j chez le rat va 
induire une hypertension de facon rapide en 7 à 10 jours ou de façon lente en 4 à 8 semaines 
(Edgley, Kett et al. 2001). Les rats recevant l’Ang II en infusion vont développer en 2 semaines  
des fibroses rénales et cardiaques ainsi qu’une hypertrophie aortique et cardiaque (Huentelman, 
Grobe et al. 2005).  
 
Dans notre étude, l’Ang II a été infusée pendant 4 semaines à la dose de 0,4 mg/kg/j à des rats 
Wistar males à l’aide de mini-pompes osmotiques Azlet. L’ang II est une hormone peptidique 
multifonctionnelle qui régule la pression sanguine, le volume plasmatique, les fonctions 
cardiaques, rénales et neuronales, et qui contrôle aussi la soif. Ce peptide joue un rôle central dans 
le développement de l’hypertension artérielle et dans le remodelage cardiaque, et il est l’effecteur 
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principal du système rénine-angiotensine qui joue un rôle majeur dans la régulation de la tension 
artérielle (Zhuo and Li 2011). Dans la présente étude, l’infusion d’Ang II a induit une augmentation 
rapide de la pression artérielle chez les rats en quelques jours et qui resté élevée tout au long de 
l’étude. La prise quotidienne de la formulation EPA:DHA 6:1 a permis de prévenir partiellement 
mais significativement l’augmentation de tension artérielle induite par l’Ang II. Ce résultats est en 
accord avec les études publiées préalablement qui montraient que la consommation d’acides gras 
omega-3 à des doses de 3,3 à 7 g/j était associée à une diminution de la tension artérielle de 2,9 et 
1,6 mmHg chez les patients hypertendus (He 2009). Ainsi, la méta-analyse de Miller et al. rapporte 
que la consommation de EPA+DHA est toujours associée à une diminution de la pression sanguine 
systolique, alors que la pression sanguine diastolique est diminuée significativement pour des 
consommations d’EPA+DHA supérieures à 2 g/j (Miller, Van Elswyk et al. 2014).  
Dans notre modèle expérimental, nous avons observé que l’infusion d’Ang II à la dose de 0,4 
mg/kg/j induisait l’apparition dans les branches secondaires de l’artère mésentérique d’une 
dysfonction endothéliale caractérisée par une diminution des réponses vasorelaxantes dépendantes 
de l’endothélium, impliquant principalement une réduction de la composante EDH et dans une 
moindre mesure de la composante NO, et d’une augmentation de la formation des EDCFs. La 
consommation chronique de la formulation EPA:DHA 6:1 a eu pour effet de prévenir la 
dysfonction endothéliale induite par l’Ang II comme l’indique l’amélioration significative des deux 
composantes de la relaxation et la réduction des réponses contractiles dépendantes de 
l’endothélium. La consommation chronique de la formulation EPA:DHA 6:1 a significativement 
diminué la surexpression induite par l’Ang II de la eNOS, de l’arginase-1, des COX-1 et COX-2, 
et a prévenu la sous-expression de SKCa  et Cx37. La supplémentation alimentaire en acides gras 
omega-3 améliore aussi la fonction endothéliale chez l’homme, sans pour autant affecter les 
vasodilatations indépendantes de l’endothélium (Wang, Liang et al. 2012). La dysfonction 
endothéliale a été associée à une atteinte des relaxations dépendantes de l’endothélium impliquant 
une réduction de la biodisponibilité du NO dans la plupart des maladies cardiovasculaires dont 
l’hypertension, l’athérosclérose, la néphropathie chronique ou le diabète (Griendling and 
FitzGerald 2003; Rush, Denniss et al. 2005; Félétou and Vanhoutte 2006). Le mécanisme sous-
jacent à la dysfonction endothéliale a été lié à une augmentation du stress oxydant vasculaire lui-
même associé à une diminution de la biodisponibilité du NO, une altération de la production des 
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prostanoïdes tels que la prostacycline, le thrombaxane A2 ou les isoprostanes, une diminution de 
la composante EDH de relaxation ainsi qu’à une augmentation de formation d’endotheline-1, 
l’ensemble de ces phénomènes pouvant contribuer à la dysfonction endothéliale de manière isolée 
ou ensemble.  
Dans la présente étude, l’infusion d’Ang II est associée à une augmentation du stress oxydant 
vasculaire chez les rats, principalement par la surexpression et l’activation de la NADPH oxydase 
induite par AT1R dans la paroi vasculaire, ce qui va à son tour affecter la fonction endothéliale en 
réduisant les deux composantes de la relaxation NO et EDH, et en augmentant la formation 
d’EDCFs (Figure 23). En effet, l’augmentation de la formation par la NADPH oxydase d’anions 
superoxyde diminue probablement la biodisponibilité du NO par la réaction chimique  produisant 
des peroxynitrites, qui peuvent à leur tour favoriser le découplage de la eNOS ce qui augmente 
encore le stress oxydant vasculaire (Förstermann 2010; Rochette, Zeller et al. 2014). 
L’augmentation du stress oxydant vasculaire va aussi altérer le fonctionnement des canaux 
potassiques dépendants du calcium SKCa and IKCa, résultant dans une altération de la conductivité 
électrique et des voies de signalisation électriques, conduisant à la réduction de la composante EDH 
de la relaxation (Behringer, Shaw et al. 2013; Ellinsworth, Sandow et al. 2016).  
Ces résultats soulignent le rôle majeur du stress oxydant dans la dysfonction endothéliale induite 
par l’Ang II via la diminution des composantes NO et EDH de la relaxation qui suivent la 
surexpression des sous-unités de la NADPH oxydase (p47phox and p22phox). La consommation 
chronique de la formulation EPA:DHA 6:1 a significativement diminué le niveau du stress oxydant 
vasculaire, du moins en partie, en prévenant  la surexpression de la NADPH oxydase et de AT1R. 
Ces résultats sont en accord avec ceux d’étude cliniques qui montrent une diminution du stress 
oxydant vasculaire chez des patients athérosclérotiques recevant des omega-3 (Eftekhari, 
Aliasghari et al. 2013).  
Dans le système cardiovasculaire, l’Ang II active la NADPH oxydase via l’activation de AT1R, ce 
qui augmente le stress oxydant vasculaire qui est fortement associé au développement des maladies 
cardiovasculaires (Manrique, Lastra et al. 2009). Plusieurs voies de signalisation en réponse à 
l’Ang II impliquent ainsi des espèces réactives de l’oxygène (ROS) (Mehta and Griendling 2007). 
Diverses enzymes ont été impliquées dans l’augmentation du stress oxydant vasculaire tels que 
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AT1R, la NADPH oxydase, la xanthine oxydase, les COX-1 et COX-2, le cytochrome P450, les 
enzymes de la chaine respiratoire mitochondriale, et la eNOS découplée. Les ROS (O2●-) peuvent 
réagir chimiquement avec le NO pour former des peroxynitrites (Koppenol, Moreno et al. 1992), 
ce qui conduit à l’oxydation du cofacteur de la eNOS, la tétrahydrobioptérine (BH4), et 
subséquemment au découplage de la eNOS augmentant à son tour le stress oxydant (Cai and 
Harrison 2000). 
La consommation chronique de la formulation EPA:DHA 6:1 est associée à une augmentation 
significative des proportions plasmatiques en acides gras omega-3, principalement sous forme 
d’EPA, de DHA et de l’intermédiaire métabolique allongé de l’EPA, l’acide docosapenténoïque 
(DPA), conduisant à la diminution significative du ratio omega-6/omega-3. Des quantités 
excessives d’acides gras polyinsaturés omega-6 ainsi qu’un ratio omega-6/omega-3 élevé 
promeuvent la genèse de nombreuses pathologies, dont les maladies cardiovasculaires, les cancers, 
les maladies inflammatoires et auto-immunes, alors qu’à l’inverse des niveaux importants en 
omega-3 (et un faible ratio omega-6/omega-3) ont des effets protecteurs. La réduction de ce rapport 
omega-6/omega-3 a été associée à un basculement vers les effets bénéfiques pour la santé des 
omega-3 (Simopoulos 2008). Les êtres humains ont évolués avec un régime alimentaire ayant un 
rapport entre acides gras omega-6 etomega-3 approchant de 1/1, alors que l’alimentation 
occidentale a un rapport de l’ordre de 10/1-22.5/1 (Simopoulos 2011). De ce fait, l’alimentation 
occidentale est trop riche en omega-6 et présente un déficit en omega-3 (Simopoulos 2008). 
Dans la présente étude, la consommation chronique de la formulation EPA:DHA 6:1 a 
significativement diminué la surexpression induite par l’Ang II de AT1R, de COX-1 et de COX-2. 
Les acides gras omega-3 ont des effets antiinflammatoires reconnus chez l’homme qui pourrait 
contribuer à leur effets bénéfiques vis-à-vis du système cardiovasculaire (Wall, Ross et al. 2010). 
Les acides gras omega-6 sont convertis en acide arachidonique qui est lui-même métabolisé en 
eicosanoïdes de la série omega-6. La consommation des omega-3 augmente le taux d’EPA dans 
les membranes cellulaires, où il va entrer en compétition avec l’acide arachidonique pour la 
conversion en ses propres métabolites, les eicosanoïdes de la série omega-3 (Wall, Ross et al. 
2010). 
L’augmentation de la concentration et de l’activité de l’Ang II est fortement associée à 
l’inflammation. L’Ang II exerce un effet pro-inflammatoire sur le système cardiovasculaire qui va 
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stimuler les dommages vasculaires, induire l’expression de molécules d’adhésion, recruter des 
cellules inflammatoires, et augmenter l’expression de cytokines (Brasier, Recinos et al. 2002). 
Dans un modèle expérimental de rat, l’infusion d’Ang II induit une hypertension associée à une 
forte infiltration monocytaire et une expression de VCAM-1 et MCP-1 pro-inflammatoire dans la 
paroi des microvaisseaux ou dans l’espace périvasculaire (Cheng, Vapaatalo et al. 2005). Dans les 
cellules endothéliales, les cellules musculaires lisses vasculaires et les mononucléaires, l’Ang II 
induit une augmentation de l’expression de MCP-1, la principal chimiokine recrutant les 
monocytes/macrophages, et d’interleukine-8, un puissant chimioattractant et activateur des 
neutrophiles (Yadav, Saini et al. 2010). L’Ang II augmente aussi la production d’interleukine-6 
dans les macrophages et les cellules vasculaires, et régule positivement l’expression des gènes du 
TNF-α et de l’interleukine-6 (Libby, Ridker et al. 2002). Les inhibiteurs de l’enzyme de conversion 
(IEC) et les antagonistes du receptuer AT1R (ARAs) réduisent l’expression des marqueurs 
inflammatoires, des molécules d’adhésion et des cytokines (Mezzano, Ruiz-Ortega et al. 2001). 
L’Ang II active les cellules vasculaires et inflammatoires pour induire la sécrétion des médiateurs 
pro-inflammatoires qui vont recruter de nouveau mononucléaire, ce qui va encore augmenter la 
réponse inflammatoire contribuant à la progression de la lésion vasculaire. Les huiles de poisson 
peuvent limiter les cytokines pro-inflammatoires et réduire l’expression des molécules d’adhésion 
cellulaires chez l’homme de façon indépendante de leurs effets sur le métabolisme des eicosanoïdes 
(Calder 2006). 
 
Conclusions et perspective 
En conclusion, la présente étude a évalué le potentiel d’une formulation optimisée EPA:DHA 6:1 
à protéger la fonction endothéliale in vivo. Les résultats obtenus montrent que l’infusion d’Ang II 
est associée avec le développement dans les branches secondaires de l’artère mésentérique d’une 
dysfonction endothéliale affectant fortement la composante EDH de la relaxation ainsi que plus 
légèrement la composante NO. La dysfonction endothéliale induite par l’Ang II passe par un 
mécanisme redox-sensible impliquant la  NADPH oxydase, COX-1 et COX-2. La consommation 
chronique de la formulation EPA:DHA 6:1 a prévenu la dysfonction endothéliale et l’hypertension 
induite par l’Ang II fort probablement en diminuant le stress oxydant conduisant à l’atteinte des 
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composantes NO et EDH de la relaxation et à l’augmentation des réponses contractile dépendantes 
de l’endothélium. 
De nombreuses études supportent le rôle clé des acides gras omega-3 dans la prévention de la 
dysfonction endothéliale, de l’hypertension et des maladies cardiovasculaires. De plus amples 
études sont nécessaires pour déterminer les métabolites actifs des acides gras omega-3 en sus des 
resolvines, protectines, thromboxane A3, leucotriène 5 and lipoxines. Il serait aussi nécessaire de 
déterminer le degré d’imprégnation des tissus vasculaires en omega-3.  
De même, des études seront nécessaires pour déterminer le potentiel curative de la formulation 
EPA:DHA 6:1 vis-à-vis de la dysfonction endothéliale et de l’hypertension dans des modèles  
d’hypertension induite par l’Ang II chez le rat (Figure 24).  
Enfin, sur la base des effets vasoprotecteurs mis en évidence par la présente étude, il serait 
intéressant de proposer une étude clinique visant à démontrer le potentiel de la formulation 
EPA:DHA 6:1 à réduire la dysfonction endothéliale et les facteurs de risques cardiovasculaires 
chez les patients hypertendus (Figure 25). 
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The omega-3 EPA:DHA 6:1 formulation prevents the monocrotaline-induced 
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Short title: The EPA:DHA 6:1 prevents the monocrotaline-induced pulmonary 
hypertension in rat 
 
ABBREVIATIONS : Ach, acetylcholine; CO, cardiac output; COX, cyclooxygenase; DHA, 
docosahexaenoic acid; DHE, dihydroethidium; eNOS, endothelial nitric oxide synthase; EPA, 
eicosapentaenoic acid; ET-1, endothelin-1; ETA/B, ET receptor A and B; MCT, monocrotaline;  mPAP, 
mean pulmonary arterial pressure; PAAT, pulmonary artery acceleration time; PAH, pulmonary 
arterial hypertension; PHE, phenylephrine; PVR, pulmonary vascular resistance; ROS, reactive 
oxygen species; RVSP, right ventricular systolic pressure and VTI, velocity time integral. 
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ABSTRACT  
Background: Pulmonary arterial hypertension (PAH) is characterized elevated pulmonary arterial 
resistance leading to right heart failure. Proliferation of pulmonary arterial smooth muscle cells, 
endothelial dysfunction, oxidative stress and inflammation promote the development of pulmonary 
hypertension. Omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acids (DHA) have been shown to protect the cardiovascular system and reduce 
inflammation and oxidative stress. The possibility that EPA:DHA 6:1 a superior omega-3 formulation 
prevents pulmonary arterial and right ventricular remodeling and dysfunction was evaluated an 
experimental model PAH.  
Methods: Male Wistar rats received 500 mg/kg/day of either EPA:DHA 6:1 or corn oil by daily 
gavage. After one week, PAH was induced by a single subcutaneous injection of monocrotaline 
(MCT, 60 mg/kg). After three weeks, cardiac function and morphology were assessed by 
echocardiography, pulmonary artery reactivity using organ chambers, vascular morphometry by 
histology, proteins level by immunofluorescence and western blot, and oxidative stress using 
dihydroethidium. 
Results: MCT treatment was associated in the pulmonary artery with a significant increased mean 
pulmonary arterial pressure (mPAP), vascular resistance, and blunted endothelium-dependent 
relaxations to acetylcholine, in pulmonary arterioles with increased wall thickness and oxidative stress, 
and in the heart with increased RV systolic pressure (RVSP), RV hypertrophy and a reduced cardiac 
output (CO). Compared to the MCT group, the EPA:DHA 6:1 treatment prevented the MCT-induced 
changes in the morphology and pressure in the pulmonary artery and the RV, and also prevented the 
decreased CO. EPA:DHA 6:1 treatment also reduced the MCT-induced pulmonary artery endothelial 
dysfunction, and the level of oxidative stress in pulmonary arterioles. The MCT-induced vascular 
oxidative stress was significantly reduced by N-acetylcysteine, VAS-2870, NG-nitro-L-arginine and 
indomethacin. The protective effect of EPA:DHA 6:1 was associated with the prevention of the MCT-
induced upregulation of eNOS, angiotensin type 1 receptors, endothelin A and B receptors, COX-1 
and COX-2, and the NADPH oxidase subunits (p22phox and p47phox) in pulmonary arterioles, and a 
reduced pulmonary infiltration of macrophages and lymphocytes. 
Conclusion: The present findings indicate that the EPA:DHA 6:1 formulation has a vascular effect in 
PAH by preventing RV failure, pulmonary arterioles remodeling and dysfunction, and inflammation in 
lungs, most likely by preventing the NADPH oxidase-, COX- and uncoupled eNOS-mediated vascular 
oxidative stress. 
KEY WORDS: Omega-3 . pulmonary vascular remodeling . right ventricular hypertrophy . 
inflammation  .  oxidative stress  
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Introduction 
Pulmonary arterial hypertension (PAH) is defined by a mean pulmonary arterial pressure 
(mPAP) ≥ 25 mmHg at rest (1). It is a chronic and progressive lung disease characterized by 
pronounced small pulmonary artery remodeling leading to chronic elevation of pulmonary 
vascular resistance and subsequence right ventricular failure (1-3). It is also characterized by 
an endothelial dysfunction involving decreased NO and thrombosis (4). Moreover, oxidative 
stress and inflammatory responses have been shown to play a critical role in both human and 
experimental PAH (5-7). Indeed, pro-inflammatory cytokines including interleukin (IL)-1β 
and IL-6 and intense lung perivascular infiltrates of macrophages and lymphocytes are 
observed in human idiopathic PAH (8, 9) and monocrotaline (MCT)-induced PAH (5, 10). 
High levels of oxidative stress are observed  in pulmonary vascular lesions of patients with 
severe PAH as a consequence of tissue hypoxia (11), ischemia (12) and possible also 
involving of inflammatory response (13, 14).  
Several studies have reported that long chain polyunsaturated omega-3 fatty acids including 
eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acids (DHA, 22:6n-3) have a 
beneficial effect on the cardiovascular system (15-17). Their potential protective effects 
include the antioxidant, anti-inflammatory, anti-proliferative and the endothelial formation of 
NO, a vasoprotective factor (18-22). Indeed EPA:DHA 6:1 a superior oméga-3 formulation 
caused pronounced endothelium-dependent relaxations of porcine coronary artery rings, and 
increased the endothelial formation of NO subsequent to the redox-sensitive activation of the 
PI3-kinase/Akt pathway leading to the phosphorylation of eNOS at Ser 1177 (15, 22).  
Therefore, the aim of the present study was to determine the ability of EPA:DHA 6:1 to 
prevent the development of PAH using MCT-induced PAH in rats. To test this hypothesis, we 
investigated the chronic efficacy of oral EPA:DHA 6:1 treatment in MCT-treated rats, and, if 
so to characterized the underling mechanism. The MCT-induced PAH is a well-established 
experimental model of PAH causing similar morphologic damage as that observed in humans 
with idiopathic PAH (23, 24). The MCT-induced PAH is associated with endothelial cell 
injury followed by an inflammatory response and vascular oxidative stress (25, 26).  
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Materials and methods 
Animals 
Experiments were conducted according to the European Union regulations (Directive 86/609 
EEC) for animal experiments, and complied with our institution's guidelines for animal care 
and handling. This study was approved by the Strasbourg Regional Committee of Ethics in 
Animal Experimentation and with the French law for the protection of animals.  
The monocrotaline (MCT) of pulmonary arterial hypertension  
Adult male Wistar rats (200 to 220 g) were purchased from Janvier Labs (Le Genest-Saint-
Isle, France) and maintained in a temperature-controlled room with a 12:12 light-dark cycle. 
Rats were randomly divided into 4 groups: control group (n = 7), EPA:DHA 6:1 group (n = 
7), MCT group (n = 13) and MCT + EPA:DHA 6:1 group (n = 13). Rats received daily by 
oral intake gavage 500 mg/kg/day of either EPA:DHA 6:1 (Pivotal Therapeutics, Inc Wood-
bridge, ON, Canada) or corn oil as control. One week after the beginning of gavage, rats 
received a single subcutaneous injection of either an isotonic saline solution (control groups) 
or MCT (60 mg.kg-1). The pyrrolizidine toxic alkaloid MCT (Sigma Aldrich, Saint-Quentin 
Fallavier, France) was dissolved in 1 N HCl and neutralized to pH 7.4 with 1 N NaOH. 
Thereafter, the oral intake of either corn-oil or EPA:DHA 6:1 was continued for 3 weeks. 
Body weight was measured weekly to adjust the dose accordingly.  
Echocardiographic and hemodynamic studies 
Three weeks after MCT-injection, transthoracic two-dimensional, M-mode, and Doppler 
pulse wave images were obtained in rats anesthetized with sodium pentobarbital (50 mg/kg 
ip) to evaluate the progression of PAH. Both long- and short-axis views at the papillary 
muscle level and apical-4 chamber views were done with a Sonos 5500 (Philips, USA) 
equipped with 12-MHz sectorial transducer.  
M-mode measurements 
Pulmonary artery diameter is obtained in the parasternal long-axis. The left ventricular (LV) 
and right ventricular (RV) end-diastolic and end-systolic diameters were measured in the 
parasternal short axis view. The fractional area change (FAC) for the RV was measured at the 
apical 4-chamber view and calculated as [(end-diastolic - end-systolic area)/end-diastolic 
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area] (27). Cardiac output and stroke volume were obtained from the B-mode long axis 
according to Simpson’s method (28). 
Doppler imaging  
Pulse-wave Doppler of pulmonary outflow was recorded in the parasternal long-axis view at 
pulmonary valve leaflets. In addition, to characterize the pulmonary outflow Doppler 
envelope, the pulmonary artery acceleration time (PAAT) and the velocity time integral (VTI) 
were measured. The VTI was obtained by tracing the outer edge of the pulmonary outflow 
Doppler profile. PAAT was measured from the time of onset of systolic flow to peak 
pulmonary outflow velocity. The tricuspid valve was used to determine the tricuspid 
regurgitation velocity (TR) with color flow and pulsed-wave Doppler in the apical 4-chamber 
view so that the tricuspid and mitral valves could be clearly visualized. If TR was observed, 
the transducer was aligned to achieve the maximal peak velocity. The RV systolic pressure 
was calculated using the peak TR velocity (Vmax) in the modified Bernoulli (RVSP = 4 × 
Vmax2) (29, 30). The pulmonary vascular resistance was calculated as [PVR = Vmax 
(m/s)/VTI (cm)] of flow wave of pulmonary artery. Right atrial area from the 4-chamber 
apical view and the inferior vena cava diameter and collapsibility were measured. All 
measurements and calculated indexes are presented as the average of three cardiac cycles.  
Hemodynamic Measurements and Tissue Preparation  
Following echocardiography, the mean pulmonary arterial pressure (mPAP) was monitored 
with a heparinized saline catheter inserted into the RV through the jugular vein and placed in 
the lumen of the pulmonary artery. The systemic arterial blood pressure was monitored with a 
pressure catheter inserted into the femoral artery, and steady-state hemodynamic was recorded 
using a blood pressure transducer (EMKA Technologie, Paris, France).  
Subsequent to hemodynamic measurements, rats were euthanized and the hearts and lungs 
were isolated, the left lungs lobe and some group of hearts were in fixated in 4% 
paraformaldehyde for 48 h for morphology study. The RV and right lungs were embedded in 
Tissue-Tek® O.C.T. and snap-frozen on liquid nitrogen and quantitative as 
immunofluorescence and Western blot analysis. 
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Assessment of right ventricular hypertrophy and remodeling  
Subsequent to hemodynamic measurements, rats were euthanized and the hearts were isolated 
to separate the right ventricle (RV) wall from the left ventricle wall and the septum (LV + S) 
and then weighed. The RV hypertrophy was assessed by the weight ratio of RV to LV plus 
the septum [RV/LV + S] as a Fulton’s index (Mam et al. 2010). Cardiomyocytes cross-
sectional area and interstitial collagen content were determined in the RV and LV to 
determine cardiac ventricle tissue remodeling. Four μm sections of heart were stained with 
hematoxylin and eosin (H-E) or Gomori’s trichrome to assess fibrosis. 50 cardiomyocytes in 
each ventricle per rat were determined on transversely cut myocardial.  
Assessment of pulmonary arteriolar wall thickness  
The left lung lobe from each rat was isolated, harvested and perfused via the trachea with a 
4% paraformaldehyde solution, and then immersed in the fixative solution for 48 h. Following 
dehydration, lungs were embedded in paraffin blocks and cut into 4 μm thick sections. Lungs 
sections were stained with H-E for morphology analysis (Olympus camera and microscope). 
The images of terminal arterioles were captured with magnification 20X and measured using 
ImageJ Software. Pulmonary vascular remodeling was evaluated by determining the 
percentage wall thickness (%WT) in H-E stained sections and wall areas were measured in 
smooth muscle α-actin-stained sections (% WA). A minimum of 16 arterioles of comparable 
size (< 50 μm) per lung sections were examined for each group. The percent WT of 
pulmonary arterioles was calculated as follows: % WT = [(2 x medial thickness/external 
diameter) x 100] and the percent wall area, %WA = [(vessel wall area /vessel lumen ratio) x 
100].  
Immunohistochemistry  
The antibodies against smooth muscle α-actin (mouse monoclonal, 1:20000; Santa Cruz) to 
assess the degree of muscularization of small peripheral pulmonary arterioles, CD68 (mouse 
monoclonal [ED1], 1:1000; Abcam) for macrophages and CD3 (rabbit monoclonal [SP7], 
1:100; Abcam) for lymphocytes staining were used for this study. Microwave antigen 
retrieval (10 mM citrate buffer, pH 6.0) of 4 μm paraffin sections was followed by incubation 
in blocking buffer. Endogeneous peroxidases were blocked (3% H2O2 for 10 min) before 
incubation with a primary antibody overnight at 4°C. Thereafter, sections were incubated with 
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a secondary biotinylated antibody for 2h, and then streptavidin-biotin-peroxidase complex 
linked to HRP (Vectastain Elite ABC kit, Vector Laboratories, AbCys, Paris, France) for 30 
min. VIP peroxidase substrate kit (Vector Laboratories) was used as chromogen. Sections 
were counterstained with methyl green, air-dried and cover slipped with Eukitt (Labonord, 
Templemars, France). Ten photographs were taken from each lung sample, and the fraction 
area occupied by the macrophages and the number of lymphocytes was evaluated from each 
photograph using the ImageJ software (National Institutes of Health, http://rsweb.nih.gov/ij/).  
Immunofluorescence studies 
Right lung lobes were embedded in Tissue-Tek® O.C.T. Compound (Sakura Finetek, 
Villeneuve d’Ascq, France), frozen in liquid nitrogen bath and cryosectioned at 14 μm.  Lung 
sections were first fixed with 4% paraformaldehyde, washed and treated with 5% bovine 
serum albumin in PBS containing 0.1% Triton X-100 for 1 h at room temperature to block 
non-specific binding. Lung sections were then incubated overnight at 4°C with an antibody 
directed against either eNOS (mousse monoclonal, 1/1000, Santa Cruz), angiotensin II type 1 
receptor (rabbit polyclonal AT-1, 1/500; Santa Cruz), endothelin-1 type A and B receptors 
(rabbit polyclonal ETA, ETB, 1/1000; Abcam), cyclooxygenase (rabbit monoclonal COX-1 
and COX-2, 1/1000, Abcam) or the NADPH oxidase subunits (p22phox and p47phox, 1/500, 
Santa Cruz). Sections were then washed with PBS, incubated with the secondary antibody 
(1/400, immunoglobulin G coupled to Alexa 488- or 633) for 2h at room temperature in the 
dark before being washed with PBS and mounted in Dako fluorescence mounting medium 
(Dako France SAS, Les Ulis, France) and cover-slipped. All samples for immunofluorescence 
studies were observed using a confocal laser-scanning microscope (Leica SP2 UV DM IRBE; 
Leica, Heidelberg, Germany) with a 20X magnification lens. Quantification of fluorescence 
levels was performed using the ImageJ software. 
Determination of vascular oxidative stress  
The redox-sensitive fluorescent dye dihydroethidium (DHE, 2.5 μM) was applied onto 25 μm 
unfixed lung cryosections for 30 min at 37°C in a light protected humidified chamber to 
determine the in situ formation of ROS. To characterize the source of ROS, sections were 
incubated with either N-acetylcysteine (NAC, antioxidant 1 mM,), VAS-2870 (VAS, NADPH 
oxidase inhibitor, 10 μM), N-nitro-L-arginine (L-NA, NO synthase inhibitor, 300 μM), 
indomethacin (Indo, cyclooxygenase inhibitor, 10 μM), or MRK (inhibitors of the 
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mitochondrial respiration chain ( myxothiazol, 0.5 μM + rotenone, 1 μM + potassium cyanide 
(KCN), 1 μM) for 30 min at 37°C before DHE staining. Sections were then washed three 
times, mounted in DAKO and cover-slipped. The level of fluorescence in each section was 
examined under a confocal laser-scanning microscope (Leica SP2 UV DM IRBE; Leica, 
Heidelberg, Germany) with a 20X magnification lens. Quantification of fluorescence levels 
was performed using the ImageJ software.  
Evaluation of O2- and NO levels  
The levels of NO and O2- in lungs was determined by electron paramagnetic resonance (EPR) 
in frozen tissues at liquid nitrogen temperature. 
Nitric oxide (NO) determination 
Lung samples were incubated for 30 min in Krebs-Hepes buffer containing bovine serum 
albumin (20.5 g/L), CaCl2 (3 mM), and L-arginine (0.8 mM). NaDETC (3.6 mg) (DETC: 
diethyldithiocarbamate) and FeSO4, 7H2O (2.55 mg) were separately dissolved under nitrogen 
gas bubbling in 10-mL volumes of ice-cold Krebs-Hepes buffer. These compounds were 
rapidly mixed to obtain a pale yellow-brown opalescent colloid Fe(DETC)2 solution (0.4 
mM), which was used immediately. The colloid Fe(DETC)2 solution was added to the 
incubation solution of lungs for 45 min at 37°C. The level of NO was determined using a 
table-top x-band spectrometer Miniscope (Magnettech, MS200, Berlin, Germany). The 
quantification of the signal is based on the mean of the height (amplitude) of the three signals. 
Values are expressed in signal amplitude (amplitude, arbitrary units).  
Superoxide anion (O2-) 
Lung samples were allowed to equilibrate in deferoxamine-chelated Krebs-Hepes solution 
containing 1 hydroxy-3 methoxycarbonyl 2,2,5,5-tetramethylpyrrolidin (CMH, Noxygen, 
Germany,500 μM), deferoxamine (25 μM), and DETC (5 μM) under constant temperature 
(37°C) for 1 h. The reaction was stopped by freezing the samples in liquid nitrogen before 
EPR spectroscopy analysis. Values were expressed as arbitrary units per milligram weight of 
dried tissue (A/Wd). 
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Vascular reactivity studies 
Vascular reactivity studies are performed in main pulmonary artery and secondary mesenteric 
artery rings. Briefly, the arteries were excised, carefully cleaned of connective tissue in Krebs 
bicarbonate solution and cut into rings (3 mm length). Rings were suspended in organ 
chambers containing oxygenated (95% O2; 5% CO2) Krebs bicarbonate solution (mM: NaCl 
119, KCl 4.7, KH2PO4 1.18, MgSO4 1.18, CaCl2 1.25, NaHCO3 25, and D-glucose 11, pH 7.4 
at37°C) for the determination of changes in isometric tension. After an equilibration period, 
rings were subjected to functional test before construction of either a concentration-
contraction curve to phenylephrine, or a concentration-relaxation curve to acetylcholine on 
rings precontracted with phenylephrine (10 μM). The concentration-response curves were 
constructed both in absence or presence of an eNOS inhibitor (L-NA, 300 μM) to assess the 
role of the basal endothelial NO formation. 
Statistical analysis 
All values are expressed as the mean ± SEM of n different rats. Statistical analysis  was 
performed using either a one-way or a two-way analysis of variance test (ANOVA), followed 
by Bonferroni’s post-hoc test as appropriate using GraphPad Prism software (version 5.04 for 
Windows, GraphPad software, Inc., San Diego, CA, USA). A P value < 0.05 was considered 
to be statistically significant.  
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RESULTS 
EPA:DHA 6:1 prevents the MCT-induced increase in mPAP and RVSP  
Three weeks after MCT injection, hemodynamic parameters were monitored by 
echocardiography and right ventricular catheterization. MCT-treated rats consistently 
developed pulmonary hypertension associated with a significant increase in mPAP from 16 ± 
0.3 to 35.2 ± 0.7 mmHg and RVSP from 17.4 ± 0.5 to 40.5 ± 1.9 mmHg (Fig. 1A, B). In 
addition, CO was significantly decreased in the MCT group compared with the control group 
(124 ± 7.4 to 67.7 ± 3.7 ml/min) (Figure 1C). Oral intake of EPA:DHA 6:1 significantly 
reduced mPAP to 29.6 ± 0.8 mmHg and RVSP to 31.9 ± 0.8 mmHg and also improved CO to 
90.2  ± 4.4 mL/min (Fig. 1A, C). 
The heart rate was slightly but significantly lowered  from 392.7 ± 8.1 bpm to 333.2 ± 4.9 
bpm by the MCT treatment and the mean systemic arterial pressure is not significantly 
different in the  four groups (Fig. 1D, E).  
EPA:DHA 6:1 prevents the MCT-induced RV remodeling and hypertrophy  
RV morphology and function were evaluated by echocardiography. The MCT group 
presented a significant dilatation of the RV indicated by the increased RV area, end-diastolic 
and systolic diameters compared to the control group. The dilatation of the RV was associated 
with a decreased of the RV fractional area chance (RVFAC %) (control vs MCT: 42.4 ± 1.6 
vs 27.6 ± 3.1). Oral intake of EPA:DHA 6:1 prevented RV remodeling by improving RV 
morphology and function (Fig. 2A-D).  
Right ventricular hypertrophy was assessed by the weight ratio of RV/(LV+S). The MCT 
group developed severe RV hypertrophy manifested by an RV/(LV+S) ratio of 0.54 ± 0.03 
compared with 0.22 ± 0.01 in the control group (Fig. 2E). Similarly, the ratio of RV weight to 
body weight was significantly higher in the MCT-treated group compared to the control 
group. The marked MCT-induced RV hypertrophy was reduced significantly to 0.33 ± 0.01 
by the EPA:DHA 6:1 treatment indicating that chronic oral intake of  EPA:DHA 6:1 was able 
to prevent PAH-induced RV hypertrophy.   
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EPA:DHA 6:1 prevents the MCT-induced RV cardiomyocytes hypertrophy and 
macrophages infiltration  
In the RV, representative H-E staining showed that the MCT treatment induced a significant 
cardiomyocytes hypertrophy as compared to the control group (Figure 3A). The RV 
cardiomyocytes hypertrophy was associated with enhanced perivascular infiltration of 
macrophages detected by anti-CD68 staining (Figure 3B). The EPA:DHA 6:1 treatment 
prevented the MCT-induced RV cardiomyocytes hypertrophy by restored RV area and 
reduced infiltration of macrophages (Fig. 3A, B). In contrast, in the left ventricle, 
cardiomyocytes size was similar in all group studied, and only a low level of infiltration of 
macrophages was observed.  
EPA:DHA 6:1 prevents MCT-induced pulmonary arterial remodeling  
Pulmonary vascular remodeling was assessed by pulse-wave Doppler of pulmonary outflow. 
MCT significantly increased the pulmonary artery diameter and pulmonary vascular 
resistance (control vs. MCT: 0.37 ± 0.03 vs. 0.84 ± 0.05 unite wood), indicating hypertrophy 
and stiffness of the pulmonary artery, and reduced the velocity-time integral (VTI) and 
pulmonary artery acceleration time (43.05 ± 2.39 vs. 26.06 ± 0.91 ms), indicating an 
increased pulmonary arterial pressure. EPA:DHA 6:1 treatment significantly prevented the 
MCT-induced  changes on pulmonary artery diameter, PVR, PAAT, and pulsatility (Fig. 4). 
Indeed, to examine the level of pulmonary vascular remodeling, morphometric analysis was 
performed on lung tissue sections stained with H-E or α-actin. Quantitative morphometric 
analyses showed pulmonary arterioles remodeling in MCT group (Figure 5). The medial 
thickness of pulmonary arterial was markedly increased in arterioles with external diameter < 
50 μm in the MCT group (control vs. MCT: 25.9 ± 0.6 vs. 73.7 ± 0.5). The medial wall 
hypertrophy was accompanied with muscularization of small pulmonary arteries evidenced by 
enhanced α-actin staining (Fig. 5).  The EPA:DHA 6:1 treatment  significantly attenuated the 
MCT-induced increase in wall thickness and pulmonary arterioles muscularization. In 
addition, an increased collagen deposition in MCT group as assessed by Gomori’s Trichrome, 
which was prevented by the EPA:DHA 6:1 treatment  (Fig. 5).  
To determine the perivascular inflammatory cell infiltration, immunohistochemical staining 
was performed in lung sections with CD68 for macrophages and CD3 for T lymphocytes. The 
MCT-treatment was associated with a significantly macrophages and lymphocytes infiltration 
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surrounding pulmonary remodeled arterioles. The EPA:DHA 6:1 treatment significantly 
prevented the MCT induced infiltration of macrophages and lymphocytes (Fig. 5B).   
EPA:DHA 6:1 treatment prevents MCT-induced vascular oxidative stress involving 
several sources in  pulmonary arterioles 
Reactive oxygen species (ROS) have been proposed as a pathogenic mechanism underlying 
the vascular remodeling observed in MCT-induced PAH (5). The pulmonary vascular level of 
oxidative stress was assessed using the redox-sensitive fluorescent probe DHE. The MCT 
treatment increased the formation of ROS as indicated by the markedly increased the DHE 
fluorescence signal throughout the medial wall in comparison to the control group. These 
effects were significantly prevented by EPA:DHA 6:1 treatment (Figure 6A). In order to 
determine the source of ROS, lung sections were treated with different inhibitors major 
vascular sources of ROS. The MCT-induced formation of ROS in the pulmonary arterioles 
wall was significantly inhibited by N-acetylcysteine (NAC, antioxidant), VAS-2870 (an 
NADPH oxidase inhibitor and antioxidant), L-NA (an eNOS inhibitor), indomethacin (a 
cyclooxygenase inhibitor) and by a combination of inhibitors of the mitochondrial respiration 
chain (MRK: myxothiazol, rotenone and KCN) suggesting the involvement of NADPH 
oxidase, COXs, uncoupled eNOS and the mitochondrial respiration chain (Fig. 6B). The 
levels of NO- and O2- in lungs was determined by electron paramagnetic resonance (EPR) in 
frozen tissues at liquid nitrogen temperature. The MCT treatment increased NO- and O2- 
production in lungs. EPA:DHA treatment significantly prevented the increased of NO- and O2- 
production (Fig. 6 C, D). 
To obtain further evidence for a role of eNOS, NADPH oxidase and COXs. Their expression 
level was determined by immunofluorescence staining in the pulmonary arterioles. A 
significantly increased immunofluorescence signal of the NAPDH oxidase subunits p22phox, 
p47phox, and of COX-1 and COX-2 was observed in pulmonary arterioles of the MCT group 
compared to the control group (Fig. 7). The EPA:DHA 6:1 treatment significantly reduced the 
MCT-induced stimulatory effect for p22phox, p47phox, COX-2 and COX-1 (Figure 7A). In 
addition, an upregulation of eNOS was observed in the MCT group which was prevented by 
the EPA:DHA 6:1 treatment (Fig. 7).  
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EPA :DHA 6 :1 prevents the expression of endotheline-1 receptors (ETA, ETB) and 
angiotensin II receptor on pulmonary arterioles wall.  
It has been suggested that PAH is associated with the increased expression of endothelin-1 
(31) and angiotensin II (32) may contribute to the arterioles remodeling. An increased 
immunofluorescence level of endothelin-1 receptors (ETA, ETB) and angiotensin II receptor 
(AT1) throughout the pulmonary arterioles wall was observed in the MCT group (Fig 7). The 
EPA:DHA 6:1 treatment prevents MCT-induced changes of ETA, ETB and AT1 expression in 
pulmonary arterioles (Fig. 7).  
EPA:DHA 6:1 prevents MCT-induced endothelial dysfunction in the pulmonary artery  
Vascular reactivity was performed in primary pulmonary artery rings to evaluate the 
endothelial function using organ chambers. The MCT treatment significantly reduced the 
contractile responses to phenylephrine, and also the acetylcholine-induced endothelium-
dependent relaxation of pulmonary artery rings pre-contracted with phenylephrine. The 
concentration-response curves were constructed both in absence or presence of an eNOS 
inhibitor (L-NA) to assess the role of the basal endothelial NO formation. The MCT treatment 
increased basal nitric oxide (NO) production. The EPA:DHA 6:1 prevented MCT-induced 
endothelial dysfunction as indicated by the increased relaxation to Ach (Fig. 8).  
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DISCUSSION  
The present study demonstrated that the optimized EPA:DHA 6:1 formulation prevents the 
development of PAH in MCT-treated rat. Since, rats were treated with EPA:DHA 6:1 one 
week before the induction of PAH, the findings indicate the capacity of the omega-3 products 
to prevent the disease and not to cure it. The MCT-induced PAH rat model has been widely 
used as an experimental model of PAH (33) and it is tough to the most similar animal model 
to the human form of the disease (34). It is characterized by pulmonary endothelial cell 
damage, associated with an inflammatory response and vascular oxidative stress. It also leads 
to small pulmonary arterial and RV remodeling and dysfunction (35, 36). Previous studies 
focused on the effects of omega-3 on the systemic circulation but provided little information 
on its pulmonary effects. 
The presents findings indicate that daily oral treatment with EPA:DHA 6:1 significantly 
prevented an elevation of mean pulmonary arterial pressure, RV systolic pressure and 
improved cardiac output in rats model of MCT-induced PAH. EPA:DHA 6:1 treatment also 
prevented pulmonary arterioles remodeling and dysfunction, RV hypertrophy and dilation, 
attenuated oxidative stress and inhibited inflammation. Our studies show that EPA:DHA 6:1 
exerts anti-inflammatory, antioxidant and antiproliferative effects in the pulmonary arteries, 
which may contribute to prevent pulmonary hypertension. Recent study showed that DHA 
therapy reduced mPAP in a rat model of hypoxia-induced PAH and this effect was linked 
with inhibition of pulmonary vascular remodeling (37). 
Echocardiography is widely used in the evaluation of PAH in the rat MCT model (38). The 
echocardiography analysis of control and MCT groups indicates that oral treatment of 
EPA:DHA 6:1 prevented  in the pulmonary arteries of the MCT-treated rats the elevation of 
vascular resistance and the reduction of pulmonary acceleration time compared to control rats, 
suggesting that this formulation has the beneficial effect of reducing the stiffness of the 
pulmonary artery. In addition, oral treatment with EPA:DHA 6:1 significantly prevented the 
MCT-induced RV dilatation as indicated by increased RV area and decreased RV fractional 
area change (RVFAC), suggesting a beneficial effect of EPA:DHA 6:1 to reduce RVSP. The 
FAC is an ideal echocardiography parameter reflecting RV dysfunction and disease severity 
in PAH (39). Oral treatment with EPA:DHA 6:1 prevent RV hypertrophy characterized by 
increased RV/(LV + S) ratio, cardiomyocytes hypertrophy and extracellular matrix changes 
with fibrosis.  
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Previous studies have been revealed that inflammation plays a key role in human PAH as well 
as in experimental models including MCT-induced PAH (7, 40) . In response to injury and 
stress, a pronoucial lung vascular inflammatory response is observed including macrophages, 
monocytes, lymphocytes and mast cells (41, 42) and they have been involved  in the initiation 
of pulmonary vascular remodeling by matrix remodeling, collagen deposition, and vascular 
cell proliferation and migration in PAH (43, 44). These process lead to increased pulmonary 
resistance and right heart failure. Consistent with these previous findings, a substantial 
increased number of CD68 (ED-1) and CD3+ positive cells were observed in the lungs of 
MCT-treated rats. In addition an increased pulmonary arterial medial thickness and RV 
cardiomyocytes hypertrophy were observed and associated with an increased the number of 
macrophages in perivascular intra-alveolar spaces, and of lymphocytes around the pulmonary 
arteries in the MCT-treated rats relative to the control group. Importantly, oral intake of 
EPA:DHA 6:1 significantly prevented the stimulatory effect of MCT on macrophages and T 
lymphocytes infiltration in the lung and right ventricle. Thus, these findings suggest that the 
EPA:DHA 6:1 formulation prevented MCT-induced PHA by reducing the inflammatory 
responses.  
In addition to the inflammatory response, oxidative stress has been implicated in the 
pathogenic mechanism underling the vascular remodeling and heart failure observed in 
pulmonary hypertension (14, 32, 45). Dysregulation of the pro-oxidant/antioxidant balance 
contributes to impair vascular tone and the pathological activation of anti-apoptotic and 
mitogenic pathways, leading to cell proliferation and obliteration of the vasculature (46). 
There is solid evidence in MCT-treated rats, that oxidative injury to the pulmonary vascular 
endothelium precedes pulmonary arterial smooth muscle cells proliferation and medial 
hypertrophy in the distal pulmonary vascular bed and the rise in pulmonary artery pressure 
Small pulmonary arterioles and RV remodeling is associated with an increased inflammatory 
infiltrate and oxidative stress as indicated by high levels of ROS formation throughout the 
pulmonary arterioles wall of MCT-treated rats. The characterization of the cellular sources of 
ROS in the small pulmonary arterioles indicated the involvement of several sources including 
NADPH oxidase, uncoupled eNOS, cyclooxygenase (COXs) and the mitochondrial 
respiration chain. Moreover, an up-regulation of several pro-oxidant enzymes including 
NADPH oxidase submits p22phox and p47phox, COX-1, and COX-2 is observed in the small 
pulmonary arteries of MCT-treated rats. Oral intake treatment of EPA:DHA 6:1 substantially 
attenuated the level of vascular oxidative stress and  remodeling by reducing in arterioles as 
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well as the upregulation of the NADPH oxidase submits p22phox and p47phox, COX-1 and 2 
and eNOS expression in MCT-treated rat.  Both in vitro and in vivo studies have shown that 
ROS promote cardiomyocyte hypertrophy as well as fibrosis (47) and also right ventricular 
failure in the MCT-induced PAH, (48). EPA:DHA 6:1 due to its antioxidant, anti-
inflammatory and cardioprotective properties, improved right ventricular function as indicated 
by an increased CO and with inhibition of cardiomyocyte hypertrophy and fibrosis.  
Endothelial dysfunction has been shown to plays a key role in the development of PAH and 
results in a decrease of vasodilatator and antiproliferative factors (prostacyclin, nitric oxide) 
and in an increase in vasoconstrictor and proliferative factors (endothelin [ET]-1) (49). 
Moreover, inflammation and oxidative stress have been shown to contribute to the MCT-
induced endothelial dysfunction most likely by reducing the bioavailability of NO and 
oxidizing tetrahydrobiopterin, an essential cofactor for eNOS (5, 10). Although decreased 
endothelium-dependent relaxation was observed in the pulmonary artery (50). The present 
findings indicated that MCT-induced pulmonary hypertension is associated with an 
endothelial dysfunction in main pulmonary artery without any effect on systemic vascular 
functions. The MCT treatment significantly reduced the contractile response of pulmonary 
artery rings to α-adrenergic agonist PHE. Blockade of NO production by L-NA enhanced 
PHE potency in MCT-treated rats. In addition, ACh-induced endothelium-dependent 
relaxation was reduced in pulmonary arteries of MCT treated-rats. Although the reduced ACh 
relaxation in the PH rats could be due to increased oxidative stress and decreased NO 
bioavailability in MCT treated-rats. The decreased bioavailability of NO reduces the 
antiproliferative effects of NO and thus contributes to the increased of pulmonary vascular 
remodeling and resistance. Previous studies have shown in isolated pulmonary arteries a 
reduced responsiveness to endothelium-dependent vasodilators including ACh and A23187, 
whereas others have suggested an increased basal NO production in the MCT-treated rats 
from (51, 52). We have showed that inflammation and oxidative stress of the lung in PAH 
stimulates the eNOS uncoupled. Oral intake of EPA:DHA 6:1 prevented the MCT-induced 
the development of PAH, reversed vascular remodeling, reduced vascular inflammation and 
improved the endothelial function, as indicated by an improvement ACh-induced relaxation. 
Thus, it could be hypothesized that EPA:DHA 6:1-induced elevation of cGMP. It is possible 
that up-regulation of eNOS contributes to the therapeutic action of omega-3. Furthermore, 
EPA:DHA 6:1 has been shown to stimulate the endothelial release of NO and to improve 
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endothelial function subsequent to phosphorylation of PI3K/Akt/eNOS signaling pathway 
(22).  
The endothelin (ET) system is activated in human pulmonary hypertension (PH) of various 
pathogeneses (53, 54). ET-1 could contribute to the development of human PH through its 
strong vasoconstrictive and promitogenic properties (55). Previous studies have shown 
enhanced ET-1-induced pulmonary vasoconstriction and vascular resistance in the MCT-PAH 
(56) and increased vasomotor tone in hypoxic PAH (5, 32). The present findings support a 
role for the ET-1 in the MCT-induced endothelial dysfunction. Indeed, an increased 
expression of ETA and ETB receptors was observed throughout the arterial wall of the MCT 
treatment group. The ETA receptors are located on smooth muscle cells, where they mediate 
vasoconstrictive and proliferative effects (57). The ETB receptor is the only subtype found 
predominantly on the vascular endothelium, where it promotes vasodilation through the 
release of nitric oxide and prostacyclin (31). There is also evidence that the ETB receptor 
indirectly modulates ET-1 synthesis through negative feedback under the action of nitric 
oxide (53). They are also consistent with the fact that chronic bosentan, a non-selective ET-
1 receptor antagonist reduced pulmonary hypertension in MCT-treated rats and prevented the 
MCT-induced endothelial dysfunction and oxidative stress (31, 58). Our data show that 
EPA:DHA 6:1 prevented the MCT-induced upregulation of the expression ETA and ETB 
receptors in MCT-induced PAH rats. 
However, the mechanism explaining best the beneficial effect of omega-3 treatment to 
prevent pulmonary hypertension most likely includes its antioxidant, anti-inflammatory and 
endothelial protective properties. Two previous studies have demonstrated potential benefits 
of oral administration of MAG-DPA to reduce inflammation (decreased NF-kB and p38 
MAPK activation) and proliferation (reduction in MMP-2, MMP-9 and VEGF expression 
levels in lung tissue homogenates) of pulmonary artery smooth muscle cells in MCT-treated 
rats (59) and DHA to inhibit the development of hypoxic pulmonary hypertension in vitro and 
in vivo studies (60). The effects of EPA and DHA have not be investigated in PAH; however, 
these two fatty acids affect cell function differently (61, 62).  
Moreover, the beneficial role of omega-3 in cardiovascular health is supported by its 
metabolism. Indeed, omega-3, unlike omega-6, decreases the production of pro-inflammatory 
cytokines and leukocyte reactive oxygen species, increase the synthesis of anti-inflammatory 
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cytokines, lead to the release of resolvins and modulate the activation of genes involved in the 
inflammatory process (63, 64). Furthermore, when administrated per os, omega-3 represents a 
stable compound that could serve as a precursor to generate proresolving (resolvins and 
protectins) molecules, which are known for their anti-inflammatory properties (65, 66). 
Study limitation  
This study indicates the ability of a formulation omega-3 to prevent MCT-induced PAH, in 
which inflammatory mechanisms related to pulmonary vascular endothelial dysfunction and 
remodeling may contribute to the development and progression of the pathology. A 
subsequent study will be necessary to determine the efficacy of omega-3 in the treatment of 
an established PAH.  
CONCLUSION  
The present findings indicate that EPA:DHA 6:1 exerts a significant anti-oxidant, anti-
inflammatory and endothelial protective effect in the pulmonary circulation and prevents the 
progression of pulmonary hypertension in MCT-treated rats by reducing pulmonary vascular 
remodeling, endothelial dysfunction, right ventricular hypertrophy and failure. The beneficial 
effects were associated with a reduced vascular inflammatory responses and oxidative stress 
mostly by preventing overexpression of NADPH oxidases, COXs and also of uncoupled 
eNOS. Further investigations are necessary to better assess the biological effects, elucidate the 
underlying mechanisms and to evaluate the political of this omega-3 formulation in the 
clinical setting.  
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Table 1. Characteristics of the different omega-3 fatty acid products 
Fatty acids Purity (in %) Ratio EPA:DHA Content of Omega-3 EPA-DHA as EE 
Sum Omega-3 as 
EE (mg/g) 
EPA (mg/g) DHA (mg/g) 
EPA:DHA 93.4 01:01 476 386 934 
EPA:DHA 91.3 06:01 694 121 913 
EPA:DHA 46.0 06:01 352 65 460 
EPA 99.5 991 995 
DHA 98.6     945 986 
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Table 2. Echocardiography parameters of the inferior vena cava, the right atrium and the left 
ventricular. 
 
Control Omega MCT MCT+OM 
RA diameter (mm) 1.6 ± 0.1 1.8 ± 0.1 2.9 ± 0.2* 2.2 ± 0.1# 
RA area (mm2) 9 ± 0.2 9.1 ± 0.1 13.3 ± 0.1* 10.2 ± 0.1# 
IVC diameter (mm) 1.6 ± 0.2 1.8 ± 0.2 2.7 ± 0.1* 2.4 ± 0.1 
IVC systolic area (mm2) 3.6 ± 0.7 3.6 ± 0.4 4.5 ± 0.3* 3.9 ± 0.2 
LV Strock volume (ml) 0.32  ± 0.02 0.31  ± 0.01 0.20 ± 0.01* 0.24  ± 0.01 
LV End-diastolic (mm) 7.9 ± 0.1 7.8 ± 0.1 6 ± 0.1* 6.4 ± 0.1 
LV End-systolic (mm) 4.3 ± 0.1 4.4 ± 0.2  3.6 ± 0.1 3.7 ± 0.2 
Septal wall thikness (mm) 1.5 ± 0.1 1.6  0.1 1.8 ± 0.1 1.7 ± 0.1 
LVP wall thickness (mm) 1.7 ± 0.1 1.7 ± 0.1 1.9 ± 0.1 1.8 ± 0.1 
LV area (mm2) 53.3 ± 1.1 50.2 ± 3.4 35.1 ± 0.7 39.6 ± 2.0 
LV fractional shortening (%) 45.3 ± 1.5 42.9 ± 2.2 39.4 ± 1.4 42.5 ± 2.4 
LV ejection fraction (%) 70 ± 1.7 67.2 ± 2.4 62.1 ± 1.6  66.4 ± 2.9 
 All values are mean ± SEM, n = 6-11/group. IVC, inferior vena cave, MCT, monocrotaline, LV, left 
ventricle; RV, right ventricle. *P < 0.05 versus control; #P < 0.05 versus MCT. 
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Figure 1.  Oral intake of EPA:DHA 6:1 prevents MCT-induced pulmonary hypertension and 
right heart dysfunction. (A) Mean pulmonary artery pressure (mPAP) was monitored by 
catheter inserted into the jugular vein and advanced to the pulmonary artery. (B) Right 
ventricular systolic pressure (RVSP) was evaluated by echocardiography from tricuspid 
regurgitation velocity (RVSP = 4 × Vmax2). (C) Cardiac output (CO) and (D) heart rate (HR) 
were monitored by pulsed wave Doppler. (E) Systemic arterial pressure (SAP). All 
measurements are presented as the average of three cardiac cycles. Values are given as mean 
± SEM. *P < 0.05 versus control, #P < 0.05 versus MCT. 
Figure 2. The EPA:DHA 6:1 treatment prevents MCT-induced right ventricular remodeling 
and hypertrophy. (A) Echocardiographic views of the right ventricle.  (B) RV end-diastolic 
(RVEDD), (C) end-systolic diameter (RVESD), (D) RV fractional area changes (RVFAC). 
Images were obtained by two-dimensional and M-mode echocardiography from a parasternal 
short-axis view. (E) RV hypertrophy was assessed by Fulton’s index, calculated as RV to LV 
weight ratio [RV/(LV+S)], (F) RV weight/body weight and (G) LV+S weight/body weight. 
Values are given as mean ± SEM. *P < 0.05 versus control, #P < 0.05 versus MCT. 
Figure 3. The EPA:DHA 6:1 treatment prevents the MCT-induced RV cardiomyocytes 
hypertrophy and macrophages infiltration. (A) Quantitative morphometric analyses of 
cardiomyocytes section area were done using hematoxylin and eosin and gomori’s blue 
trichrome staining of right and left ventricle walls. (B) Evaluation of macrophage infiltration 
was performed by quantitative analysis of the macrophages counted in 10 fields of 
immuhistochemical staining with CD68 antibody (20X, objective). Results are presented as 
representative micrographies (left) and corresponding cumulative data (right). Values are 
given as mean ± SEM. *P < 0.05 versus control, #P < 0.05 versus MCT.  
Figure 4. The EPA:DHA 6:1 treatment prevents MCT-induced pulmonary artery remodeling. 
(A) Notching of the pulse wave Doppler profile in the pulmonary artery outflow, (B) 
pulmonary artery diameter, (C) pulmonary artery acceleration time (PAAT), (D) pulmonary 
vascular resistance (PVR) and (E) pulsatility. Pulse-wave Doppler of pulmonary outflow was 
recorded in the parasternal view at the level of the aortic valve. PAAT was measured from the 
time of onset of systolic flow to peak pulmonary outflow velocity. Values are given as mean ± 
SEM. *P < 0.05 versus control, #P < 0.05 versus MCT. 
28 
 
Figure 5. The EPA:DHA 6:1 treatment prevents pulmonary vascular remodeling, pulmonary 
macrophages and lymphocytes infiltration in MCT-treated rats. (A) Representative images of 
hematoxylin-eosin, gomori’s blue trichrom and immunohistochemical (α-actin as a mesure of 
the dedree of muscularization) staining of lung section in rats for determination of the wall 
thickness and wall area of small pulmonary arteries sized < 20 μm. Images are shown on the 
left and quantification analysis on the right. Sixteen pulmonary arteries from 6 
rats/experimental group were analyzed (n= 8). (B) Immunofluorescent (green) and 
immunohistochemical (purple arrows) staining with antibodies against CD68 [ED-1] for 
detection of macrophages and CD3 for lymphocytes T, respectively. Quantification of 
positive cells was analyzed of the fraction area occupied macrophages and lymphocytes T 
were counted in 10 different fields. Scale bar, 20 μm (20X objective). Values are given as 
mean ± SEM. *P < 0.05 versus control, #P < 0.05 versus MCT.  
Figure 6. The EPA:DHA 6:1 treatment prevents MCT-induced vascular oxidative stress in 
pulmonary arterioles. (A) The determination of the vascular formation of ROS formation was 
done in unfixed cryosections of the right lung using the redox-sensitive probe 
dihydroethidium (DHE). (B) The characterization of the source of ROS formation was 
performed in presence of either N-acetylcysteine (NAC, antioxydant 1 mM), VAS-2870 ( 
NADPH oxidase inhibitor, 10 μM), N-nitro-L-arginine (LNA, NO synthase inhibitor, 300 
μM), indomethacin (Indo, cyclooxygenase inhibitor, 10 μM), or MRK (inhibitors of the 
mitochondrial respiration chain, myxothiazol, 0.5 μM + rotenone, 1 μM + potassium cyanide 
(KCN), 1 μM) for 30 min before DHE staining. Thereafter, ethidium fluorescence was 
determined by confocal laser-scanning microscope (Leica SP2 UV DM IRBE). (C and D) 
Nitric oxide (NO.) and superoxide anion (O2.-) measured by electron paramagnetic resonance 
in small pulmonary arterioles. Values are given as mean ± SEM. *P < 0.05 versus control, #P 
< 0.05 versus MCT. 
Figure 7. The EPA:DHA 6:1 treatment prevents MCT-induced changes of protein expression 
in pulmonary arterioles. Protein expression levels were determined in unfixed cryosections of 
right lung, the determination of the expression level of endothelial NO synthase (eNOS), 
NADPH oxidase subunits p22phox and p47phox, cyclooxygenase (COX-1 and COX-2), ET-1 
receptors (ETA, and ETB) and the AT1R was done by immunofluorescence. All samples for 
immunofluorescence studies were observed using a confocal laser-scanning microscope 
(Leica SP2 UV DM IRBE).  
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Figure 8. The EPA:DHA 6:1 treatment prevents MCT-induced endothelial dysfunction in the 
main pulmonary artery as assessed in organ chamber. The concentration-contraction curves in 
response to phenylephrine (A and B) and the concentration-relaxation curves to acetylcholine 
in pulmonary artery rings pre-contracted by phenylephrine (10-6 mol/L) (C and D) were 
constructed in the absence (A and C) and the presence (B and D) of eNOS inhibitor (L-NA, 
300 μM) to assess the role of the basal formation of endothelial NO. (n = 7 to11). Values are 
given as mean ± SEM. *P < 0.05 versus control, #P < 0.05 versus MCT. 
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Figure 2. 
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Figure 3.  
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Figure 4. 
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Figure 6. 
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Figure 7.  
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Figure 8. 
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Abstract 
Ethnopharmacology relevance: Phyllanthusamarus(Euphorbiaceae family) has been reported 
in traditional medicine to possess beneficial effects in the management of hypertension. In 
different animal models of hypertension, an impairment of the vascular function has been 
linked to an endothelial dysfunction. Therefore, the aim of the present study was to determine 
if an aqueous extract of Phyllanthus amarus (AEPA)obtained by decoction was able to 
prevent hypertension and endothelial dysfunction in DOCA-salt rats, and, if so, to clarify the 
underlying mechanism. 
Materials and methods:Male Wistar rats were randomly assigned into the control group, the 
AEPA group (100 mg/kg/day, by gavage), the DOCA-salt group (50 mg/kg, s.c, per week), 
and the DOCA-salt + AEPA group (100 or 300 mg/kg/day, by gavage). DOCA-salt-treated 
rats were allowed free access to water containing 1% NaCl. Systolic blood pressure (SBP) 
was determined by tail-cuff plethysmography twice a week, in the morning during 5 weeks. 
Vascular reactivity using main mesenteric artery rings was assessed in organ chambers. 
Dihydroethidine (DHE) and immunofluorescence methods were used for the determination of 
the vascular formation of reactive oxygen species (ROS) and the expression level of proteins, 
respectively. 
Results: After 5 weeks, SBP (mmHg) increased significantly in DOCA-salt hypertensive rats. 
It was significantly lowered by the treatment with AEPA (100 or 300 mg/kg/day) by 24 and 
21mmHgrespectively. In mesenteric artery rings, the phenylephrine induced contractile 
response was increased significantly in the DOCA-salt group in comparison to the control 
group. After treatment by AEPA, the contractile response was shifted to the right. Both the 
NO-mediated (assessed in the presence of indomethacin and TRAM-34 plus apamin) and the 
endothelium-dependent hyperpolarization (EDH)-mediated (assessed in the presence of 
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indomethacin and Nω-nitro-L-arginine) relaxation to acetylcholine were significantly reduced 
in the DOCA-salt group compared to the control group. Fluorescence study showed that the 
endothelial dysfunction was associated with a reduced expression level of Cx37, an increased 
expression of eNOS and the formation of ROS in main mesenteric artery. The 
antihypertensive effect of AEPA was related to an improvement of the blunted NO- and 
EDH- mediated relaxation, and an increased vascular oxidative stress and modulation of the 
expression levels of target proteins in DOCA- salt rats. 
Conclusion: Altogether, our study shows that AEPA is able to act as an antihypertensive 
agent, and to prevent endothelial dysfunction in DOCA-salt hypertensive rats, in part, by 
preventing vascular oxidative stress.   
 
Keywords: Phyllanthusamarus, DOCA-salt, hypertension, endothelial dysfunction, 
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Introduction 
Hypertension is a major public health problem (WHO, 2013). In chronic situation, 
hypertension increases the risk factor for cardiovascular diseases including atherosclerosis, 
coronary disease, congestive heart failure and stroke (Kannel, 2000; Tsotetsi et al., 2001; 
D’Agostino et al., 2008). For a better understanding of hypertensive disease physiopathology, 
several animal models such as spontaneously hypertensive rats (SHR), angiotensin II (Ang 
II)-induced hypertension, Dahl salt-sensitive hypertensive rats, DOCA-salt rats and other 
models are usedas a mimetic of human essential hypertension (Galisteo et al., 2004;  Wilcox 
and Pearlman, 2008). A DOCA-salt model isa characteristic of human volume-overload 
induced hypertension with sodium retention (Galisteo et al., 2004; Iyer et al., 2010 ), 
obtainedthrough several weeks administration of a synthetic mineralocorticoid 
deoxycorticosterone acetate (DOCA) to rat allowed free access to water containing NaCl.This 
model isalso associate to a low rennin and potassium-depleted (Galisteo et al., 2004; Liu et 
al., 2014). 
Almost deleterious effects found in human hypertension are observed in DOCA-salt 
hypertensive rat as a model ofendothelial dysfunction, cardiac hypertrophyand renal damage, 
and inflammation (Fenning et al., 2005).These phenomena are related to an excessive 
production of reactive oxygen species (ROS) by NADPH oxidase (O’Brien et al., 2010). Left 
ventricular hypertrophy is found in most animal models of hypertension (Perez-Vizcaino et 
al., 2009). Numerous studies have indicated that endothelial dysfunction in pathological 
modelswas linked to animpairment of endothelium-derived relaxing factors mediated-
relaxations, such as NO and EDH component(Li et al., 2013; Rashid et al., 2014). 
Hypertension management required the use of classic antihypertensive drug agents such as 
diuretics, beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II type 1 
receptor (AT1R) blockers, and calcium channel blockers. Since efficacy of antihypertensive 
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drugs was relative, in most patients, two or more drugs combined are required in 
antihypertensive therapy (Chobanian et al., 2003). Moreover, chemical drugs cause a risk of 
side effects. During the last few decades, besides chemical drugs, other therapeutic 
approaches were privileged. Within this framework, the modifications of lifestyle or the use 
of natural products derived from plant extractsgained muchattention (Perez-Vizcaino et al., 
2009; Zapata-Sudoetal., 2014). Besides, many researches are focusingon herbal preparations 
for their cardioprotective properties. For instance, Moringa oleifera (Moringaceae) seeds 
show a beneficial effect on cardiac structure and function in SHR associated with an 
upregulation of PPARα and δ signaling (Randriamboavonjy et al., 2016). Euterpe oleracea 
(Arecaceae) prevented cardiac dysfunction, hypertrophy and fibrosis on rats subjected to 
myocardial infarction (Zapata-Sudo et al., 2014). 
In Ivorian folk medicine, Phyllanthus amarus Schum. & Thonn. a plant belonging to the 
Euphorbiaceae family is used by local population as decoction of whole/leave of plant to treat 
hypertension and cardiovascular disorders (N’guessan et al., 2009). P. amarus is an erect 
annual found in all the tropical regions of the world for instance, Africa, India or South 
America (Kuttan and Harikumar, 2012).  
P.amarus extracts are rich in several secondary metabolites such as lignans, hydrolysable 
tannins, flavonoids, alkaloids, triterpenes, sterols and volatile oils (Kuttan and Harikumar, 
2012; Patel et al., 2011). Preliminary phytochemical analysis of aqueous extract of 
phyllanthus amarus revealed the presence of alkaloids, polyphenols, terpenes and sterols 
(Amonkan et al., 2013). 
Numerous studies have indicated that P. amarus extractexhibited different pharmacological 
activities such as, anti-inflammatory (Kiemer et al., 2003),antioxidant (Roengrit et al., 2014) 
orvasodilatation and hypotensive effects(Srividya and Periwal, 1995; Amaechina et al., 2007; 
Inchoo et al., 2011).P. amarus induced a potent anti-inflammatory effect resulting by 
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inhibition of iNOS, COX-2, and cytokines via the NF-kB pathway (Kiemer et al., 2003). The 
antihypertensive activity has been shown to be related to stimulation of muscarinic receptor 
and involving endothelium-derived nitric oxide (NO) and also to blocking of calcium channel 
(Amaechina et al., 2007; Amonkan et al., 2013). Little data are available about 
cardioprotective and antihypertensive effects of P. amarus in chronic hypertension. Therefore, 
the aim of the present study was to determine if an aqueous extract of P. amarus (AEPA) 
obtained by decoction is able to prevent hypertension, cardiac hypertrophy and endothelial 
dysfunction in DOCA-salt hypertensive rats, and, if so, to clarify the underlying mechanism. 
 
Materials and Methods 
Plant material and extraction procedure 
The whole plant of Phyllanthus amarus (Euphorbiaceae) was collected in the district of 
Cocody (Abidjan, Côte d’Ivoire) in April 2014. The plant is registered under No. 3, 141 and 
248 at the Centre National de Floristique (CNF). Extraction procedure was similar to a 
method previously described (Amonkan et al., 2013).  Briefly, the whole plant was harvested, 
washed, and extracted in boiling distilled water for 30 min at ratio of 500 g of plant for 1 liter. 
The decoction was filtered and then lyophilized to obtain a powder of aqueous extract of 
Phyllanthus amarus (11.72 g from 1 kg of plant). 
 
Animals and experiments groups 
Experiments were performed in accordance to the Guidelines for experiments involving 
animals (McGrath et al., 2010).Male Wistar rats (Janvier, Le Genest-Saint-Isle, France) 
weighing between 180 and 200 g were maintained under standard laboratory conditions (21-
22 °C) with dark and light cycle (12/12 h) and had free access to a standard dry pellet diet 
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from Scientific Animal Food and Engineering (SAFE, France) and water ad libitum. Animals 
were randomly assigned 7-8 rats per group, into the control group, the AEPA group (100 
mg/kg/day, by gavage), the DOCA-salt group (50 mg/kg, s.c, per week), and the DOCA-salt + 
AEPA groups (100 or 300 mg/kg/day, by gavage). DOCA-salt-treated rats were allowed free 
access to water containing 1% NaCl.  
 
Blood pressure measurements 
Prior to start the blood pressure monitoring, rats were subjected to a period (one week) of 
adaptation to the system. Systolic blood pressure (SBP) was determined by tail-cuff 
sphingomanometry twice weekly during 5 weeks using blood pressure analysis system 
(Bioseb, Vitrolles, France). Blood pressure was monitoredat 9 a.m.,and at least 12 
determinations were made for each session.  
Echocardiographic studies 
After the 5 weeks treatment, the rats were anaesthetized by intraperitoneal injections of 
pentobarbital (50 mg/kg). Cardiac structure and function were determined by 
echocardiography transthoracic using the Phillips Sonos 5500 machine equipped with a probe 
12 MHz, transducer. Two-dimensional short axis views of the left ventricle and M-mode 
tracings were recorded through anterior and posterior LV walls at the papillary muscle level. 
Morphological characterization of the cardiac left ventricle (LV) was assayed following the 
determination of these parameters: LV end-diastolic diameter (LVEDD), LV end-systolic 
diameter (LVESD), posterior and septum diastolic wall thickness (PWT and SWT, 
respectively). Left ventricular mass (LVM) and LV ejection fraction (% LVEF) were 
subsequently derived from these parameters. The pulsed Doppler was used to assess the 
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isovolumetric relaxation time (IVRT), measured as the interval between aortic closure and the 
start of the mitral flow. 
Assessment of cardiac and kidney weight indices 
 At the end of study, rats were prior weighed, anaesthetized by intraperitoneal injections of 
pentobarbital (50 mg/kg) and sacrificed. Blood was taken directly by cardiacpuncture. The 
heart and the left kidney, werecarefully taken, cleaned, and then weighed. The heart was after 
separation into left and right ventriclerespectively,also weighed.  Thereafter, cardiac and renal 
weight ratios were determined.  
 
 
Biochemical analysis 
After taken blood pressure, it was put into heparinized tubes and, thereafter the plasma was 
obtained by centrifugation 1500 g for 15 min. Plasma aliquots were stored at -80°C for 
subsequent determination of the electrolyte content, urea and uric acid. 
 
Vascular studies 
Vascular studies were performedusing main mesenteric artery rings according to a similar 
method described previously in our team (Lee et al., 2013).Briefly,rings were contracted with 
1 μM of phenylephrine (PE) before the application of increasing concentrations of 
acetylcholine (ACh)ranging from0.1 nM -10 μM to construct concentration-response curves. 
In some experiments, rings were exposed to an inhibitor for 30 min before contraction with 
PE. The NO-mediated component of relaxation was determined in the presence of 
indomethacin (10 μM) and TRAM-34 (1 μM) plus apamin (100 nM) to inhibit the formation 
of prostanoids and EDH-mediated relaxation, respectively. The EDH-mediated component of 
the relaxation was determined in the presence of indomethacin (10 μM) and Nω-nitro-L-
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arginine (L-NA, 300 μM) to inhibit the formation of prostanoids and NO, respectively. In 
endothelial-intact rings, rings were contracted with an increasing concentration of PE (0.1 
nM-10 μM) in order to obtain PE induced contractile responses. 
 
 
Immunofluorescence studies 
Main mesenteric arteries ring were removed, embedded in OCT compound (Tissue-Tek®, 
Sakura Finetek, Villeneuve d'Ascq, France) and snap-frozen in liquid nitrogen. Frozen arteries 
rings were cryosectioned at 14 μm. Sections were air-dried for 15 min and stored at -80 °C 
until use. The slides were fixed with paraformaldehyde (4%), washed and treated with 10% 
milk containing 0.1% Triton X-100for 1 h at room temperature to block non-specific binding. 
Next, overnight at 4 °C, mesentery artery sections were incubated with an antibody directed 
against either eNOS(1:50), NADPH oxidase subunits p22phox (1:50),cyclooxygenase-
1(COX-1, 1:250), cyclooxygenase-2 (COX-2, 1:200), or connexin 37 (Cx, 1: 100).  Sections 
were then washed with PBS, incubated with the secondary antibody (1/400, 633-conjugated 
goat anti-rabbit or anti mouse IgG ) for 2 h at room temperature in the dark before being 
washed with PBS and mounted in Dako fluorescence mounting medium (Dako, Carinteria, 
USA) and cover-slipped. For negative controls, primary antibodies were omitted. The samples 
were kept in the dark until, observation using a confocal laser-scanning microscope (Leica 
TSC SPE-Mannheim, Germany).Analyse for quantification of protein levels expression was 
performed using Image J software (NIH, Bethesda, Maryland, USA). 
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Determination of vascular reactive oxygen species formation 
 
Determination of in situ formation of reactive oxygen species (ROS) was performed into the 
main mesenteric artery rings using the oxidative fluorescent dye dihydroethidium (DHE) 
method. Mesenteric arterial rings (3-4 mm length) were embedded in OCT compound and 
snap-frozen in liquid nitrogen. Frozen arteries were cryosectioned at 25 μm. Sections were 
air-dried for 15 min and stored at -80 ◦C until use. Dihydroethidium (2.5 μM, Sigma) was 
applied onto unfixed cryosections of mesenteric arteries for 30 min at 37 °C in a light-
protected humidified chamber, before being mounted in Dako fluorescent mounting medium 
and cover-slipped. The sample were kept in the dark until fluorescence was determined using 
a confocal laser-scanning microscope. Analyse forquantification of the fluorescence intensity 
was performed using ImageJ software. 
 
Drugs 
DOCA was obtained from Sigma 
Antibodies 
Antibodies were purchased as indicated:  mouse anti-eNOS (BD Transduction Laboratories, 
East Rutherford, New Jersey, United States), COX-1 monoclonal antibody (Abacam, Paris 
France), COX-2 polyclonal antibody (Abacam, France), rabbit anti-p22phox (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), Alexa  633-conjugated goat anti-rabbit or anti mouse 
IgG, ( Life technologies, USA). 
 
Statistical analysis 
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Data are expressed as means ± standard error of mean (SEM) of n experiments. Mean values 
were compared by ANOVA followed by the Bonferroni post-hoc test to identify significant 
difference between treatments, using GraphPad Prism (version 5 for Microsoft windows. 
GraphPad software, Inc, San Diego, CA, USA). The difference was considered to be 
significant when the P <0.05. 
 
Results 
 
Intake of AEPA improves the DOCA-salt-induced hypertension 
 
After 5 weeks, the SBP (mmHg) increased significantly in DOCA-salthypertensive rats, 
compared to the control group (P < 0.05; Fig. 1).  Daily oral administration with AEPA (100 
or 300 mg/kg/day) significantly prevented the increasing of SBP observed in DOCA-saltrats 
by 24 and 21 mmHg, respectively at the end of treatment. The SBP of animal receiving only 
AEPA (100 mg/kg/day) remained unaffected compared to the control groups (P >0.05; Fig. 
1). 
 
Effect of AEPA treatment in cardiac structure and function 
 
Transthoracic echocardiography revealed that after 5 weeks, DOCA-salthypertensive rats 
developed an important modification of cardiac structure, marked by left ventricular 
hypertrophy, compared to the control group. We observed asignificant increase of PWT 
(1.58± 0.02 mmversus 2.24±0.05 mm in the control and DOCA-salthypertensive group 
respectively; Fig. 2A) and SWT (1.54±0.03 mm versus 1.77±0.05 mm in the control and 
DOCA-salt hypertensive group respectively; Fig. 2B). The LVM was also significantly 
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greater in DOCA-salt hypertensive group than control (1103.61±40.13mg versus 
755.29±24.66 mg; Fig. 2C). No significant modification of LVEDD was observed (P >0.05; 
Fig. 2D). The AEPA treatment (100 or 300 mg/kg/day) reduced significantly the increase of 
PWT by 0.36 mm and 0.30 mm respectively,SWT by 0.18 mm and 0.17 mm, LVM by 
268.55mg and 251.61mg respectively. Parameters for AEPA (100 mg/kg/day) remained 
unaffected compared to the control groups (P >0.05). 
Concerning cardiac function, our results show that, in DOCA-salt rats, IVRT was 
significantly increased compared to the control (35.5± 2.83ms versus 45.71±1.96 ms, 
respectively; Fig. 3A). AEPA treatment (100 or 300 mg/kg/day) improves these parametersat 
a value close to normal, 36.67±3.47 and 36.88± 2.37 ms respectively (Fig. 3A). No significant 
difference was observed between rats treated only with AEPA (100 mg/kg/day) and control 
group. The ejection fraction was affected slightly but not significantly in DOCA-salt rats 
compared to the control (P >0.05; Fig. 3B). 
 
Analyse of morphological parameters 
 
Post mortem morphometric analysis of organ shows that except right ventricularDOCA-salt 
rats increase significantly the cardiac (3.4 ± 0.23 versus 2.73 ± 0.08), left ventricular (1.34 ± 
0.11 versus 1.04 ± 0.05) and , left kidney (3.71 ± 0.18 versus 3.18 ± 0.12) weight indices, as 
compared respectively to the control group (Table1). The cardiac and kidneyweight indices 
were reduced in the DOCA-salt + AEPA groups (100 or 300 mg/kg/day), compared to the 
DOCA-salt rats (P ˂ 0.05; Table 1). These parameters remained similar between AEPA (100 
mg/kg/day) group and control rats (P > 0.05; Table 1). 
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Effect of DOCA-salt on plasma electrolyte levels 
DOCA-salt treatment increases the plasma uric acid level (11.25 ± 0.48 in DOCA-salt rats 
versus 7.00 ± 1.00 in control; Table 2) and decrease the plasma potassium level (4.18 ± 0.08 
versus 5.54 ± 0.2 in the control; Table 2). EAPA treatments (100 or 300 mg/kg/d) normalize 
the plasma levels of potassium (5.26 ± 0.3 and 5.14 ± 0.3 respectively; Table 2) and uric acid 
level (6.67 ± 0.52 and 8.0 ± 0.50 respectively; Table 2). 
At the end of experiment, the plasma sodium level in DOCA-salt rat increase slightly, but not 
significantly compare to the control group (147.50 ± 0.65 in DOCA-rats versus 143.20 ± 1.11 
in control; Table 2). The plasma chlorine and urea levels remained also unaffected (Table 2). 
 
 
AEPA improves the DOCA-salt-induced endothelial dysfunction in the mesenteric artery 
In mesenteric artery rings with endothelium, DOCA-salt treatment increase significantly 
phenylephrine-induced vasoconstriction compared to the control rats (P ˂ 0.05; Fig. 4A). In 
the DOCA-salt + AEPA groups (100 or 300 mg/kg/day), the phenylephrine induced-
contractile response was shifted to the right (Fig. 4A). The significant effect was obtained 
with AEPA at dose of 300 mg/kg/day (P ˂ 0.05; Fig. 4A). 
DOCA-salt group, present an endothelial dysfunction, marked by a significant reduction 
ofacetylcholine induced endothelium-dependent vasorelaxation, compared to the control 
group (P ˂ 0.05; Fig. 4B).Treatment with AEPA (100 or 300 mg/kg/day) improve these 
endothelial dysfunction (P ˂ 0.05; Fig. 4B). 
AEPA improves the DOCA-salt-blunted NO- and EDH-mediated relaxations in the mesenteric 
artery 
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In mesenteric artery rings with endothelium, both the NO-mediated (assessed in the presence 
of indomethacinand Tram-34 plus Apamin) and the endothelium-dependent hyperpolarization 
(EDH)-mediated (assessed in the presence of indomethacinand Nω-nitro-L-arginine) 
relaxation to acetylcholine were significantly reduced in the DOCA-salt group compared to 
the control group (P˂ 0.05; Fig.5A and Fig. 5B). Treatment with AEPAimproves the DOCA-
salt-blunted NO- and EDH-mediated relaxations in the mesenteric artery (Fig. 5A and Fig. 
5B). 
AEPA prevents the DOCA-salt-induced increased vascular oxidative stress and up-regulation 
of NADPH oxidase 
Immunofluorescence studies show that DOCA-salt treatment induced an important increased 
of vascular oxidative stress, attest by the significant increase of DHE fluorescence signal 
amounted to 124.17 ± 4.89 %, compared to control (100.00 ± 3.97 % ; Fig. 6A). This 
oxidative stress was accompanied by a significant increase of NADPH oxidase subunits 
p22phox (198.82 ± 17.17% in DOCA-salt rat versus 100.00 ± 17.34 %; Fig. 6B). AEPA 
treatmentprevents the DOCA-salt-induced increased vascular oxidative stress and up-
regulation of NADPH oxidase (P˂ 0.05; Fig. 6A and Fig. 6B). 
 
AEPA prevents the DOCA-salt-induced increased expression of eNOS and decreased 
expression of Cx37 
Immunofluorescence staining indicated a significant increased expressionofeNOS (188.22 ± 
12.91 %; Fig. 7A) and a decreased expression of Cx37 (32.39 ± 3.23 %; Fig. 7B) in DOCA-
salt rats compared to control rats. (P ˂ 0.05). AEPA treatment normalized these deleterious  
effect by preventing the DOCA-salt- induced increased expression of eNOS and decreased 
expression of Cx37 (P ˂ 0.05; Fig. 7A and Fig. 7B).   
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DOCA-salt-induced increased expression of COX-2, but not expression of COX-1 
The expression of COX-2 signal was significantly increased in DOCA-salt rats compared to 
the control (153.72 ± 12.44 %, versus 100.00 ± 9.07%; Fig. 8A). After treatment, a preventing 
effect was observed by a significant reduction of COX-2 levels expression in DOCA + AEPA 
(100 or 300 mg/kg/day) group (P ˂ 0.05; Fig. 8A). In contrast to COX-2 signal, the 
expression COX-1 levels expression remained unaffected (P ˂ 0.05; Fig. 8B). 
Discussion 
The present findings show that after 5 weeks ofinjection of deoxycorticosterone acetate 
(DOCA) followed by1% NaCl diet, ratsbecome hypertensive. This hypertension is associated 
to left cardiac hypertrophy and endothelial dysfunction. 
Concerning cardiac structure, our result is in agreement with previous study indicated that 
DOCA-salt induces cardiac hypertrophy, especially in left ventricular in rat (Fenning et al., 
2005). Transthoracic echocardiography result show an increase of PWT and SWT associated 
with an increase of LVM without any significant dilation of the left ventricular 
chamber, indicating that hypertrophy observed in rat was concentric type (Chan et al., 2006). 
Analyses of cardiac function show an impairment of diastolic function in DOCA-salt rats, 
attest by an increase of IVRT. Ejection fraction (LVEF) was slightly reduced, in DOCA-salt 
group. However, this parameter remained in the normal range i.e. upper than 50 % 
(Kawaguchi et al., 2003). This result is in agreement with previous study indicating that in 
hypertension, at early stages, cardiac diastolic function was prior affected before systolic 
function (Ayme-Dietrich et al., 2015). 
Moreover, the beneficial cardioprotective effect of AEPA in DOCA-salt rats was related to its 
ability to exhibit an antihypertrophic effectby reducing near to the normal PWT,SWT and 
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LVM, together with an improvement of cardiac function. Similar effect was reported with oral 
extract of Moringaoleiferaseeds which decreases the LVM and improves diastolic function in 
SHR (Randriamboavonjy et al., 2016). 
The experimental models of salt-insensitive hypertension induce also a renal damage 
(Manning et al., 2005).In this study, we found an increase of kidneyweight indices, an 
increase of uric acid and a depletion of potassium plasma levels in untreated pathological rats.  
Chronic hypokalemia has been involved incardiac hypertrophy, thus, 
potassiumsupplementations seem to be a strategy to prevent the development of cardiac 
hypertrophy (Wang et al., 2005; Liu et al., 2014). Our result shows that in hypertensive rats, 
EAPA treatment was able to restore near to the normal, the potassium plasma level. The same 
result was obtained with sesame oil and quercetin in DOCA-salt hypertensive rats (Galisteo et 
al., 2004; Liu et al., 2014). 
Endothelial dysfunction is a common vascular deleterious effect found in hypertension 
(Perez-Vizcaino et al., 2009). In the present study, we demonstrated that AEPA treatment 
prevent endothelial dysfunction by reducing the maximal contractile response to 
phenylephrine and an improvement of vascular effect of acetylcholine in DOCA-salt 
hypertensive rat. Moreover, endothelial dysfunction was corroborating by an impairment of 
both NO- and EDH-mediated relaxations in the mesenteric artery in DOCA hypertensive rats. 
Previous reports indicatethat in animal artery, endothelium-dependent relaxations to 
acetylcholine most likely involve a NO component (Furchgott and Zawadzki 1980) and an 
EDH component (Pannirselvam et al., 2006). Thus EAPA treatment prevent endothelial 
dysfunction by improvement of the bluntedof NO- and EDH-mediated relaxations in the 
mesenteric artery. Other natural product derived from plant extract such as red wine 
polyphenols (RWPs) or the sesame lignan, sesamin have been reported to restore endothelial 
function in DOCA-salt hypertension mainly by preventing vascular oxidative stress 
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(Jiménezet al., 2007;Nakano et al., 2008). We therefore examine the possibility that AEPA 
exert a beneficial effect on cardiovascular system by such mechanism, since the DOCA-salt 
hypertensive rat is described as a model of cardiovascular oxidative and inflammatory stress 
(Iyer et al., 2010). Interestingly, in the present study,in mesenteric artery of DOCA-
salthypertensive rat, we observed an increaseof reactive oxygen species production and an 
overexpression of NADPH oxidase subunits p22phox. It is well established that NADPH 
oxidase activation induces a release of ROS production, contributing to vascular endothelial 
dysfunction (Nediani et al., 2007). 
eNOS expression was up-regulated in the mesenteric artery of DOCA-salt hypertensive. We 
can explain this phenomenon by the fact that, in presence of vascular oxidative stress, 
tetrahydrobiopterin (BH4) can promote oxidation, anda compensatory mechanism take place 
and lead consequently to eNOs uncoupled (Landmesser et al., 2003).Thus, the effect of AEPA 
was similar in part toresveratrol which attenuates hypertension spontaneously inhypertensive 
rats by preventing endothelial nitric oxide synthase uncoupling (Bhatt et al., 2011).Connexin 
(Cx) protein subunits present into the gap junctions play a crucial role in EDH component of 
endothelium-dependent relaxation (de Wit et al., 2010). In accordance with our results, 
previous results haveindicated that vascular oxidative stress also reducesconnexin subunits 
expression such as Cx37, and thus leading to an impairment of EDH- mediated relaxation 
(Rashid et al., 2014). 
DOCA-salt hypertension promotes an overexpression of COX-2 in artery (Callera et al., 
2006).Such effect was most likely restored and the value observed was close to the normal 
level after AEPA treatment. These resultsare in agreement with previousin vivo and invitro 
studies, which have been showed that Phyllanthus species such as P. amarus or P.acidusare 
able to reduce inflammatory stress by inhibiting COX-2 overexpression(Kiemer et al., 
2003;Hossen et al., 2015). 
18 
 
In most human and experimental salt sensitivehypertension, antioxidant level is down-
regulated, thus antioxidant therapy can be helpful (Manning et al., 2005). Taken together, the 
antioxidant properties ofP. amaruspreviously described (Roengrit et al., 2014), might 
contribute to explain theability of AEPAto counteract the deleterious effectsdescribed in 
DOCA-salt rats. 
Altogether, our study indicates that AEPA has antihypertensive properties, and prevents 
endothelial dysfunction and cardiac hypertrophy in DOCA-salt hypertensive rats, in part, by 
preventing vascular oxidative stress. The antihypertensive effect of AEPA was associated 
with an improvement of the blunted NO- and EDH- mediated relaxation, and a reduced 
vascular oxidative stress level and improvement of target proteins (eNOS, Cx37, COX-2 and 
p22phox) and cardiac hypertrophy in DOCA-salt rats. 
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Optimized EPA: DHA 6:1 
formulation prevents 
Angiotensin-II induced 
hypertension and endothelial 
dysfunction in rats 
Logo 
partenaire 
Résumé 
La présente étude évalue la capacité de EPA:DHA 6:1, une formulation d’omega-3 capable d’induire 
la formation continue de monoxyde d’azote par la NO synthase endothéliale, à prévenir 
l’hypertension et la dysfonction endothéliale induites par l’angiotensine II (Ang II) chez le rat. 
L’hypertension induite par l’Ang II est associée à une dysfonction endothéliale caractérisée par une 
altération des composantes de la relaxation et une augmentation des réponses contractiles 
dépendantes de l’endothélium. L’Ang II augmente le stress oxydant vasculaire et l’expression de 
NADPH oxydase, COXs, eNOS, et  AT1R, alors que SKCa et connexin 37 sont sous-exprimés. 
EPA:DHA 6:1 prévient l’hypertension, la dysfonction endothéliale et la surexpression des protéines 
cibles. En conclusion, la consommation chronique de EPA:DHA 6:1 prévient l’hypertension et la 
dysfonction endothéliale induites par l’Ang II chez le rat, probablement en  prévenant le stress 
oxydant dû à la NADPH oxydase et aux cyclooxygénases.  
 
 
Résumé en anglais 
EPA:DHA 6:1 has been shown to be a superior omega-3 formulation inducing a sustained 
endothelial NO synthase-derived formation of nitric oxide. This study examined whether chronic 
intake of EPA:DHA 6:1 prevents hypertension and endothelial dysfunction induced by angiotensin II 
(Ang II) in rats. Ang II-induced hypertension was associated with endothelial dysfunction 
characterized by blunted components of relaxation and increased endothelium-dependent contractile 
responses. Ang II increased the vascular oxidative stress, and the expression of NADPH oxidase 
subunits, COXs, eNOS, and AT1R whereas SKCa and connexin 37 were down-regulated. Intake of 
EPA:DHA 6:1 prevented the Ang II-induced hypertension and endothelial dysfunction, and improved 
expression of target proteins. In conclusion, chronic intake of EPA:DHA 6:1 prevented the Ang II-
induced hypertension and endothelial dysfunction in rats, most likely by preventing NADPH oxidase- 
and cyclooxygenase-derived oxidative stress.  
 
